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1 Summary of thesis 
Physiological barriers maintain and safeguard homeostasis of certain body compartments by an 
increased resistance against free diffusion. Distribution and pharmacokinetics of drugs can be altered 
as well, if they have to cross these barriers in order to reach their target. Knowledge of the 
physicochemical and structural requirements for drug permeation is a key topic in drug design, 
development, and clinical application. 
 
To assess processes on cellular barriers, in vitro methods are usually applied to elucidate single 
transport mechanisms or to study isolated transport. As the pharmacokinetics of a living system are 
often more complex and composed by a concatenation of several barriers, in vivo methods are 
required. However, this time consuming and expensive testing is not suited to answer the need for 
high-throughput screening of thousands of compounds in chemical databases. For these purpose in 
silico methods are ideally suited, which produce computational models to predict pharmacokinetics, 
drug distribution, or transport across single barriers. As these models are information compressions, 
they can give by themselves new insights into the process they predict. 
 
In the present thesis, in silico models were developed to predict intestinal absorption, blood brain 
barrier permeation, drug permeation into breast milk, and active drug transport by the ATP binding 
cassette (ABC) transporter MRP2. In addition, a nature inspired modeling paradigm, ant colony 
optimization, was adapted and applied in the field of antimalaria drug therapy. These projects can be 
summarized as follows: 
 
The first project concerned the modeling of human intestinal absorption. After oral administration and 
intestinal dissolution, a drug has to cross the gut wall in order to become available for the body. The 
process is mostly determined by passive diffusion and active transport. Active export and import of 
molecules on the enterocyte is regulated by a multitude of transport proteins and metabolic enzymes. 
A dataset of small drug-like compounds, on which information on their human intestinal absorption was 
available, was collected. Models trained on these data predicted human intestinal absorption with high 
accuracy. Several machine learning methods were compared as well as different feature sets. The 
features used to predict intestinal absorption resembled those known from modeling passive diffusion, 
which are measures of charge and lipophilicity. The models revealed also less commonly used 
descriptors to model human intestinal absorption, such as gravitational indices and moments of inertia. 
 
The aim of the second project was to develop computational models to predict blood brain barrier 
(BBB) permeation. Development of new central nervous system (CNS) active drugs is hampered by 
limited brain permeation. As invasive methods have proven themselves to be ineffective and risky for 
patients, systemic application is the preferred route for drug administration into the brain. Hence, BBB 
permeability is a feature absolutely mandatory for any drug, which targets the CNS. Limited passive 
diffusion and active efflux and influx systems account for the complexity of this highly regulated barrier. 
To establish our models, a database of 163 compounds with information on the in vivo surface 
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permeability product (LogPS) in rats was collected. Decision trees performed with high accuracy (CCR 
of 90.9 - 93.9%.) and revealed descriptors of lipophilicity and charge, which were yet described in 
models of passive BBB permeation. However, other descriptors as measures for molecular geometry 
and connectivity could be related to an active drug transport component. Moreover, a fragment-based 
approach indicated the involvement of stereochemistry to predict LogPS values.  
 
The third project explores the physicochemical and structural requirements for drugs to pass from 
maternal blood into breast milk. While experimental assessment in humans is limited, computational 
methods are appropriate to model drug permeation into breast milk. Data preparation for these models 
was a challenging endeavor. Endpoints were reported in imprecise ways, which asked for a careful 
selection and binning of the instances. Despite these facts, the 10-fold cross-validated decision trees 
predicted the endpoint with high accuracy (CCR: 85.3 - 95.3%). Prominent descriptors were measures 
of molecular size, branching, charge and geometry. Importance of polar fragments was revealed by a 
fragment-based analysis.  
 
The efflux transporter MRP2, a member of the ABC transporter family, was subject of the fourth study. 
Efflux transporters contribute substantially to barrier function by extruding potentially toxic substances. 
Three datasets were assembled from literature for MRP2 substrates, inducers, and inhibitors. For 
inducers and inhibitors, decision trees with high accuracy were grown. However, the substrate dataset 
did not qualify for decision tree induction, due to an underrepresentation of negative instances. 
 
The fifth project deals with an ant colony optimization (ACO) algorithm, which was adapted for 
fragment based feature selection. The paradigm was tested to predict antimalarial activity of 
molecules. ACO was able to reveal chemical substructures characterizing antimalarial drug activity, 
which comprised passive diffusion through the erythrocyte membrane and parasite toxicity. The 
paradigm outperformed other algorithms such as decision trees or artificial neural networks on the 
same dataset.  
 
 Aim of thesis 
 
- 11 - 
2 Aim of thesis 
Drugs have to cross several physiological barriers in the body in order to reach their target. Some of 
these barriers consist of specialized cells, which can exhibit increased tight connections between each 
other to reduce free diffusion. At these cell layers molecules can be actively transported with and 
against concentration gradients by a multitude of transport proteins. Barriers are found in the intestinal 
wall, the central nervous system, and the lactating breast epithelium. While they help to maintain 
homeostasis within the body and prevent permeation of toxic substances, these barriers can also 
substantially alter drug distribution or even completely prevent access to the site of action. It was 
therefore the aim of the present work to develop computational models using modern machine learning 
methods to predict drug permeation across physiological barriers.  
  
We initially assessed human intestinal absorption using computational methods. After oral 
administration and intestinal dissolution, a drug has to cross the gut wall in order to become available 
for the body. Knowledge of intestinal absorption capacity is desirable as low intestinal absorption of a 
drug may limit its clinical application.  
 
The second project aims to create methods to predict drug brain penetration, which is substantially 
restricted by the blood brain barrier. Knowledge on blood brain barrier permeation is therefore critical 
to develop drugs, which target the central nervous system.  
 
The aim of the third project was to explore physicochemical and structural requirements for drug 
passage from maternal blood into breast milk. This topic is of particular relevance for drug safety in 
nursing. As ethical constraints limit in vivo experiments, computational methods are ideally suited to 
model this endpoint.  
 
It was the aim of the fourth project to study a representative of the ABC transporter family, MRP2, as 
efflux transporters contribute substantially in maintaining barrier functions.  
 
In the final study, we aimed to adapt an ant colony optimization algorithm to perform a fragment based 
feature selection. The paradigm was tested on the highly combined endpoint of antimalarial drug 
activity, which comprises passive diffusion through the erythrocyte membrane and toxic action on the 
parasite.  
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3 Introduction 
3.1 A historical perspective 
The use of drugs is as old as mankind. In fact, the use of herbal medicines might even predate modern 
homo sapiens. Findings of various different medicinal plants in Neanderthal tombs (60 000 years BC) 
indicate their use as remedies.[1] The 5300 year old “Oetzi” or “iceman” found in the Tyrolean Alps was 
carrying two pieces of birch fungus (Pitoporus betulinus) with him. It is nowadays believed that he 
knew of its beneficial effects (antibiotic and anti-inflammatory) and that it served him as an early first-
aid kit.[2-4]  
 
Despite its long history, drug discovery as a systematic, scientific, and multidisciplinary endeavor exists 
not much longer than a century. A dramatic development in chemistry induced a quantum leap of 
pharmaceutical sciences in the 19th century: The benzene theory formulated by Auguste Kekulé in 
1865 led to intensive research on coal-tar derivatives, especially for their use as dyes.  
 
The application of dyes inspired medical and pharmaceutical science. Paul Ehrlich discovered in the 
early 19th century a selective affinity of dyes for biological tissues. His observations led him to postulate 
the existence of “chemoreceptors” that should be exploited as therapeutic targets. With his statement 
“Corpora non agunt nisi fixata”, he was the first to formulate a basic principle of modern pharmacology. 
Namely, that active components have to bind their corresponding molecular target structure in order to 
cause a specific action. This theory was further refined by Emil Fischer (Key-lock principle, 1890) and 
Daniel E. Koshland (induced fit concept).[5] It became clear that a drug candidate should exhibit high 
target selectivity in order to be a good therapeutic. On the other hand, unspecific binding made a drug 
more prone to cause unwanted or toxic side effects.  
 
Although, knowledge on target structures grew during the first decades of the 20th century, the 
greatest “block buster” drugs were still discovered by serendipitous accidents. The most famous 
example is probably the discovery of penicillin by Sir Alexander Fleming due to a fungus contamination 
of his bacterial cultures. His discovery conquered some of mankind's most ancient scourges, including 
syphilis, gangrene and tuberculosis. The more targeted identification of specific sites of action led also 
to remarkable results. William Campell for example isolated the avermectins from a soil sample 
collected from a golf course in Japan, which proved powerful against parasites. From systematic series 
of compounds, the semi-synthetic ivermectin turned out to be the most effective drug and was 
marketed ever since.[6] Another example of a success story was the development of Cyclosporine A. 
The immunosuppressive effect of the drug was discovered in a screening test developed by Hartmann 
F. Stähelin in Basel.[7] 
 
In the late 1970s, genomic science led to a fast identification of drug target structures. In vitro assays 
were developed to quickly screen compounds for specific pharmacological properties. An automation 
of these experiments allowed for high-throughput screening, where thousands of compounds could be 
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screened on one day. Despite the initial euphoria, its success stayed far behind expectations: although 
the number of molecules tested rose from 200 000 in 1990 to over 50 Million in 2000, the productivity 
of pharmaceutical industry, with respect of bringing new drugs to marked, could not be improved ever 
since.[8] 
 
Many of these high-troughput screened compounds failed in the late and costly stage of drug 
development due to their unexpected or unfavorable pharmacokinetic behavior. The efficacy and 
safety of a drug is detrimentally dependent on its absorption characteristics, its tissue distribution, 
metabolism, as well as its excretion. A quick metabolism and elimination of a drug could abolish any 
therapeutic concentration on the target site, while a slow clearance leading to high plasma levels could 
cause toxic side effects. Several cellular and biochemical barriers can hamper distribution into body 
compartments and make predicting drug pharmacokinetics a challenging endeavor.  
 
3.2 Pharmacokinetics in Drug Discovery 
Depending on the application route and formulation, pharmacokinetics and bioavailability of a drug can 
substantially vary. The preferred route of administration is per oral since it is safe, cost-effective, and 
associated with high patients compliance. Low intestinal absorption of a drug may limit its clinical 
application, except in settings where the compounds target lies within the gastro-intestinal lumen (e.g., 
vancomycin, mesalazine). However, most orally applied drugs have to cross the intestinal epithelium 
and will be exposed to hepatic metabolism before reaching their site of action.  
 
Limiting factors for intestinal drug absorption include low solubility or chemical instability in the 
gastrointestinal tract (GIT), high gastrointestinal metabolism, and poor intestinal membrane 
permeability.[9] Absorption kinetics are highly dependent on a compound’s solubility and hence galenic 
formulation, which influences exact location of dosage form disintegration in the GIT.[10] After 
intestinal absorption, molecules are transported via the portal vein to the liver where they might be 
subjected to hepatic metabolism. Metabolism can be pronounced to such an extent that a drug can be 
completely withdrawn from circulation by the first liver passage. For compounds undergoing extensive 
hepatic first pass metabolism, other administration strategies have to be found.1  
 
To bypass intestinal absorption and hepatic metabolism, drugs could be applied intravenously. 
Intravenous application (i.v.) has the advantage to make drugs immediately available for distribution as 
they reach circulation without prior hepatic metabolism. Other invasive methods comprise sub- or 
intracutaneous application.2 However, injections are associated with a certain infection risk and are 
generally not favored for self-application by a patient. 
 
                                                      
1 One could think of pro-drug administration, where the active drug component becomes available just after being metabolized in 
the liver. However, this strategy requires a functional liver parenchyma.  
2 A major drawback is related to the varying constitution of the subcutaneous tissue depending on the body part. Varying blood 
flow rate and subcutaneous fat content can substantially alter drug kinetics.   
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A more elegant and non-invasive way to avoid first pass metabolism is the application over the 
mucosal tissue. Drugs diffuse passively into the submucosal capillaries and into venous circulation. 
Determinants for passive diffusion are molecular size, lipophilicity, and charge. Besides the buccal 
mucosa, other mucosal tissues can be used for drug application as well. Nasal and rectal applications 
are available for many drugs.[11] 
 
Although the drug application via the skin seems at first glance very attractive, it is hampered to a 
certain extent by the physiological function of the epidermis, which is to safeguard the body from 
environmental impacts. To reach dermal microcirculation a drug has to diffuse through the numerous 
layers of epidermis.3  As a result transdermal drug delivery can be delayed and prolonged, and is 
sometimes hard to control. Typical application domains are treatment of ischemic heart disease 
(nitroglycerine patch) and acute and chronic pain (opioid patches, like buprenorphine or fentanyl 
patches).[12, 13] 
 
In cases where the pharmacological target is hardly reachable from the circulation (e.g., due to 
barriers) one could consider direct application into the target organ, surgically or by injection.4 
However, this administration route does usually not qualify for self-application. Trained staff and a 
medical facility are needed for safe administration. Thus, a single dosing becomes much more tedious 
and expensive than an oral formulation would and limits the drugs application range dramatically. 
Moreover, there are targets that do not qualify for direct application.5 This is especially the case when 
strongly invasive surgical procedures would be needed and the potential risk of infections demands for 
an exhaustive risk-benefit assessment. In these cases, scientific ingenuity is needed to improve 
pharmacokinetic properties to qualify for safer application routes. However, one of the greatest 
obstacles is to overcome pharmacological barriers. 
 
3.2.1 Barriers 
Where body compartments are more sensitive to fluctuations of nutrients or exposure to xenobiotics, 
they need the ability to control and influence passage of molecules from circulation. Highly specialized 
cells fulfill this task by establishing biological barriers. Molecular trafficking can be controlled by active 
transport, often in combination with an increased tightness of the cellular layer, where the whole 
process is catalyzed. The characteristics of these barriers depend substantially on their location and 
the physiological requirements of the protected organ. We will discuss some of these barriers in the 
following in more detail.  
 
                                                      
3 Of which, the stratum corneum imposes the major diffusion barrier as it mainly consists of several layers of dead ceratinocytes. 
Compounds would have to diffuse intercellularily through this inert barrier. In comparison, diffusion over the stratum lucidum, 
granulosum, spinosum, and germinativum of the epidermis is much faster due to a higher fluid content in these living cells. 
4 For the anti-angiogenetic agent Pegaptanib used in age-related wet macular degeneration the intravitreal injection is the 
common and most effective application route.[14] 
5 E.g., the brain. 
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3.2.1.1 Intestinal absorption  
One of the first hurdles an orally administered compound encounters after dissolution in the gut is its 
intestinal absorption, i.e. its passage from the gut lumen into the portal vein. The cellular barrier in the 
GIT is mediated by a simple columnar epithelium of enterocytes. Current understanding indicates that 
passive diffusion (transcellular and paracellular) is a determining factor in drug absorption.[15] 
 
The cellular membrane of the enterocyte consists of a self-assembling phospholipid bilayer. The 
aliphatic parts are oriented towards the inside, while the polar phosphate and head groups are directed 
toward the watery surrounding (e.g., cytosol and gut lumen). Before a compound moves by Brownian 
motion through the membrane it has to withdraw hydrating water molecules and to brake up hydrogen 
bonds. Generally, the higher the hydrogen bonding capacity, the more energy the permeation will cost 
and consecutively the poorer is the molecule’s absorption. Due to this energy-consuming step, 
lipophilic and uncharged compounds permeate much better than their polar counterparts.[16, 17] 
Molecules passing through the polar head groups of the phospholipids encounter tightly packed lipid 
chains in the glycerol backbone. Hence, small molecules pass this region more readily than greater 
structures. Typically, measures of lipophilicity (polar surface area [PSA], partition coefficient [LogP]), 
size (molecular weight), and charge (hydrogen bonding capacity, PSA) are used to predict intestinal 
absorption in rules of thumb.[16, 18] The majority of molecules diffusing passively will take the 
transcellular route due to the great exchange area on the microvilli. But also paracellular diffusion 
occurs.[19, 20] Tight junctions between enterocytes control this undirected transport by claudine-pores, 
which act like a molecular sieve. Only small molecules (180-200kD) and mostly cations are able to 
cross. [21] 
 
However, many vital substances are neither lipophilic, nor small (e.g., sugars and proteins) and will not 
diffuse passively in efficient manner through the enterocyte membrane. To ensure sufficient supply of 
such poorly permeable yet indispensable molecules, selective transport is warranted by several 
transmembrane transport proteins and channels. Beside specific import of molecules, there exists as 
well active extrusion of potentially noxious substances on the enterocyte. As they can transport their 
substrates against a concentration gradient, efflux transporters can modify absorption considerably. In 
enterocytes, transporters are physiologically involved in absorptive uptake (from the gastric lumen 
through the epithelial cells into the blood), in efflux (from the epithelial cell membrane back into the 
gastric lumen), and in secretory efflux (from the blood into the gastric lumen). 6 
 
Active influx and efflux at the level of the enterocyte are regulated by several transport systems, such 
as the influx transporter PEPT1 (Section 3.2.3.2) and the well-known efflux transporter P-glycoprotein 
(P-gp) (Figure 1) (Section 3.2.3.1).[23-25] 
                                                      
6 Digoxin is secreted by P-gp form blood into the gastric lumen.[22] 
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Figure 1 - A schematic view of enterocytes is given. On the apical side (gut lumen) P-glycoprotein (P-
gp), breast cancer resistance protein (BCRP) and multidrug resistance protein 2 (MRP2) mediate 
efflux. Influx transporter peptide transporter 1 (PEPT1) mediates di- and tripeptide uptake. On the 
basal side (blood) multidrug resistance protein 3 (MRP3) transports substrates into the blood. 
 
There is clear evidence that transport proteins interplay with metabolic enzymes. The effect of 
enterocytic cytochrome P450 (CYP450) metabolism, even though small when compared to the effect 
of hepatic CYP450, still serves as an example of metabolic degradation of the parent substance 
resulting in lower plasma levels.[26, 27]  
 
3.2.1.2 Blood brain barrier 
Development of new CNS active drugs is hampered by limited brain permeation. As invasive methods 
have proven themselves to be ineffective and risky for patients, the systemic application is the 
preferred route for drug administration into the brain.[28, 29] Hence, blood brain barrier (BBB) 
permeability is a feature absolutely mandatory for any drug, which targets the CNS. It is desirable to 
have estimates on a compounds behavior at the BBB as early as possible in the drug development 
process.  
 
The microvascular endothelial cells of the brain establish the BBB. The membrane of brain endothelial 
cells exhibit negatively charged polar head groups, which oppose acids.[17]7 Circumferential tight-
junctions connecting adjacent cells eliminate paracellular leakage and seal the physical barrier against 
paracellular diffusion of blood borne molecules (Figure 2). Lack of endothelial fenestration enforces the 
cellular barrier additionally.  
 
 
                                                      
7 Acids penetrate poorly the BBB due to the negatively charged head groups of the lipid bilayer. This is also reflected in the fact 
that approximately 75% of the most prescribed drugs are basic, 19% are neutral, and only 6% are acids.[30] 
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Figure 2 - A schematic intersection of a cerebral microvessel is shown. The microvascular endothelial 
cell (E) constitutes the blood brain barrier, which controls passage of molecules from the blood (B) into 
the brain. Tight junctions establish high intercellular resistance. The brain microvascular endothelial 
cells stand in close contact to astrocytes (A), neurons (C) and pericytes (D), which are thought to 
modify endothelial cell characteristics. 
 
Therefore, most compounds have to take the transcellular route in order to cross the BBB. Small 
gaseous molecules (e.g., O2, CO2) and small lipophilic agents (e.g., ethanol) cross the endothelial cell 
membrane by passive diffusion.[31]8  
 
The process of passive permeation is well described and major physicochemical determinants 
summarized in rules of thumb, which are lipophilicity,9 molecular weight, and measures of molecular 
polarity.[32-36] However, such expert-based rules do not accurately reflect the complexity of 
interactions as they disregard the pharmacokinetic processes mediated by transport proteins.[37] 
Typically, several anti-cancer drugs, corticosteroids, and anti-epileptics are well-documented examples 
where molecular properties for brain penetration would seem to be fulfilled but in fact significantly lower 
CNS concentrations are achieved due to their susceptibility to active transport.[38, 39] Physiologically, 
the ABC transporter super family and solute carriers mediate active transport across the BBB and 
constitute a biochemical barrier to safeguard the brain tissue from potentially toxic compounds, such 
as xenobiotics. 
 
                                                      
8 High lipophilicity improves brain permeation, which is nicely demonstrated on the example of morphine: Addition of methyl 
groups to morphine produces codein, which penetrates 10 fold better into the brain. When two acetyl groups are added, which 
make the compound even more lipophilic, heroin is produced which further increases permeability (up to 100 fold). 
9 However exaggerated lipophilicity makes a compound susceptible for nonspecific binding. It is therefore important to balance 
lipophilicity in order to achieve optimal pharmacokinetics. 
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Figure 3 - An intersection of microvascular endothelial cells is shown. Influx is mainly mediated by 
organic anion transporting polypeptides OATP2A2 and OATP2B2. P-glycoprotein (P-gp), breast 
cancer resistance protein (BCRP) and multi drug resistance protein 4 (MRP4) are examples of efflux 
transporters. 
 
P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2) are the most 
prominent and best characterized representatives and show the highest mRNA expression levels of all 
ABC transporters on the human BBB.[40-44] Their impact on substrate drug uptake has been shown to 
be, at least for P-gp, clinically relevant.[45] There are speculations that both transporters act together 
to prevent brain entry of several toxic compounds (Section 3.2.3).[46-48] Only a very small proportion 
of compounds show enhanced permeation due to uptake transporters (Figure 3). The physiological 
role of these transporters is uptake of nutrients like sugars, peptides, amino acids, and other 
endogenous compounds (Section 3.2.3).[49, 50] 
 
In the past, the most commonly used brain penetration data were derived from in vivo pharmacokinetic 
studies, which produced a drug in brain to drug in plasma/blood ratio at steady state. Usually its 
logarithm was used termed LogBB. This measure can give some indication of distribution in the brain, 
however it suffers from limitations.10 Single time point measurements might not accurately reflect brain 
penetration due to varying kinetics in plasma and brain. Moreover, LogBB reflects a volume of 
distribution that is determined largely by cytoplasmic binding of drugs in brain and much less by BBB 
permeability. This measurement cannot resolve whether the fraction of free drug is camouflaged by 
nonspecific or specific binding nor does it provide any information on active transport.[51] Therefore, 
the permeability surface product values are recommended, which are usually calculated from internal 
carotid artery perfusion studies in rats, given as its logarithm, LogPS. This procedure is considered 
                                                      
10 The term was loosely applied for variously calculated data: LogBB was sometimes derived from area under thr curve (AUC) 
values, steady state or single time point measurements. In order to make use of these values, the scientist had to have 
knowledge on how the data were derived. 
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superior to blood/brain partitioning measurements at steady state, as it lacks systemic distribution 
effects, which distort brain penetration substantially.[51] 
 
3.2.1.3 Blood milk barrier 
To date, experts estimate a nursing rate of 60–90% in western countries11 and breastfeeding is 
considered the best nutrition for the first months of a baby's life.[52-56] While in general mother and 
baby profit from nursing, maternal medication intake can impose a safety concern. As many drugs 
pass easily into breast milk, babies can be accidentally exposed to medication. Although the majority 
of drugs do not impose a hazard, some cases of significant infant intoxication exist.[57] 
 
Almost all lactating women receive some medication immediately postpartum and during nursing.[58]12 
Despite its social, economic, and medical impact, compatibility of drug intake in nursing is still a 
relatively unexplored field. Ethical constraints hamper clinical trials and animal tests give only a rough 
estimate of human pharmacokinetics. As a consequence, for many drugs only case reports exist.13  
 
Passive diffusion is a leading mechanism of drug passage into breast milk.[61, 62] To our knowledge, 
highly passive diffusing molecules are determined by factors such as low molecular weight, high 
lipophilicity, and low polarity (Section 3.2.1.1).[63] Pharmacokinetics and plasma protein binding in 
maternal circulation determines the amount of drug, which becomes available for excretion.  
 
Although excretion into breast milk is predominantly guided by passive diffusion, the occurrence of 
drug accumulation in human and animal milk suggests the presence of active transport in the 
mammary gland.[61, 64-66] The lactating mammary gland epithelium has to secrete vitamins and 
nutrients against a concentration gradient. Coherently, a multitude of transport proteins were found to 
be expressed.[67, 68] 
 
Members of the ABC transport protein family, like breast cancer resistance protein (BCRP, ABCG2), 
are expressed on the mammary gland epithelium.[64-66] Surprisingly, in the lactating breast, BCRP 
concentrates drugs, carcinogens, and toxins into milk.[69, 70] This behavior stands in sharp contrast to 
its detoxifying function in other organs, for example in the placenta, where it transports noxious 
substances against a concentration gradient from fetal to maternal circulation (Section 3.2.1.4). 
Herwaarden and co-worker suspected that toxin accumulation in breast milk is most likely due to a 
usurped physiological mechanism. BCRP might serve to concentrate vitamins and nutrients in breast 
milk as secretion of Riboflavin (Vitamin B2) by BCRP has been shown.[71] 
 
                                                      
11 The nursing rate in developing countries is presumably even much higher. 
12 An increased vulnerability to psychiatric conditions (e.g., depression)[59] and treatment re-uptake after pregnancy leads to a 
high incidence of drug prescriptions in breastfeeding mothers. 
13 Consequently, manufacturers’ information on drugs is often overly cautious due to lacking experimental experience. Hence, 
mothers are often advised to stop nursing rather than to risk drug exposure for the baby.[60]  
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The probability of adverse events from accidental drug intake via maternal milk might rise with 
increasing exposure (e.g., accumulation), but toxicity of a compound also depends significantly on drug 
clearance of the infant. To link milk plasma/serum ratios (MP) with infant drug clearance and milk 
intake a simplified "Exposure Index" has been proposed by Ito and co-workers:  
 
 
 
where A is a coefficient (10ml/kg/min), M/P ratio is the milk plasma ratio, and Clearance is the drug 
clearance of the infant expressed as ml / kg / min. [72] Infantile drug clearance depends highly on renal 
and hepatic metabolism and excretion. Characteristically, the glomerular filtration rate of a newborn 
achieves adult values 3-5 months after birth, while tubular secretion rate matures more slowly, 
accounting for prolonged elimination half-lives.[73] Expression of drug efflux transporters on liver and 
gut wall, such as P-gp and BCRP might be highly subjected to individual development.[74] Estimating 
drug clearance in infants is therefore a difficult undertaking. 
 
3.2.1.4 Placenta barrier 
The physiological function of the placenta is the exchange of gas, import of nutrients as well as export 
of fetal waste products. Moreover, it has a protective function as it saves the fetus from toxic 
compounds from maternal circulation. In contrast to former beliefs, the placenta barrier does not 
mandatorily protect against harmful drug exposure, as the Thalidomide scandal in the 1950s 
impressively demonstrated.[75]  
 
In the placenta, the main diffusion barrier is mediated by the fetal syncytiotrophoblasts, which directly 
invade the uterine wall. The predominant mechanism of molecule exchange is transcellular diffusion 
(Section 3.2.1.1). Active transport mechanisms support passive permeation of glucose, peptides, and 
other vital molecules (Section 3.2.3). ABC transporters like BCRP and P-gp are strongly expressed 
and mediate efflux on the syncytiotrophoblasts.[76] 
 
3.2.2 Metabolism 
Once absorbed, drugs are transported via the portal venous system into the liver, where hepatocytes 
absorb and modify molecules to increase water-solubility. Drug uptake on level of hepatocytes 
happens mostly against concentration gradients and is facilitated by a multitude of transport proteins 
(Section 3.2.3). After modification, drugs are either eliminated (via bile) or re-circulate into systemic 
blood flow and are distributed in the body. 
 
The compulsory shunting of intestinally absorbed molecules to the liver accomplishes two important 
tasks. Nutrients, such as fats or sugars, are modified and/or stored and noxious substances can be 
removed from circulation before they are distributed in the body. The liver exhibits the capability of 
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eliminating drugs completely in the first passage from portal venous circulation. Hence, hepatic first 
pass metabolism can influence bioavailability considerably.  
 
Metabolic modification can also lead to activation of drugs. This principle is exploited by pro-drugs. 
While the administered compound is inactive, the drug is activated by biotransformation in the liver. 
This strategy was applied to improve absorption of the drug oseltamivir, where the active ingredient 
(oseltamivir carboxylate) exhibits poor intestinal absorption capacity. By methylation the drug becomes 
absorbable orally and is almost completely hydroxylized in the liver to its active component.[77] Pro-
drugs can also be used to enforce oral application, e.g., to avoid i.v. drug abuse.14 
 
To reach the site of metabolism substances have to be efficiently transported into the hepatocyte. 
Principally, the same active and passive transport mechanisms are involved as in enterocytes (Figure 
4).  
 
Figure 4 - Schematic view of transport proteins on hepatocytes. Organic anion transporting polypeptide 
OATP1B1 mediates influx of substrates into the cells. After metabolic modification, compounds are 
either excreted apically into the bile canaliculi (A) or transported back into circulation (B) for renal 
excretion or/and systemic distribution. In the hepatocyte, P-glycoprotein (P-gp), breast cancer 
resistance protein (BCRP) and multidrug resistance protein 2 (MRP2) mediate apical export. Multidrug 
resistance protein 3 (MRP3) and 4 (MRP4) transport substrates back into the blood flow. 
 
Transport proteins are of particular importance in hepatic clearance. They enhance biotransformation 
by facilitating uptake into hepatocytes, where molecules encounter metabolizing enzymes (Section 
3.2.2). They also mediate clearance by increasing the efflux of metabolites into the bile canaliculi or 
back into the blood stream. Single transport proteins are discussed in Section 3.2.3.  
                                                      
14 Valorone N is a mixture of the opiate tilidine and the opioid antagonist naloxone. It is claimed that due to naloxone’s high first 
pass metabolism, oral administration is mandatory to experience a pharmacological effect of tilidine. When applied 
intravenously, naloxon becomes systemically available and antagonizes the effects of tilidine.  
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3.2.2.1 Sites of metabolism 
Although, the majority part of metabolism takes place in the liver, metabolic enzymes are practically 
ubiquitarily expressed and contribute substantially to modification and excretion of nutrients and 
xenobiotics.  
 
Intestinal metabolism can affect drug absorption. On the other hand, several drugs and nutrients (e.g., 
green tea extract or hypericum) can induce intestinal metabolic enzymes, such as CYP 450. [78, 79] In 
the brain, glial cells and neurons express metabolic enzymes and there is further evidence that also 
brain endothelial cells have a metabolic function, at least in disease.[80-83] The list could be 
continuously elongated. However, the wide spread presence of metabolic enzymes underlines their 
impact on both the maintenance of homeostasis and also drug excretion.  
 
3.2.2.2 Molecular mechanisms of metabolism 
Metabolism is usually a two-step process, which has not necessarily to occur in sequence. The first 
reaction is characterized by modification of molecular structures by oxidation, hydroxylation, or 
reduction. Step two-reactions are usually additions (conjugations) of polar groups, such as glucuronic 
acid, amino acids, or glutathione, which increase hydrophilicity. A compound does not mandatorily 
need to undergo step one before step two, if it already has a functional group qualifying for 
conjugation. 
 
The most prominent phase I enzymes are monooxygenases which include the CYP450 family. They 
are localized on the endoplasmic reticulum and abundantly expressed in hepatocytes. CYPs are also 
found in the intestine, colon, lung, brain, and skin.[84, 85] Several members of the CYP protein family 
show polymorphisms, which led to unexpected pharmacokinetics of substrate drugs in certain 
populations.[86, 87] Numerous drugs and herbal preparations are inducers of CYP and complicate 
drug therapy considerably. [88] 
 
Uridine 5'-diphospho-glucuronosyltransferases (UGT)15 play the predominant role in phase two of 
metabolism. Substrate molecules are conjugated to either a glucuronic acid moiety, a hydroxyl 
carboxylic acid or an amine group. Glucuronisation increases water solubility and hence eases renal 
and biliary elimination. Some hereditary diseases are connected with UGT abnormalities or 
deficiencies, such as Gilbert-Meulengracht Syndrome16 and Crigler-Najjar17 Syndrome. 
                                                      
15 UGT is expressed practically in all animals and plants, except in cats (genus felis), where it accounts for a series of unusual 
toxicities.[89]  
16 Gilbert-Meulengracht Syndrome is characterized by a mild hyperbilirubinemia and is found in approx. 5% of the population. 
The disease is caused by a reduced activity of UGT1A1. Substrate drugs show an increased toxicity in these patients (e.g., 
Irinotecan). However phenobarbital can induce and restore activity of UGT1A1.  
17 Crigler-Najjar Syndrome is a very rare autosomal recessive disease. Type 1 is characterized by sever non-hemolytic 
hyperbilirubinemia caused by a complete lack of UGT1A1. Untreated, the hyperbilirbunemia leads to severe brain damage or 
even death. In Type 2, disease is less severe, as UGT1A1 expression is reduced and not completely abolished.  
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Besides UGT, sulfotransferase, glutathion-S-transferase, and N-acetyltransferase catalyze phase II 
metabolism, conjugating sulfate groups, glutathion, and amines, respectively. After conjugation, 
compounds are subjected either to excretion in the bile or to recirculation into the systemic blood flow 
for renal clearance. 
 
3.2.3 Active Transport across membranes 
Transport proteins have specified substrates and exploit individual transport mechanisms. Some 
transport their substrates along the concentration gradient (facilitated diffusion) while others use 
energy to overcome this gradient actively.[90] In contrast to passive diffusion, these active transport 
processes exhibit saturation kinetics (Figure 5). 
 
Principally speaking, transport occurs when the drug contains a moiety that is similar to transporters 
natural substrate or if it has structural elements that facilitate binding to the transport protein (e.g., P-
gp). Transporters affect absorption, distribution and toxicity properties in various ways, which have to 
be considered in drug development. 
 
For certain drugs, an enhanced intestinal absorption can be observed, despite unfavorable 
physicochemical properties.[50] Examples of these drugs are peptidomimetics, like beta-lactam 
antibiotics or ACE inhibitors, and anti-viral, and anti-cancer, drugs which are transported via PEPT1. 
[91-93] Inversely, some molecules are badly or not absorbed (e.g., anti-cancer drugs) due to efflux 
transporters.[94] They can oppose distribution or enhance elimination.  Competitive inhibition as well 
as induction of transporters can additionally modify pharmacokinetics.[95]  
 
 
 
Figure 5 - Diagram of active (dashed line) and passive transport (continuous line) kinetics. Active 
transport is characterized by an increased uptake until all transporters operate at full capacity, i.e. are 
saturated. Transport rates are stabilized regardless of excess substrate. Passive diffusion shows a 
linear kinetics, which continuously increases with increasing concentrations. 
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Owing to the finite number of transport proteins on the cell surface, active transport can be saturated if 
substrate is available in sufficiently high concentrations. The flux of molecules increases until the 
maximum capacity of the transport proteins is reached. Above this level the flux does not increase. 
This effect is not seen in passive diffusion, which exhibits linear and not saturation kinetics (Figure 5).18 
Transporters are found at barrier membranes throughout the body. Some of the most important ones 
shall be discussed in more detail.  
 
3.2.3.1 ABC transport proteins 
P-Glycoprotein (P-gp, ABCB1) is probably the best-characterized member of the ABC transporter 
super family. It is an ATP-dependent drug efflux pump exhibiting broad substrate specificity.[96, 97] P-
gp exhibits 12 trans-membrane domains (Figure 6). To undergo transport, substrates have to attach to 
the binding domains of P-gp, of which one appears to be within the cellular membrane. By 
hydrolyzation of two ATP molecules on the ATP binding regions, P-gp changes conformation, opening 
a pathway for the substrate to be extruded into the extracellular fluid.[90, 98] 
 
 
Figure 6 - Schematic view of P-glycoprotein, with typical 12 trans-membrane domains. The ATP-
binding sites are indicated by dark grey boxes (A1 and A2). 
 
P-gp was discovered, as decreased drug concentrations and a consecutive multidrug-resistance in 
tumor cells was observed.[96] It has a protective and excretory function in physiological tissues, and is 
abundantly expressed on several barriers. Thierbaut and co-workers demonstrated the expression of 
the transporter on the apical side of enterocytes, hepatocytes, brain endothelial cells, and the proximal 
tubule of the kidney. [99]  
 
P-gp exhibits broad substrate specificity and can substantially influence pharmacokinetics in clinically 
                                                      
18 This holds in the case of stable concentration gradients. 
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relevant manner.19 In the intestine it reduces or abolishes uptake of substrates, whereas it enhances in 
the liver and kidney clearance of substrates into bile and urine, respectively.[90] Schinkel and co-
workers reconfirmed its relevance in drug transport as they found significantly elevated substrate levels 
in P-gp deficient mice. [98, 102, 103]20 
 
P-gp plays a detrimental role in supporting cellular barriers such as the BBB or placenta barrier. 
Recent reports even indicate P-gp expression on the mammary gland epithelium. [104, 105] The 
intentional application of P-gp inhibitors as a "chemo-sensitizer" in order to enhance efficacy of drugs 
or to reduce the active component in a single dose was recently discussed.[106-108] Although 
tempting, this approach might harbor risks. Inhibition of this transporter, which is expressed in many 
tissues might corrupt its protective function in other organs as well, e.g., the BBB (Section 3.2.1.2), 
potentially leading to acute intoxication by overdose.  
 
Breast cancer resistance protein (BRCP, ABCG2) was identified from chemotherapeutically resistant 
breast cancer cells.[109] It is a "half" ABC transporter as it exhibits only six trans-membrane 
domains.[110] Physiologically, BCRP shows high expression levels in the gastro intestinal tract, liver, 
kidney, brain endothelium, mammary gland and the reproductive organs.[111] Physiologically, BCRP 
contributes to efflux of porphyrines and shares many substrates with P-gp. As both transporters are 
often found in co-localization and show a broad substrate overlap, it was suspected that they work in a 
concerted manner. Gastrointestinally expressed, it limits absorption of its substrates, such as 
sulfasalazil.[112] In reproductive organs, BCRP safeguards sensitive tissues from noxious agents. 
Additionally, the transporter is found on the apical membrane of the hepatocytes, where it mediates 
together with P-gp and MRP2 excretion.[90] BCRP substrates comprise antiviral drugs (e.g., 
zidovudine), statins (e.g., rosuvastatin), antibiotics (e.g., ciprofloxacin), and calcium channel blockers 
(e.g., azidopine).[111, 113] The extraordinary role of BCRP in the lactating breast is discussed in 
Section 3.2.1.3. 
 
The multidrug resistance proteins (MRPs, ABCC family) share less than 15% amino acid identity with 
other members of the ABC transport protein family. The similarity resides almost exclusively with the 
nucleotide biding domains. MRPs are primary active transporters and mediate the ATP-dependent 
unidirectional transport of lipophilic substances conjugated with glutathione, glucuronate, or sulfate and 
conjugated and unconjugated amphiphilic anions. The expression of MRPs was first described in the 
doxorubicin selected lung cancer cell line H69AR, which showed resistance to many chemotherapeutic 
agents.[114] Their expression was thereafter confirmed for a broad range of human tumors and 
various healthy human tissues.[115] The family of the MRPs consists of at least six members, of which 
MRP3 (ABCC3) and MRP4 (ABCC4) have a certain role in disposition, and the apically localized 
                                                      
19 When rifampicin, a potent inducer of P-gp, is coadministered with digoxin, a P-gp substrate, the absorption ratio of digoxin was 
significantly reduced.[100] The inverse effect was observed when quinidin, an inhibitor, is given instead of rifampicin. Serum 
levels of digoxin increased up to two- and threefold in healthy subjects.[101]  
20 In fact, serum levels of P-gp substrate ivermectin were 20 times higher than in wild type animals. 
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MRP2 (ABCC2; also known as cMRP or cMOAT) is suspected to have emerging clinical importance. 
[90, 116, 117] MRP2 is strongly expressed on the apical canalicular membrane of hepatocytes, where 
it promotes biliary efflux of glucuronides, sulfates, glutathion, and amphiphilic organic anions.[118] 
However, MRP2 is also found on apical membranes, on the proximal tubules of the kidney, in the 
intestine, as well as on the placenta, and in the lung.[119-121] It is often co-localized with phase two 
metabolism enzymes (e.g., UGT), which produce some of MRP2's substrates.[122] Moreover, it was 
shown that vectorial transport in MRP2 transfected cells happened only in presence of influx 
transporters, such OATPs, which indicates that MRP2 might mediate drug interaction in coordination 
with influx transporters and metabolism.[123-125] MRP2's presence on the human BBB is debated.[90] 
However, its overexpression was associated with phenytoin resistant epilepsy in rats.[126, 127] 
 
Physiologically, the transport protein plays an important role, as its localization on many apical 
membranes (e.g., in the liver or kidney) makes MRP2 the final elimination step for many drugs and 
xenobiotics.[128] Dysfunctional expression or inhibition of MRP2 can results in unusual toxicities, like 
the conjugated hyperbilirubinemia in Dubin-Johnson syndrome.[129]21 MRP2 can alter 
pharmacokinetic properties of anti-cancer drugs (e.g., methotrexate and mitoxantrone), antibiotics 
(e.g., ampicillin and rifampicin), angiotensin receptor antagonists (e.g., valsartan and olmesartan).[90, 
131, 132] The exact substrate binding sites and mechanisms leading to induction and inhibition are not 
yet completely elucidated.[133] Moreover, the controversial role of glutathion as transport stimulator 
and co-transported agent indicates the complexity of the process.[134, 135]   
 
3.2.3.2 PEPT1/2 
The tertiary active peptide influx transporter PEPT is expressed in two isoforms, PEPT1 and PEPT2. 
Both are expressed on the proximal tubule of the kidney, while PEPT1 is exclusively found on the 
apical membrane of enterocytes.[90] It typically recognizes di- and tripeptides, but not individual amino 
acids. Peptides are internalized against a concentration gradient in co-transport with a proton. In order 
to keep the intracellular proton concentration low, the Na+/H+-Exchanger protein 3 extrudes protons on 
the apical side in exchange with Na+-ions. A basolaterally located Na+/K+-ATPase maintains 
intracellular Na+ ion concentrations. PEPT transports not only peptides but also drugs, which resemble 
peptides. Peptide-like drugs, like beta-lactam antibiotics and ACE inhibitors are absorbed in higher 
concentrations, as their physicochemical properties would let expect.[91, 92] 22 
 
                                                      
21 The autosomal recessive Dubin-Johnson Syndrome exhibits a deficiency for MRP2 and is characterized by intermitting 
hyperbilirubinaemia. Though it seems that MRP3 may rescue the export of conjugates across the basolateral membrane. This 
was also reported for other conditions where the canalicular secretion of MRP2 substrates is impaired.[130].  
22 To improve unfavorable intestinal absorption, drugs can be linked to an amino acid rest to resemble peptide structure and 
become PEPT1 substrates. The pro-drug valacylovir achieved 50% better absorption ratios by conjunction to valin than to its un-
linked parent compound acyclovir.[136] Other successfully modified drugs are L-dopa (L-Dopa-L-Phe) and gangcyclovir 
(valgangyclovir).[137] 
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3.2.3.3 OATP 
Organic anion transporting polypeptides (OATP) are a family of influx transporters, which 
physiologically import conjugated and unconjugated bilirubin, bile acids, conjugated steroids, and 
thyroid hormones.[138-140] OATP1B1, OATP1B3, OATP2B1 are mainly expressed on the sinusoidal 
membrane of hepatocytes where they mediate substrate influx from the blood flow. [141] 
 
OATP1B1 is probably the best-characterized member of this family. It is difficult to estimate the role of 
OATP1B1 in drug-drug interaction in isolation as OATPs share many substrates with other transport 
proteins (e.g., MRP2) and metabolic enzymes.[142] However, several drugs are known to be 
transported by OATP1B1, such as statins, ACE inhibitors, and angiotensin II receptor antagonists. A 
typical substrate often used in experimental settings is the antihistamine fexofenadine.[141] A typical 
inhibitor of OATP1B1 is cyclosporine as its coadministration lead to increased statin levels.[143] OATP 
polymorphisms can cause marked differences in pharmacokinetics. A polymorphism of OATP1B1 lead 
to reduced substrate specificity of simvastatin, which increased the risk of drug induced 
myopathy.[144]23 
 
OATP1A2 is mostly located at the luminal membrane of small intestine and the BBB.[146] Its 
physiological and drug substrates resemble those of OATP1B1. Its uptake function can be inhibited by 
naringin found in grapefruit and orange juice.[147, 148] 
 
3.2.4 Ways to assess pharmacokinetics 
Assessment of pharmacokinetics is a complex and difficult endeavor as it becomes clear from the 
multitude of processes involved outlined above. In vitro models can give information on 
pharmacokinetics on the cellular level. In order to assess pharmacokinetics as a more realistic 
multistep process, animal models are usually needed, however, this has the significant disadvantage 
that testing compounds in vivo is expensive and time consuming. As nowadays, pharmaceutical 
companies harbor chemical libraries of millions of molecules, computational methods pose an 
economic and efficient alternative to screen for potential lead compounds. In silico methods can 
compress immense quantities of information in predictive models. By the mathematical projections of 
molecules they can reveal new mechanistic explanations of the process itself.   
                                                      
23 Interestingly, fluvastatin seems not to be affected by this polymorphism.[145] 
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3.3 QSAR, Quantitative Structure Activity Relationship 
3.3.1 Fundamentals 
The first attempts to relate chemical structure and biological action were taken in the mid-19th century 
in the field of toxicology. In 1863, Cros stated in his thesis a relationship of toxicity and water solubility 
of primary aliphatic alcohols.[149] He related pharmacological behavior to molecular properties, which 
in turn were determined by a compounds structure. Crum-Brown and Fraser refined this 
observation.[150] They stated that the physiological action of a molecule in a certain biological system 
(!) is a function (ƒ) of its chemical constitution (C): 
 
 
 
From this, they deduced, that an alteration in chemical constitution ("C) would be reflected in a change 
of biological activity ("!). 
 
3.3.1.1 Similarity principle 
A fundamental prerequisite for QSAR was the formulation of the similarity principle. It relates chemical 
structure to functional behavior, stating similar structures exhibit similar activity. In 1874, Körner 
proposed the first correlations between molecular structures and physicochemical properties.[151, 152] 
His work dealt with the ortho-, meta-, and para- derivatives of benzene. The different colors of the 
derivatives were related to the differences in chemical structure. The indication of ortho-, meta-, or 
para-substitution can be seen as the first molecular descriptor.24 
 
First quantitative property-activity studies (QSPR) in classical meaning where published in 1893 by 
Charles Richet. He correlated water solubility of ethanol, diethyl ether, urethan, paraldehyde, amyl 
alcohol and absinth extract with their lethal doses in dogs.[154] He stated, “plus ils sont solubles, 
moins ils sont toxiques”, the more water soluble, the less toxic compounds are. This was the first 
inverse linear relationship formulated of solubility and biological activity. 
 
At the turn of the century, several works correlated narcotic drug potential to water/oil partition 
coefficients, to molecular chain length, or to surface tension.[155-157]25 Louis Plack Hammett 
compared in 1938 dissociation rates of different benzoic acid derivatives with meta- and para- 
                                                      
24 A decade later, Mills found a relationship between structure and melting and boiling point of a homologous series of 
compounds.[153] 
25 Overton positively correlated narcotic potential of drugs with their solubility in olive oil. His observations were independently 
reconfirmed by Meyer and were put forward as the Meyer-Overton hypothesis. However, the thereof resulting lipid theories 
cannot explain receptor-mediated reactions. 
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substituents.[158] He observed that similar substitutions on different aromatic compounds resulted 
similar effects, which led him to deduced the seminal Hammett equation, which states 
 
 
 
where # is the reaction constant, depending solely on the reaction type, $ is the substituent constant 
depending on the substitute. K and K0 are the dissociation constants of two distinct molecules. In other 
words, the reaction depends solely on the reaction type and the substitute group. 
 
In the end of the 1940s, the first relationships of biological activities to theoretical numerical indices 
were drawn. Examples are the Wiener Index and the Platt Number derived from graph theory (Section 
4.2.3).[159-162] In the following decade, a multitude of features were derived from the graph theory, 
marking the beginning of systematic studies on molecular descriptors. 
 
In mid-1960s, Hansch and co-workers gave the quantitative structure activity/property relationship 
(QSAR/QSPR) approach its modern face, by publishing their pioneering work on structure activity 
relationships in plant growth regulators and their dependency on Hammett constants and 
hydrophobicity.[163] They determined a series of octanol-water partition coefficients (LogP) and 
introduced a new hydrophobic scale to characterize permeation of molecules through hydrophilic 
environments, such as blood or membranes. 
 
3.3.1.2 Dimensionality 
Dimensionality of QSAR models usually refers to the techniques and descriptors used to create them. 
In the beginnings of QSAR, activity was related to experimentally assessable parameters and those 
deducible from chemical notation, i.e., physicochemical properties. These features are usually referred 
to as one-dimensional (1D) descriptors (e.g., molecular weight).  
 
At the end of the 1960s, Free and Wilson proposed modeling biological responses on substitution 
effects on common molecular skeletons.[164] Additionally, introduction of graph theory lead to 
descriptors, which make statements on connectivity of molecules as a whole. The molecular graph is a 
two-dimensional representation of a compound and hence the thereof deduced descriptors are usually 
termed two-dimensional (2D) descriptors. 
 
The consideration of actual spatial distribution and geometry of a molecule led to three-dimensional 
(3D) descriptors. These are typically charged partial surface area (cPSA) introduced by Stanton and 
Jurs, and gravitational indices by Katritzky and co-workers.[165, 166] It was debated that the 
connection table holds enough implicit sterical information that effective use of 3D coordinates would 
not add much more geometrical information.[167]  
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The introduction of induced fit modeling expanded the dimensionality to four-dimensional (4D) and 
even higher dimensional levels. Although higher dimensional models hold in general more information, 
it was argued that increasing dimensionality does not mandatorily yield superior models.[168] 
Generally, the model should be suited to reflect the underlying data and to meet the demands of their 
application. There are completely different requirements on a database screening compared to a single 
molecule analysis using pharmacophores and computing conformational changes. For these reasons, 
the question on superiority of models cannot be finally answered. 
 
3.3.2 Applicability Domain 
Whether a QSAR model can establish an accurate and reliable prediction of an unseen structure, is 
determined by its applicability domain. It is defined as the information space a model has been 
generated on. The accurateness of predictions is only warranted within the scope of its applicability 
domain and this holds usually true for interpolation rather than for extrapolation. 
 
As no generally acknowledged measure for the applicability domain has jet been proposed, it is 
recommendable to describe it with the most relevant parameters, which are usually the 
(physicochemical) descriptors used to create the model. The molecules can be represented in the 
multi-dimensional space spanned by their descriptors and can be compared for structural similarity. 
However, the perception of similarity is subjective and a multitude of measures exist. Different 
endpoints require individual measures of similarity. Common similarity measures are summarized in 
Table 1. 
 
Similarity measure Notation 
Tanimoto coefficient  
Hamming distance  
Euclidian distance  
 
Table 1 - Three similarity measures and their formulas are given. I is the intersection of the samples A 
and B. 
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4 Materials and methods 
4.1 Molecular representation 
One of the most fundamental prerequisites for computational chemistry is the formulation and definition 
of an accurate and unique chemical structure representation. The seminal idea of applying a graph 
theoretical approach to molecular representations revolutionized chemistry.[169] One could deduce 
from a chemical structure a two-dimensional hydrogen depleted molecular graph, where atoms and 
bonds are represented by vertices and edges, respectively. The simplest chemical graphs do not 
discriminate higher ordinal bonds or atom types. This made application of mathematical operations 
from the field of graph theory possible for molecules. A multitude of molecular descriptors (Section 
4.2.3) and the SMILES representation for chemical structures (Section 4.1.1) are deduced from this 
pioneering idea.  
 
4.1.1 Simplified Molecular Input Line Entry System (SMILES) 
David Weininger defined in the late 1980s the SMILES concept that has become a standard through 
out computational chemistry. He proposed a string representation of molecules based on the chemical 
graph theory.[170, 171] Molecules are represented as ASCII string, which is human legible and easy to 
compute. While atoms are represented by their atomic symbols, branching points are indicated by 
parentheses and a numeric label indicates ring connection points. Lower case letters indicate 
aromaticity. Disconnected elements, such as salts, are indicated with a point (Table 2). 
 
SMILES notation Generic name Structure 
C Methane 
 
O Oxygen 
 
CC(=O)O Acetic acid 
 
C1CCCCC1 Cyclohexane 
 
c1ccccc1 Benzene 
 
[Na+].[Cl-] Sodium chloride  
 
Table 2 - Examples for SMILES notation, the corresponding generic names and three-dimensional 
structure are given.  
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If not specified, bonds are implicitly assumed to by single or aromatic bonds. Multiple bonds can be 
specified using the equality sign (=) and the number sign (#) for double and triple bonds, respectively. 
Table 3 gives an overview.  
 
SMILES notation Generic name Structure 
C-C-O (or simply CCO) Ethanol 
 
O=C=O Carbon dioxide  
C#N Cyanide 
 
 
Table 3 - Bond notation of SMILES notation is illustrated. 
 
4.1.2 SMILES Arbitrary Target Identification (SMARTS) 
Typically, chemical databases are screened for similarity regarding molecular structure or activity. An 
efficient way to find resembling molecules would be a substructure search, i.e., the formulation of a 
subgraph of the molecular representation. The subgraph can then be used as a search pattern. 
SMART language is closely related to the SMILES code and allows for efficient search query 
definition.[172] SMARTS is built on the SMILES language, but is extended with logical operators and 
wild cards for bond or atom types. Some examples are given in Table 4. Equipped with these 
additional features, SMARTS language is a very efficient way to specify sensible search queries. 
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SMARTS Short explanation Example 1 Example 2 
[#6]~[#6] 
Two carbon atoms (atom 
No. six) connected by any 
bond 
 
 
[a] Any aromatic atom 
  
[!c] Not a aromatic carbon 
  
[O]~[*] Any atom connected by 
any bond to oxygen 
 
 
 
Table 4 - A selection of SMARTS expressions and a short explanation is given. Additionally, two 
example structures are shown, which fulfill the corresponding SMARTS query.  
 
4.1.3 Fingerprints 
Fingerprints represent structural information on a compound as a feature vector and were initially 
intended for similarity or substructure search. The feature vector does not necessarily hold information 
in numerical form and can represent structural features also as a bit vector, where every bit codes for 
presence or absence of a chemical substructure. This is especially advantageous when large 
databases have to be screened for similarity. Once all fingerprints have been computed for a set of 
molecules, overlaps of bits can be compared in order to prescreen for similar fragments. 
 
Which chemical substructures or properties are used to describe the molecules depends on the type of 
fingerprint used. Therefore, the vectors may also substantially vary in length. They range from 3D 
pharmacophore keys, which can be exceedingly extended, over fixed length 2D fingerprints, hashing 
connectivity patterns or chemical fragments to 1D features. Extended connectivity fingerprints were 
designed to explicitly consider features relevant for molecular activity and capture the local atomic 
neighborhood.[173] Another set of broadly used fingerprints are the fixed length 166 bit MACCS keys. 
Initially defined by the company MDL,26 these fingerprints are most commonly used binary fragment-
based keys.[174] All bits in the set represent a predefined set of chemical fragments (e.g., a aromatic 
ring structure or double bound oxygen) represented as SMARTS strings, which can either be present 
                                                      
26 The company MDL (now known as Symyx, which has merged with the company Accelrys) also developed the MDL mol file, a 
standard chemical file format. 
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(bit set to ON) or not (bit set to OFF). In order to compare the ability of fingerprints to describe a 
dataset, one could use the so-called "fingerprint darkness". This concept refers to the fraction of bits 
set to ON in a binary vector. It is obvious that the more features a fingerprint captures the more 
discriminatory power it has.  
 
4.2 Descriptors 
Descriptors are probably best explained as mathematical representation of chemical properties. When 
applied in QSAR, they desirably help to identify molecules with comparable activity but at as high 
structural diversity as possible.27 This conflicting situation might be a reason that we are in a 
continuous search for new molecular representations. In the following section, we will discuss some of 
the most widely used descriptors. 
 
4.2.1 Constitutional descriptors 
Constitutional descriptors are features that reflect molecular composition without any geometrical or 
topological information. In the early days of QSAR, some of these features were manually determined 
for a set of compounds but nowadays it is general practice to compute these features, which holds the 
advantage of not underlying experimental variation.  
 
4.2.1.1 Atom count descriptors 
Count descriptors are a relatively simple way to get information on molecular constitution. Atom 
numbers (or atom count) is the simplest measure for molecular size. Usually only non-hydrogen atoms 
are counted. The information index on size (Isize) can be derived thereof, which gives the total 
information content on atom counts. The formula is adapted from [175] 
 
 
 
where the atom count A can also take hydrogen atoms into account, depending on its definition. Other 
count descriptors assess the contribution of heteroatoms (heteroatom count) or functional groups, like 
hydrogen bond donors and acceptors (Section 4.2.2.1). 
 
4.2.1.2 Bond count descriptors  
Bond number or edge counting refers to the simplest graph invariant of the molecular graph where also 
multiple bonds are considered as single edges. As a result it does not discriminate chemically non-
equivalent groups. If information on molecular saturation is desired from the set of constitutional 
descriptors, double-, triple-, or aromatic-bond counts can be considered. Bakken and Jurs proposed 
the multiple carbon bond index to assess carbon bonds by their simple addition.[176] Another 
                                                      
27 Favorably, descriptors should be easily computable and not underlie experimental variation. 
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constitutional measures for unsaturation is the multiple bond count (b*), which was expressed by [175] 
as 
 
 
where B represents all bonds in the molecule and !* is the conventional bond order. 28 
 
4.2.1.3 Rotatable bonds count 
Rotatable bonds count is the sum of bonds, which can freely rotate around themselves, giving 
indications on molecular flexibility. A rotatable bond is typically a single bond between two non-terminal 
heavy atoms.29, 30 Moreover, they should not be part of a ring structure. However, potentially rotatable 
bonds like hydroxyl or methyl groups are often not included in calculations. Several QSAR studies 
imply that molecular flexibility is an important feature to describe interactions with biological 
targets.[177-179] 
 
4.2.1.4 Molecular weight 
Molecular weight (MW) is probably the simplest measure of molecular size. In contrast to simple atom 
or bond count descriptors the feature holds information on atom types. It is easily calculated by 
summing up the individual atomic weights of the compound, which is expressed as  
 
 
 
where i runs over all atoms (A) in the molecule and m is the atomic mass. The formula is adapted from 
[175]. Molecular weight is despite its simple calculation a fundamental parameter to describe biological 
and pharmacological behavior of compounds, as size plays a crucial role in permeation capacity and 
passive diffusion. Several rules of thumb use molecular weight to determine drug absorption and 
permeation (Section 3.2.1.1 and 3.2.1.2). 
 
                                                      
28 Note that for saturated molecules, b* = 0. 
29 Non-terminal can also designate, in this context, a heteroatom connected to hydrogen. 
30 This bond should not be a triple bond, unless it is connected to another atom. 
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4.2.1.5 Partition coefficient (LogP) 
The partition coefficient P measures the distribution of a compound between a hydrophobic and an 
aqueous phase.31 It is probably the oldest and most widely used measure for lipophilicity. For easier 
handling, in place of P, its decadic logarithm LogP is commonly used.  
 
Lipophilicity substantially influences a compound's distribution within the body. Hydrophobic 
compounds will eagerly permeate through lipid bilayers and enrich in lipidic environments (e.g., CNS), 
while their hydrophilic counterparts will distribute in aqueous compartments (e.g., blood serum).  
Several computational methods were proposed to calculate LogP. The most widely used ones are 
atom-centered (aLogP, xLogP) and fragment centered approaches (cLogP). 
 
Moriguchi proposed a very generalized method to assess partition coefficients computationally 
(xLogP).[180] He proposed a regression analysis, where 13 structural elements of each molecule are 
determined and weighed in an equation. Ghose and co-workers introduced an atom-centered method, 
which considers the lipophilic contribution of each atom in dependence of immediate atomic 
neighborhood (aLogP).[181, 182] Both methods can be applied to a wide spectrum of molecules 
regardless of their complexity but in certain cases at the expense of accuracy. However, it can be 
helpful to get a rough estimate at very low computational expense.  
 
The hydrophobic fragmental constants proposed by Leo and Hansch are probably the most accurate 
way of determining LogP values.[183] Non-overlapping fragments are generated by a simple set of 
rules, and their fundamental hydrophobic constants are determined. For simple compounds only 
containing one functional group this method is very accurate. For more complex structures, containing 
more than one functional group, correction factors were derived to improve LogP prediction.32 Its 
computational implementation by Chou and Jurs became known as the calculated LogP (cLogP).[184] 
 
4.2.2 Electronic Descriptors 
Distribution and amount of a molecule's electricity is fundamental for its reactivity and behavior in 
chemical and biological systems. 
 
4.2.2.1 Hydrogen bonding descriptors 
Hydrogen bonding can be described as a dipol-dipol interaction between a hydrogen atom and 
electronegative atoms, which are usually constituted by oxygen, nitrogen or fluorine. Although 
hydrogen bonds are not as strong as covalent binding, they are still stronger than van der Waals 
interactions.  
                                                      
31 The lipid phase has changed over time from olive oil to octanol and n-alkanes.  
32 This extensive list of fragments and correction factors holds information on proximity effects, hydrogen bonding, branching and 
many more.  
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However, the strength and distance of the bond depends on the kind of electronegative atom 
involved.33 
 
Hydrogen bonds occur when strong positive molecular charge attracts a lone pair of electrons on a 
heteroatom. Generally, we designate a heteroatom with covalently bound hydrogen as a hydrogen 
bond donor. A heteroatom with a lone pair of electrons is termed hydrogen bond acceptor. However, a 
hydrogen bond donor can also accept hydrogen bonds and vice versa. Carbon can principally also 
participate in hydrogen bonding, if it is bound to an electronegative atom which decentralizes the 
electron cloud, leaving the molecule with a positive partial charge. 
 
In a pharmacological context, a compound with strong hydrogen bonding capacity shows reduced 
permeation capacity. In order to permeate lipidic membranes hydrogen bonds have to be broken from 
the watery phase of e.g., blood serum, which is an energy-consuming step. This fact found reflection in 
several rules of thumb. For example, Lipinski’s Rule of Five generally associates high hydrogen donor 
and acceptor counts with bad "drug-ability" and brain permeation. Notably, the number of hydrogen 
bond donors is considered to be more detrimental for brain penetration than the number of hydrogen 
bond acceptors.[186, 187]  
 
4.2.2.2 Charged partial surface area 
Stanton and Jurs introduced charged partial surface area (cPSA), which describes the distribution of 
charge on the molecular surface. In this way, the descriptors consider features responsible for polar 
interaction between molecules. The molecular surface was defined as the overlap of the atomic van 
der Waals radii, which is traced by a sphere, representing a solvent molecule.[165] The molecular 
electron distribution is then projected on this accessible surface area.[188] Stanton and Jurs derived 
25 descriptors that combined the solvent accessible surface with partial atomic charge. Table 5 
summarizes the descriptors as they are implemented in the Chemical Development Kit (CDK) (Section 
4.6.3).[189] 
                                                      
33 The bond strength varies between 155 kJ/mol of fluorine bound hydrogen to fluorine and 8kJ/mol of nitrogen bound hydrogen 
to oxygen.[185] 
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Descriptor Summary 
pPSA1, pNSA1 Partial positive and negative surface area  
pPSA2, pNSA2 Partial positive and negative surface area multiplied by the total 
positive charge on the molecule  
pPSA3, pNSA3 Charge weighted partial positive and negative surface area 
dPSA1 Difference of pPSA-1 and pNSA-1 
dPSA2 Difference of fPSA-2 and pNSA-2 
dPSA3 Difference of pPSA-3 and pNSA-3 
fPSA1, fPSA2, fPSA3 pPSA1, pPSA2, pPSA3 / total molecular surface area 
fNSA1, fNSA2, fNSA3 pNSA1, pNSA2, pNSA3 /total molecular surface area 
wPSA1, wPSA2, wPSA3 pPSA1, pPSA2, pPSA3 multiplied by total surface area, divided 
by 1000 
wNSA1, wNSA2, wNSA3 pNSA1, pNSA2, pNSA3 multiplied by total surface area, divided 
by 1000 
rPCG, rNCG Relative positive and negative charge 
rPCS, rNCS Relative positive and negative charged surface area  
tHSA Sum of solvent surface area atoms with partial charge less than 
0.2 
rHSA tHSA / total molecular surface area 
 
Table 5 - Listing of cPSA descriptors as they are implemented in the Chemical Development Kit (CDK).  
 
In 2000, Ertl and co-workers proposed a fragment-based method to assess PSA, called TPSA. Single 
polar fragments are summed up to calculate surface contribution.[190] There exist two options for 
TPSA computation. The first variant considers only strongly polarizing fragments, which contain 
nitrogen and oxygen groups (TPSA[NO]). The second option considers additionally weak polarizing 
fragments like sulfur and phosphorus (TPSA[tot]).[175]  
 
The topological method (TPSA) may be superior to conventional cPSA calculations regarding 
computation time,34 and in addition, one does not require a 3D molecular geometry as it relies on a set 
of predefined polar features. However, a discrimination of positive and negative charge is not 
performed by TPSA, which reduces its information content. Moreover, its applicability for higher 
                                                      
34 Ertl stated a two to three order of magnitude decrease in computation time. 
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molecular structures such as antibodies or proteins remains questionable, as in the initial study 
exclusively small molecules and drug-like structures were considered.35 
 
4.2.3 Topological descriptors 
Topological or connectivity descriptors are derived from the molecular graph. Topological indices are 
typically graph invariants, which means that they are not conformation or representation sensitive. 
Weighting schemes for edges or vertices can add additional information. 
 
4.2.3.1 Adjacency matrix 
The adjacency matrix is a fundamental graph theoretical matrix. It considers the immediate neighbor 
hood of single atoms in a molecule, i.e., whether two vertices are connected by an edge or not. The 
matrix entries equal one (1), if two vertices are connected and zero (0) if they are not. 
 
Figure 7 - Atom numbering of 2-Methylpenthane and corresponding molecular graph is shown. 
 
Although the symmetric adjacency matrix (Table 6) does not account for multiple bonds, this 
information can be introduced by adding weighting schemes. From the adjacency matrix, we can 
derive the vertex degree (%) by adding up each row.[175]  
                                                      
35 Accessibility of polar substructures could be reduced due to folding effects. 
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Atom 1 2 3 4 5 6 %  
1 0 1 0 0 0 0 1 
2 1 0 1 0 0 1 3 
3 0 1 0 1 0 0 2 
4 0 0 1 0 1 0 2 
5 0 0 0 1 0 0 1 
6 0 1 0 0 0 0 1 
 
Table 6 - Adjacency matrix with corresponding vertex degree (") is given for the molecule shown in 
Figure 7. 
 
From the adjacency matrix, path counts can be derived, where the path from the vertex i is counted to 
any other vertex in the graph. The path order is defined as the length of the path. 
 
4.2.3.2 Weighted matrices 
The principle of an augmented adjacency matrix was proposed by Randic.[191-193] He replaced zero 
values from the symmetry axis of the adjacency matrix by characteristic values for atom types in the 
molecule (e.g., physicochemical properties). Its vertex degree is analogously called augmented vertex 
degree.  
 
The Burden matrix (Table 7) and its eigenvalues were proposed by Burden in 1989.[194] In analogy to 
the augmented adjacency matrix, the Burden matrix replaces the diagonal zeros by atomic numbers of 
the corresponding atoms. The edges are weighted by their corresponding bond order, taking also 
aromaticity into account. 
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Atom 1 2 3 4 5 6 %  
1 6 0.11 0 0 0 0 6.11 
2 0.11 6 0.1 0 0 0.11 6.23 
3 0 0.1 6 0.1 0 0 6.2 
4 0 0 0.1 6 0.11 0 6.21 
5 0 0 0 0.11 6 0.01 6.12 
6 0 0.11 0 0 0.01 6 6.22 
 
Table 7 - The Burden matrix is given for the molecule depicted in Figure 7. Here, diagonal elements 
are the atomic numbers (i.e., carbon). If atoms are connected, conventional bond order is put into the 
matrix (i.e., 0.1 for single bonds, 0.2 for double bond, 0.3 for triple bonds and 0.15 for aromatic bonds). 
Terminal bonds are augmented by 0.01. 
 
A popular extension of the Burden matrix are the eigenvalue-based BCUTS descriptors, where 
diagonal elements are replaced by varying weights.[195] 
 
4.2.3.3 Kappa shape indices  
Kier proposed in 1985 and 1986 the kappa shape indices &, which relate the hydrogen depleted 
chemical graph (Pi) to a minimally (Pmin) and a maximally (Pmax) connected reference graphs in a way 
that their relationship holds as follows[196]: 
 
 
 
By putting the chemical graph in relation to different reference graphs, Kier proposed three kappa 
indices, which give information on different aspects of molecular shape. For the &1 index, the minimal 
graph was defined as the linear graph, while the maximum graph is the complete graph, where every 
vertex is connected to each other. The information rising form &1 is related to numbers of cycles in a 
molecule (Figure 8). 
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Figure 8 - For #1, the maximal and minimal graph (Pmax and Pmin ) are the complete and the linear 
graph, respectively. 
 
The &2 index measures spatial distribution of atoms in a molecule. Reference graph extremes are the 
linear and the star graph (Figure 9). 
 
 
Figure 9 - For #2, the maximal graph (Pmax) is the star graph, while the minimal one (Pmin) is the linear 
graph. 
 
The &3 index encodes information on centrality of molecular branching, as its values increase when 
molecules are not branching or only branching at their extremities. Upper limit is the twin star graph 
while the under limit is the linear graph (Figure 10). 
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Figure 10 - For #3, the maximal and minimal graph (Pmax and Pmin) are the twin star and the linear 
graph, respectively. 
 
4.2.4 Geometrical Descriptors 
Although geometrical descriptors differ in definition, they all deal with actual molecular spatial 
distribution and shape. Usually, 3D-coordinates are derived from computational force fields or from 
christallographic data. An example is the length over breadth descriptor, where maximum and 
minimum ratio of molecular length and breadth are considered. Other typical measures are 
gravitational indices, or the principal moments of inertia. 
 
4.2.4.1 Gravitational Index 
Gravitational indices give information on intramolecular mass distribution. In other words, they describe 
molecular density and cohesion. Molecules can be considered either with or without hydrogen atoms. 
Gravitational Indices four to six consider all atom pairs, regardless of whether they are bonded or not. 
Wessel and co-workers also proposed the use of the square and cubic root of the descriptors.[197] 
 
4.2.4.2 Principal moments of inertia 
Another way of quantifying mass distribution is the consideration of molecular rotational dynamics by 
the principal moments of inertia. According to Todeschini and co-workers the moment of inertia for any 
of the three principal axes X, Y, and Z is defined as 
 
 
 
A is the atom number of a molecule, i stands for the i-th atom in that molecule, while m is the atomic 
mass and r is the perpendicular distance to the considered axis.[175] Moment of inertia, calculated 
along the three principal axes as well as their ratios are used for modeling. 
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4.2.4.3 Radius of Gyration 
Closely related to moments of inertia is the radius of gyration (RG). The descriptor assesses the 
molecular compactness by relating atomic distance from the center of molecular mass to molecular 
weight. This can be formulated as follows, adapted from [198]  
 
 
 
Analogously to the formula of the moment of inertia, A is the atom number of a molecule, i stands for 
the i-th atom in the molecule, while m is the atomic mass and r is the perpendicular distance to the 
considered axis. Molecular weight is abbreviated as MW. 
 
4.2.4.4 Petitjean Shape Indices 
Petitjean proposed in 1992 the shape coefficient (I), which measures molecular anisotropy based on 
the graph theoretical approach. He used minimal (generalized radius [R]) and maximal (generalized 
diameter [D]) paths in the molecule and defined the following relationship:[199] 
 
 
 
He suggested that this index would correlate graph theoretical and geometrical shapes. Bath proposed 
the geometrical shape index by extending Petitjean’s principle. He applied the geometrical matrix 
instead of a graph theoretical one.[200] However, he relativized Petitjean's claims by his observation 
that there is only a low degree of correlation between these two measures. 
 
4.3 Machine learning paradigms 
4.3.1 Decision tree induction (DTI) 
Human learning is characterized by splitting problems into smaller sub-problems, in order to ease 
classification. This principle is mimicked by decision tree induction (DTI). The paradigm is efficient and 
powerful in solving even non-linearly separable problems. Moreover, the trees branches can be read 
as single rules, which eases practical implementation and their use to predict future instances. A tree 
grows by splitting data on its attributes (i.e., splitting criteria) in smaller subsets (Figure 11). This 
process is then recursively repeated on the subsets, until a certain degree of purity is achieved. This 
process is termed recursive partitioning. Tree growth is terminated, if either the leaves contain only one 
class (e.g., have reached perfect purity) or further splitting does not improve purity.  
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Figure 11 - A dummy decision tree of the famous Fisher's Iris data set is shown.[201] 
 
Concerns were raised, that DTI is highly vulnerable and unstable when no stratification is used in 
generating test and training sets.[202] Perturbing the training set would then cause significant changes 
in the predictor. To avoid such shortcomings, one could typically use y-scrambling, where endpoints 
are randomly perturbed. The model trained on such data can then be used to uncover randomly 
correlating features.  
 
4.3.1.1 Pruning  
The aim of pruning is to simplify the final tree and improve its predictivity by reducing overfitting and 
noise. Pruning generally replaces a node or a whole subtree with a leaf,36 sometimes at the expense of 
accuracy on the training set but for the sake of avoiding overfitting on unseen instances. The decision 
whether a node shall be replaced or not, could be made by comparing the error on the hold out data of 
the pruned and unpruned tree. If the error becomes smaller, the original tree will be pruned. Pruning 
can be applied during tree growth (forward pruning), which is advantageous as it would avoid time-
consuming subtrees growth for futile branches. However, post pruning considers the tree after its 
complete building. It offers the possibility to overcome situations, where single splitting attributes have 
less discriminatory power than the consecutive combination of them. In this case, the branch would 
have been prematurely terminated by forward pruning. Most DTI algorithms apply backward pruning. 
 
                                                      
36 In subtree raising, nodes are replaced with nodes below them.  
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4.3.1.2 Classification and regression tree (CART) 
Leo Breimann introduced in 1984 the classification and regression tree algorithm (CART). It produces 
binary trees, which can handle categorical and ordinal and continuous data. Depending on the data 
trained on, CART builds regression or classification trees. CART uses backward pruning.[203] For 
splitting criterion selection, CART maximizes Gini impurity.[204, 205] The Gini impurity (also called Gini 
coefficient) is a measure for curve deviation from chance line. It gives indications on the distance of a 
curve (e.g., ROC curve or a cumulative curve) to the chance line, which allows drawing conclusions on 
its slope or it's information content (Figure 12). 
 
 
 
Figure 12 - The curve illustrates the improvement of classification by splitting criteria added. The 
diagonal is the chance line or the line of no discrimination. A is the area under the curve, while A+B 
indicates the area under the chance line which equals 0.5. 
 
The diagonal line of the ROC area indicates the chance line or perfect equality in cumulative curves. 
The area under this curve equals 0.5. The Gini impurity can accordingly be formalized as  
 
 
 
where A stands for the area under the curve. This formulation is independent of the curve's deviation 
(i.e., concave or convex). The Gini impurity is scaled from 0 to 1, where 0 stands for total equality and 
the value 1 stands for perfect inequality. CART applies the coefficient to decide whether a criterion is 
worth splitting on. A good splitting criterion with high discriminatory power has preferably a value near 
1. This indicates that it has a very unequal distribution in the dataset, i.e., it will have a high 
discriminatory power.  
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4.3.1.3 Chi-squared automatic interaction detector (CHAID)  
CHAID is the oldest DTI paradigm, proposed in 1964 by Sonquist.[206] Typically, CHAID uses forward 
pruning, in contrast to most of the other DTI algorithms. Attributes for splitting are chosen by the chi-
square test. The chi square test rates which child node adds the most information to the tree. The null 
hypothesis states that there is no difference in information between child and parent node. With an 
increasing chi-square, the information a child node adds to the tree diverges from the null hypothesis, 
hence a real information gain exists. The node with highest chi-square, i.e., the feature that adds the 
maximum information compared to the parent is selected to split on. In contrast to CART, CHAID 
handles exclusively categorical data.  
 
4.3.1.4 Random Forests 
In 2001, Breimann and Cuttler introduced the principle of Random Forests (RF).[207] As the name 
implies, Random forests consist of multiple decision trees. Principally, any DTI paradigm can be use to 
create a random forest. Each tree is grown to maximal depth with a randomly composed subset of all 
available features and is not pruned.[208] The final prediction is yielded by a majority vote of all trees 
on the final classifier. Random forests were praised as outperforming many other machine learning 
paradigms and efficiently handling enormous data and feature sets. However, they are suspected to be 
susceptible to overfitting and noise.[209]37 
 
4.3.2 Artificial neural networks (ANN) 
The ANN paradigm is an abstraction of a biological network of neurons. Instances are represented as 
vectors containing their features.[210] Each feature is passed to one of the input neurons to which a 
weight is assigned. Based on these weights, input is passed to the output layer over a number of 
interspersed optional hidden layers. The output layer combines these signals to produce a result. 
Initially, weights are set to random values. As the network is repeatedly presented with training 
instances, these weights are adjusted so that the total output of the network approximates the 
observed endpoint values associated with the instances. 
 
4.3.3 Support vector machines (SVM) 
Support vector machines (SVM) were introduced by Cortes and Vapnik.[211] A major advantages of 
SVM are their low computational expanse, as they do not search for separating hyperplanes by 
considering all instances but only those data points which confine borders of classes. Moreover, the 
paradigm exhibits an extraordinary robustness concerning classification of noisy data as the separating 
"solution plane" is spanned with maximal distance to the class borders of the training set, thus allowing 
also correct classification of instances lying even nearer to the decision plane than instances from the 
original training set did. The output of the SVM is basically a plane equation, which is solved for new 
instances as either >1 or <-1, while for instances exactly on the plane it is 0. 
                                                      
37 Segal argued that Breiman used datasets for testing RF which could hardly be overfitted. 
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As SVM is in principle a linear paradigm, it could be considered useless in solving non-linear problems. 
However, in theory for any non-linear problem, a linear solution can be found by sufficient (some times 
up to infinite) up-transformation of the original feature space. It is evident, that such models would 
become difficult to computationally handle as well as they would increasingly suffer from an overfitting 
bias. To avoid unreasonably high dimensionalities of the feature space, kernel tricks are usually 
applied.[212] Kernels implicitly transform the feature space into an inner product space searching for 
meaningful linear solutions, which can then be computed without an explicit transformation of the 
original space. Common kernel functions include the polynomial kernel 
 
 
 
and the radial basis function (rbf) kernel.  
 
 
 
In SVM with rbf kernels, there are two learning meta-parameters that greatly influence performance 
(Cost [c] and gamma [']). Determining these parameters is an optimization task.  
 
4.3.4 Naive Bayes 
Thomas Bayes' (1702-1761) theorem was posthumously published and was to revolutionize the 
doctrine of probability.38 He stated that one could deduce the conditional probability Y given X (Y|X)39, 
when we know the unconditional (prior) probabilities of X and Y and of their conjunction, the conditional 
probability X given Y (X|Y). Then the following statement holds true 
 
 
 
Bayes' theories had a revival in the 1950's and proved especially useful in conjunction with Markov 
chain methods (Bayesian networks).[214, 215] Additionally, Naive Bayes are very robust against 
missing values: the probability ratios are based on the actual number of occurrence and not on the 
instance number. On the other hand, one must take care that none of the probabilities equals zero. 
This could be the case if a particular attribute or condition does not occur in conjunction with the other 
one. Hence, this particular fraction would equal zero and due to multiplications, the final estimate 
would have a zero occurrence. To avoid such shortcomings one should introduce an a priori probability 
to every case, also known as Laplace estimator. 
                                                      
38 It is thought that Thomas Bayes, an English mathematician and Presbyterian minister, did not publish his observations during 
his lifetime as he calculated a value of less than 1 for the probability of god's existence. In fact, Stephen D. Unwin used his 
theorem and calculated a probability of 67% that god exists.[213] 
39 (Y|X) is also called the posterior probability. 
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Naive Bayes presumes independence of prior probabilities. However, this precondition is rarely fulfilled 
by real world data. Therefore one could argue that such a simplified approach would produce rather 
over-optimistic classifiers. However, Naive Bayes predicted very strong on realistic data and frequently 
outperformed rather sophisticated machine learning paradigms (Section 5.1).[216, 217] Zhang 
discussed reasons and conditions under which this effectiveness cannot be accounted to overfitting. 
He stated, that if variable dependence is equally distributed between classes or is canceled out, Naive 
Bayes would produce reasonable results.[218] Another explanation was proposed by Domingos, who 
argued that Naive Bayes' performance is owed to the so-called zero-one loss function.[219] This 
function defines the error as the number of incorrectly allocated class labels to classified 
instances.[220] This means that Naive Bayes are still able to assign the correct class to an instance, 
although the exact probability estimate might be poor.[219] In accordance to Ockham’s Razor, simple 
solutions should be preferred to complicated ones and Naive Bayes is therefore an elegant technique 
worth considering. In fact, its intriguing clearness and its robustness to missing values makes it a good 
choice for machine learning. 
 
4.3.5 K-nearest neighbor  
The K-nearest neighbor (KNN) paradigm is a lazy learning paradigm. This means the classifier does 
not produce a model in advance but compares new instances at runtime with its known instance 
space, which is spanned by its instance database. New, unseen instances are assigned to the class of 
its immediate neighborhood.[221] The concept of neighborhood can be measured in various ways of 
which two are illustrated in Table 8. 
 
Distance measures Illustration Equation 
Euclidian distance 
 
 
Manhattan/city block 
distance40 
 
 
 
Table 8 - Euclidian distance and Manhattan or city block distance are illustrated. 
                                                      
40 Manhattan distance approaches Euclidian distance with increasing resolution.  
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4.3.6 LAZAR 
The LAZAR engine [222] is a lazy learning fragment-based predictor. Relevant fragments are 
determined by finding all linear fragments in the training dataset (without size limits) and removing 
those that are statistically insignificant (p<0.95) in the chi-square test. Remaining relevant fragments 
are used to determine activity-specific similarities of all compounds in the training set with a weighted 
Tanimoto index. LAZAR classifies unknown compounds with a modified k-nearest-neighbor (KNN) 
algorithm. 
 
4.3.7 Notes on lazy learning 
In contrast to methods which produce a model during the training period (i.e., eager learning methods), 
lazy learning paradigms compare unseen instances at runtime to their knowledgebase. Therefore, lazy 
classifiers do not use any information compression. This is an advantage, when new instances should 
be incorporated into the classifier: the paradigm can be easily extended by simply adding these new 
instances to the database. However, for the same reasons, lazy learning classifiers have a reduced 
portability compared to models produced by eager learning paradigms.  
 
4.4 Feature selection and optimization tasks 
Without reducing the abundance of descriptors we are able to generate, one runs the risk of detecting 
meaningless correlations with highly accurate predictions, i.e., overfitting models. The obvious solution 
is to propose a hypothesis of the relationships involved. This should be in fact the starting point of 
every statistical analysis of data. Ideally, we base feature selection on our mechanistic knowledge of 
the process which should be modeled. Once we have reduced the feature space, we could still end up 
with too many descriptors compared to the size of the dataset. Generally, we should adapt the feature 
number to the instance set size. For this purpose, a feature reduction algorithm could be helpful. These 
paradigms are designed to pick out the variables with low intercorrelation and strong explanatory 
power.  
 
Best first feature selection (BFS) searches the feature space for the best combination of samples, 
continuously expanding the feature set (or reducing it, depending on the direction of the search). 
Forward selection starts with comparing all features in isolation and selecting the best performing one, 
according to BFS's heuristic function. To this selected feature, one of the remaining features is 
combined and again tested, incrementally expanding the feature set. When no more improvement can 
be obtained by adding new features the search is terminated. Backward selection starts with the whole 
feature set, reducing it by one feature and testing whether the new set performs better. If this is the 
case, the set is decremented and tested again. The paradigm terminates the search if the result cannot 
be improved. Accordingly, backward search will generally end up with bigger features sets than 
forward selection.[223]  
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Feature selection is essentially an optimization problem, where we do aim to find a solution, but will not 
mandatorily end up with the best one.  At first glance, this might be disappointing; however, although 
available computing power is rapidly growing, there are many problems which are inherently non-
solvable in reasonable time. For these so-called nondeterministic polynomial problems (NP), the best 
solution cannot be found in on polynomial time. Although we cannot find the best solution, we still are 
capable of finding a reasonable solution by a heuristic optimization. Heuristic procedures are often 
more reliable and robust than searching for the best solution (Figure 13).41  
Figure 13 - A target function is shown. Solutions for the local maxima (C and B) are easier found and 
most likely more robust than the solution on the global maximum (A). Minor deviations of the target 
function from the global maximum can lead to a substantially decreased performance. If a solution is 
found on a plateau (B), the function will perform robustly even if deviations in the target function do 
occur. 
 
A typical example of an optimization problem which is NP-hard is the "traveling salesman"-problem: 
given a list of cities and their corresponding pairwise distance, the shortest tour has to be found, 
visiting every city only once (Figure 14). 
 
Figure 14 - An abstraction of the traveling salesman problem is shown. The agent (here an ant) has to 
visit every point only once, but using the shortest route. 
                                                      
41 E.g., in engineering, robust solutions are preferred to isolated global maxima as in real life applications deviations in 
parameters of the target function are often seen. 
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In recent years, the field of natural computing has produced intriguing heuristics for such optimization 
problems. Ant Colony Optimization (ACO), was introduced in the 1990s, where real world ants foraging 
behavior is simulated.[224] When real-world ants find a food source, they will return in a more or less 
direct way back to their colony, marking the path with a pheromone track, which should guide other 
ants to the same food source. Pheromones are subjected to evaporation, which will eventually lead to 
a preference for shorter paths as more and more ants will use the one, which exhibits the most 
pheromone. In this way, the colony exhibits a tendency to converge. Once convergence is reached, 
ants will be unlikely to explore other paths. This holds for virtual as well as for real-world ants: in the 
so-called "double bridge" experiment, an obstacle hinders direct access to a food source. The ants will 
nevertheless find a path around it and the path will then be reinforced. However, when the obstacle is 
removed, the ants will still follow the prior, and now suboptimal, path.42  
 
In ACO, ants are abstracted agents scurrying about a graph at random until finding a solution (a food 
source). Other ants explore the graph and weigh their choices of route by previously deposited 
pheromones. The optimization has been successfully applied to a fragment based feature selection 
task (Section 5.5). 
 
4.5 Quality measures 
4.5.1 Confusion matrix and derived metrics 
Results from classification can be represented as a contingency or confusion matrix (Table 9). Each 
row represents instances in a predicted class, while each column represents instances in the actual 
class. In this way, exact numbers of truly classified positives (TP), truly classified negatives (TN), 
falsely classified positives (FP) and falsely classified negatives (FN) are presented in tabular form.  
 
Table 9 - The confusion matrix is depicted. In TP and FP indicate true and false positive instances, FP 
and FN true and false negative instances, respectively. 
 
                                                      
42 The experiment was conducted using the argentinian ant species Iridomyrmex humilis [225]  Linepithema humile, and Lasius 
niger.[226] 
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In presence of a confusion matrix one can easily compute quality measures of which we will discuss 
the most important. 
 
Accuracy (Formula 1) is the measure of proximity of a value to its actual (true) value. It is a common 
measure to start performance analysis. 
 
Formula 1 – Accuracy, where TN and TP stand for true positive and negative instances. N0 and N1 
stand for all positive and all negative instances. 
 
However, the measure underlies the accuracy paradox, which states that a model with a given 
accuracy might have a higher predictive power than a model with higher accuracy. This problem arises 
as the measure does not take false classified instances into account. A model predicting a highly 
unbalanced dataset is considered below (Table 10). Assigning all instances to the majority class would 
produce a useless model, but with higher accuracy than in highly unbalanced datasets to predict. 
 
 
 
Table 10 - The confusion matrix for a hypothetical classification is given to illustrate the accuracy 
paradox. Accuracy of both predictors is indicated. The right example assigns all instances to the 
majority class resulting in a useless model, but exhibiting a higher accuracy than the left predictor, 
which has actually discriminatory power. 
 
Precision or positive predictivity is a measure for reproducibility and assesses the degree of variance in 
measurements performed repeatedly under the same conditions. 
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Formula 2 - Precision TP and FP stand for true and false positive classified instances. 
 
It is the proportion of positive test results, which were correctly assigned. In a clinical context, it is a 
most important quality measure for diagnostic tests as it reflects the probability that a positive result 
reflects a tested condition. It is important to note that a method or a test can exhibit high accuracy but 
low precision and vice versa (Figure 15). However, it would be desirable to have both, high precision 
and high accuracy. 
 
 
Figure 15 - Target A shows bullet holes with high accuracy and low precision. The holes in target B 
show a high precision, but low accuracy. 
 
Recall or sensitivity measures the rate of positive instances classified positively, while specificity 
assesses the correctly classified negative instances. Although both performance estimates give an 
intuitive quality estimate, they should not be used independently of each other. 
 
 
Table 11 - Confusion matrix is shown to illustrate the composition of the quality measures 
recall/sensitivity and specificity. 
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The formula for recall/sensitivity and specificity are indicated below: 
 
 
 
 
 
4.5.2 Corrected classification rate and Matthews correlation coefficient 
It is trivial, that assignment of all instances to the majority class, (i.e., a perfect overfitting), would 
produce a recall/sensitivity of 100%, which overestimates the actual predictive power (i.e., accuracy 
paradox). For this reason, accuracy, recall/sensitivity, and precision are usually not considered in 
isolation. Especially in unbalanced datasets, where overfitting might easily occur, the use of measures 
that consider also falsely classified instances is an advantage. Usually, a combined measure such as 
the corrected classification rate (CCR) or Matthews correlation coefficient (MCC) is used. 
 
 
 
Formula 3 - CCR, where TN and TP refer to compounds classified as true negatives and true positive 
instances. N0 are all negative and N1 are all positive instances.  
 
 
 
Formula 4 - In the MCC formula, additionally falsely negative (FN) and falsely positive (FP) classified 
molecules are considered. 
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4.5.3 Receiver operating characteristics (ROC) 
Another approach to analyze classification performance is the use of receiver operating characteristics 
(ROC) curves.43 ROC graphs depict relative tradeoffs between benefits (true positives, TP) and cost 
(false positives, FP) in a two-dimensional plot. Sensitivity is usually depicted on the ordinate and the 
reciproque of specificity (1-specificity) is represented on the abscissa. In other words, every correctly 
classified instance will increase steepness of the discontinuous curve, while incorrectly classified ones 
decrease it by stepping further on the abscissa. A perfect classifier would yield a point in the upper 
most left corner, while points on diagonal dividing the ROC space (also known as chance line, or "line 
of no-discrimination") represents a complete random guess. All points lying under the no-discrimination 
line indicate poor classifiers, but can simply be inverted to become predictive.  
 
One of the favorable advantages of ROC curves is their insensitivity to skewed datasets as they 
consider only TP and FP. For model comparison, the area under the ROC curve (AUC) is usually used. 
Interestingly, the AUC of a classifier is equivalent to the probability that the classifier will rank a 
randomly chosen negative instance. This is equivalent to the Wilcoxon test of ranks and is closely 
related to the Gini coefficient (Section 4.3.1.2), which is twice the area between the diagonal and the 
ROC curve. Moreover, ROC curves are often used for model optimization tasks. This can be done by 
determination of optimal thresholds or cutoff points. A frequently used measure for evaluating model 
effectiveness is the J-index, first introduced in the medical literature by Youden.[227] 
 
 
 
Youden's J is measured over all cut points on the ROC curve to find the maximum vertical distance 
from the curve to the chance line in the upper left corner, ranging between zero an one. The intuitive 
interpretation of Youden's J index is that its maximal value is the point on the curve farthest from 
chance in the upper left corner of the ROC space. 
 
4.6 Validation 
4.6.1 Holdout validation 
There are several approaches to validate machine-learning models. Holdout validation is a commonly 
used method, where the data is split in a test and training set. One-third is usually held out for testing, 
while the other two thirds are used for training. Holdout validation has the distinct advantage of taking a 
short time to compute. However, the drawback of this procedure is the difficulty to predict whether a 
sample drawn in such way will be representative for the data or not. When a class is underrepresented 
                                                      
43 Introduced in world war II for analysis of radar signals, they were employed in the 1950 in psychophysics to assess human 
detection of weak signals. From there, ROC found extensive use in the medical field for evaluations of diagnostic tests and 
medical decision-making. Recently they have been used increasingly in machine learning and data mining. 
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or even missing in the training set, the classifier will not be able to consider it appropriately. Moreover, 
when validated, the method will almost completely fail to classify, as the missing class will be 
overrepresented in the test set. This holds also for the opposite: when test sets consist exclusively of 
the majority class, validation is prone to be over optimistic. One might address this issue by refining the 
partitioning scheme and distributing variance of individual attributes evenly over training and test set, 
e.g., using stratified datasets. However, there is considerable information crossover between both sets, 
again increasing the risk of overfitting. 
 
4.6.2 K-fold cross-validation 
In k-fold cross-validation, a data set is randomly divided into k subsets.[228] Of these subsets, k-1 sets 
are recombined to make up a training set, with the resulting model tested against the remaining 
instances. This procedure is repeated k times until all instances have served both as training and test 
data, thereby making sure that no classes are left out. This procedure is basically k-fold repetition of 
holdout validation. It is evident that it makes much more efficient use of the data. Consequently, 
independence on dataset composition increases and variance in performance is reduced the higher k 
is selected. The most extreme example is leave-one-out (LOO) cross-validation, where all instances 
are used for training except for one, which is used for testing. However, k is usually set to 10. 
 
4.6.3 Software used 
Molecular descriptors were generated with the open-source cheminformatics package Chemical 
Development Kit (CDK, Version 1.2.3, 2009, http://sourceforge.net/projects/cdk).[189] For several 
descriptors, 3D structures had to be derived from SMILES representations by the Ghemical force field  
(http://www.uku.fi/~thassine/projects/ghemical/).[229] We used Weka [223] (Version 3.6; 
http://www.cs.waikato.ac.nz/~ml/Weka/) for RF, SVM, ANN, KNN, and Naive Bayes. We performed 
DTI with PASW Statistics version 18 for Windows (http://www.spss.com/statistics/) and linear 
correlation analysis with R (http://www.r-project.org/). Chemical structure diagrams were created using 
ChemAxon MarvinSketch (Version 5.2.5; http://www.chemaxon.com/).  LAZAR is available at 
http://www.in-silico.de/. Tanimoto coefficient calculations and grid screening for SVM meta-parameters 
were done with in-house software. 
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5 Projects 
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Abstract 
Intestinal drug absorption in humans is a central topic in drug discovery. In this study, we use a broad 
selection of machine learning and statistical methods for the classification and numerical prediction of 
this key endpoint. Our dataset is based on a selection of 458 small drug-like compounds with FDA 
approval.  
 
Using easily available tools, we calculated one- to three-dimensional physicochemical descriptors and 
used various methods of feature selection (best-first backward selection, correlation analysis, and 
decision tree analysis). We then used decision tree induction (DTI), fragment-based lazy-learning 
(LAZAR), support vector machine classification, multilayer perceptrons, random forests, k-nearest 
neighbor and Naive Bayes analysis to model absorption ratios and binary classification (well-absorbed 
and poorly absorbed compounds). 
 
Best performance for classification was seen with DTI using the chi-squared analysis interaction 
detector (CHAID) algorithm yielding corrected classification rate of 88%, (Matthews correlation 
coefficient of 75%). In numeric predictions, the multilayer perceptron performed best achieving root 
mean squared error of 25.823 and a correlation coefficient of 0.6. In line with current understanding is 
the importance of descriptors such as lipophilic partition coefficients (LogP) and hydrogen bonding. 
However, we are able to highlight the utility of gravitational indices and moments of inertia, reflecting 
the role of structural symmetry in oral absorption. 
 
Our models are based on s diverse dataset of marketed drugs representing a broad chemical space. 
These models therefore contribute substantially to the molecular understanding of human intestinal 
drug absorption and qualify for a generalized use in drug discovery and lead optimization.   
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Introduction 
See Section 3.2.1.1. 
 
Materials and Methods 
Dataset 
The dataset used for the present study is based on a list of FDA approved small molecule drugs (n = 
458) for which experimental data were available and sufficiently documented.[230] Omissions were 
due to missing information. Intestinal absorption (%Abs) is defined as the percentage of the dose 
absorbed from the gastrointestinal tract following oral administration. This is not necessarily the same 
as the amount of drug reaching systemic circulation, which is also affected by pre-systemic metabolism 
(e.g., hepatic first-pass effect). The arithmetical mean was used wherever an absorption range was 
given. We also did not omit compounds that are known substrates of efflux transporters such as P-
glycoprotein (e.g., digoxin) because insufficient information on specific absorption and excretion 
pathways was supplied in the original data source.  
 
As classification algorithms require nominal class labels as end points, we re-coded the numerical 
absorption ratios into three different ordinal classes (“TRUE”, “UNKNOWN”, “FALSE”, see Table 12). 
Thresholds were determined so as to produce sufficiently large number of instances for each class. 
 
Class label %ABS Number of Instances 
true a ! 80% 303 
unknown 30% < a < 80% 82 
false a " 30% 73 
 
Table 12 - Ordinal classes and corresponding absorption values (%Abs). 
 
To achieve a better separability, members of the class "UNKNOWN" were exempted from classification 
learning. This class, corresponding to moderately absorbed compounds, was clearly underrepresented 
in the data source and hence was not deemed suitable for modeling. For numerical predictions, the 
entire dataset was used. Pre-study analysis (data not shown) indicated that data transformation, i.e. 
linearization, does not improve model performance. 
 
Lastly, the data source provided generic drug names but no structural information. We therefore 
retrieved the corresponding structures from the National Library of Health database PubChem 
(http://pubchem.ncbi.nlm.nih.gov/). For salts, the counterion was removed prior to further processing. 
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Descriptors 
See Section 4.2. 
An overview is given in Table 13. For a full list and explanations see Section 4.2. 
 
Class Type 
Charge Analysis Hydrogen bonding capacity 
 Charged partial surface descriptors  
 Partitioning coefficients  
 Molecular polarizability 
Constitutional Counts of atoms, rings, and bonds 
 Length over breadth descriptors 
 Gravitational indices 
 Moment of inertia  
 Molecular weight 
Topological Eccentric connectivity index 
 Weighted Burden matrix 
 Kier-Hall kappa shape indices 
 Petitjean number and index 
 Wiener path and polarity numbers 
  Zagreb Index 
 
Table 13 - Overview of descriptors (n = 80) used in this study. A detailed listing of all features is given 
in the supporting information. 
 
The structural information retrieved from PubChem was two-dimensional. For certain descriptors, 
however, three-dimensional structures are required. We extrapolated these using OpenBabel (Version 
2.2.3, http://www.openbabel.org/) to perform a search of lowest energy conformers within the 
‘Ghemical’ force field.[229] 
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Machine learning techniques 
Decision tree induction 
See Section 4.3.1. 
 
Random forest 
See Section 4.3.1.4 
 
Artificial neural networks 
See Section 4.3.2 
 
K-nearest Neighbor 
See Section 4.3.5. 
 
LAZAR 
See Section 4.3.6. 
 
Support vector machines 
See Section 4.3.3. 
 
Naive Bayes and Bayesian nets 
See Section 4.3.4. 
Bayesian nets represent probability distributions as directed acyclic graphs, where each node 
represents an attributes probability. Predictions are made by summing up probabilities for each 
instance. For learning the networks presented here, we used the K2 algorithm.[231] 
 
Cross-validation 
See Section 4.6.2. 
All models were built with k=10, except for LAZAR where k=n (leave-one-out (LOO) cross-validation). 
Other means of validation are possible (e.g., holdout validation) and have been used in the past (Table 
19). 
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Chemical similarity 
See Section 3.3.1.2. 
 
Feature reduction 
See Section 4.4. 
In this study, we compare several approaches: 
1. Best first feature selection (BFS) using a greedy hill-climbing algorithm.[223] 
2. Linear correlation analysis (CFS) by performing linear regressions for every descriptor. The nine 
best correlating (by measure of R2) were selected. 
3. DTI splitting criteria (DTIS) were used as the final subset. Features were taken from DTI models 
produced beforehand. 
 
Quality measures 
See Section 4.5 
 
Receiver operating characteristics (ROC) 
See Section 4.5 
 
Comparison of numerical predictors and classifiers 
The results of numerical models cannot be directly compared with those of the classification 
paradigms. One approach is the comparison of numerically predicted absorption with the classes from 
the original dataset by means of receiver operating characteristics (ROC) and their areas under the 
curve (AUC).  
 
Results 
Dataset 
Drugs used for modeling and simulation cover a broad chemical range (Tanimoto coefficient: 0.702). 
This seems reasonable considering the dataset consists of commercially available drugs and thereby 
exhibit certain similarities, e.g., drug like properties. The mean (±SEM) weight of molecules within the 
database was 346.1 (±8.3).  
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Figure 16 - Ordinal classes and corresponding absorption values (%Abs). 
 
The present dataset exhibits a bimodal distribution with accumulation of compounds at 100%Abs and 
0%Abs (Figure 16). This clearly reflects the two major routes of applications of common drugs (oral 
(high %Abs) or i.v. and topical administration (low %Abs)). 
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Feature Reduction 
The descriptors selected by the different means of feature reduction are summarized in Table 14.  
 
Best first Set Correlation Set DTI Set 
aLogP (LogKow aLogP2) Molar refractivity (AMR) aLogP2 (LogKow aLogP2) 
bCUTS (highest atom 
weighted) bCUTS (lowest atom weighted) H- bond donor count 
H- bond donor count H- bond acceptor count  H- bond acceptor count  
H- bond acceptor count  gravitational index 4 molecular weight 
gravitational index 4 gravitational index H1 longest aliphatic chain descriptor 
moment of inertia descriptor 
(Z-axis) gravitational index H2 tPSA 
moment of inertia descriptor 
(XY-axis) 
length over breadth descriptor 
(LOBMAX) rNCS 
pPSA3 pPSA2  
dPSA1 pPSA3  
dPSA3   
fNSA2   
fNSA3   
tPSA   
rHSA     
 
Table 14 - In order to avoid overfitting, we applied three different selection methods to identify the most 
relevant physicochemical features in a complete descriptor set. The best first algorithm uses a greedy 
hill-climbing algorithm and revealed 13 features (BFS). A linear correlation of each feature with the 
endpoint was performed and the nine descriptors with highest R2 were used for modeling (CFS). For 
the final set, we used the seven splitting criteria revealed by Classification and Regression Trees  
(CART), which was produced beforehand (DTIS). For a more detailed listing of all descriptors see 
supporting information. 
 
All methods selected descriptors from the charged partial surface area (cPSA) subset, partition 
coefficients and hydrogen bonding capacity, reflecting well-known properties of drug absorption. 
Strikingly, measures of molecular symmetry and mass distribution (gravitational indices, moments of 
inertia, longest aliphatic chains) are singled out as well. To our knowledge, compound shape is not 
widely used in modeling these end points.  
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Model Performance 
Classification models 
The most effective classification model in our study was built by DTI with the CHAID algorithm (CCR: 
0.88, MCC: 0.75, Figure 17), followed closely by the CART algorithm (CCR: 0.84, MCC: 0.70, Figure 
18). 
 
 
Figure 17 - Decision tree with Chi-squared interaction detector (CHAID). A maximum depth of five 
nodes and a minimum five cases in the parent and two cases in the child node were allowed for tree 
growth. Splitting criteria (boxes) and corresponding cut off values are given. Leaves are depicted as 
rounded boxes. Predictions achieved a corrected classification rate (CCR) of 0.88 (MCC: 0.75). The 
whole descriptor set was used (n = 80) for decision tree induction. 
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Figure 18 - Classification of human oral absorption with CART (classification and regression tree) 
decision tree. The 10-fold cross-validated tree performed with corrected classification rate (CCR) of 
0.84 (MCC: 0.7). The Gini coefficient was used as homogeneity measure. 
 
Of all methods applied on reduced feature sets, Bayesian techniques performed best (using the BFS 
subset, CCR: 0.81, MCC: 0.62). Other paradigms such as SVM did not achieve similar performance 
with any of the feature sets. Classification models are summarized inTable 15.  
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 Whole Feature Set   
Method Specificity Sensitivity CCR MCC 
LAZAR 0.438 0.974 0.706 0.529 
CART 0.740 0.947 0.843 0.698 
CHAID 0.822 0.944 0.883 0.751 
Random Forest 0.589 0.947 0.768 0.583 
     
 Best first Set    
Method Specificity Sensitivity CCR MCC 
SVM rbf 0.644 0.934 0.789 0.597 
SVM polynomial 0.521 0.974 0.747 0.596 
Multilayer Perceptron 0.534 0.974 0.754 0.607 
KNN 0.534 0.974 0.754 0.607 
Naive Bayes 0.685 0.934 0.809 0.629 
Bayesian Nets 0.699 0.934 0.816 0.639 
     
 Correlation Set   
Method Specificity Sensitivity CCR MCC 
SVM rbf 0.575 0.974 0.774 0.639 
SVM polynomial 0.521 0.967 0.744 0.578 
Multilayer Perceptron 0.589 0.970 0.780 0.641 
KNN 0.603 0.931 0.767 0.558 
Naive Bayes 0.521 0.931 0.726 0.492 
Bayesian Nets 0.616 0.957 0.787 0.628 
     
 CART Set    
Method Specificity Sensitivity CCR MCC 
SVM rbf 0.479 0.970 0.725 0.553 
SVM polynomial 0.521 0.974 0.747 0.596 
Multilayer Perceptron 0.589 0.964 0.776 0.623 
KNN 0.589 0.947 0.768 0.583 
Naive Bayes 0.671 0.941 0.806 0.632 
Bayesian Nets 0.685 0.941 0.813 0.643 
 
Table 15 - We used the ordinal classes "true" (!80 %Abs) and "false" (" 30 %Abs) for classification. 
Compounds of the class “unknown" (30% < %Abs < 80%) were omitted from learning to achieve better 
separability for classifiers. Apart from sensitivity and specificity, highest values of corrected 
classification rates (CCR) and Matthews correlation coefficients (MCC) are in boldface. Results are 
shown for the whole dataset, best first feature selection (BFS), linear correlation analysis (CFS) and 
decision tree splitting criteria (DTIS). 
    Projects 
 
- 69 - 
Numerical models 
The multilayer perceptron yielded the strongest numerical predictions (using the CFS subset, RMSE: 
25.823, R2: 0.600). Performance is illustrated in Figure 19. 
 
 
Figure 19 - Scatterplot of predicted (y-axis) vs. observed (x-axis) %abs values. Best models on 
numeric %abs values are given. A) Multilayer Perceptron on best first feature set (BFS) B) Multilayer 
Perceptron on linear correlation analysis set (CFS). C) Support vector machines with rbf kernel on 
decision tree splitting criteria (DTIS).  
 
SVMs with the rbf kernel achieved comparable efficacy on the DTIS subset (RMSE of 26.953; R2: 
0.590). Other methods did not perform as well (Table 16). 
 
 Best first Set 
Method CC RMSE 
SVM rbf 0.574 27.648 
SVM polynomial 0.561 27.807 
Multilayer Perceptron 0.590 26.390 
 Correlation Set   
Method CC RMSE 
SVM rbf 0.559 27.828 
SVM polynomial 0.546 28.535 
Multilayer Perceptron 0.600 25.823 
 DTI Set  
Method CC RMSE 
SVM rbf 0.590 26.953 
SVM polynomial 0.544 28.773 
Multilayer Perceptron 0.588 26.099 
 
Table 16 - Prediction of %Abs was assessed using Support vector machines with kernels and 
multilayer perceptron. Methods were applied on reduced feature sets: best first feature selection 
(BFS), linear correlation analysis (CFS) and decision tree splitting criteria (DTIS). As quality measures 
root mean squared error (RMSE) and correlation coefficient (R2) are given. Best results are given in 
boldface. 
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Recoding of numerical predictions into classes 
As a means of salvaging predictive power from the rather mediocre numerical models, we attempted to 
recode the predicted %Abs values into classes based on a retrospective analysis using ROC curves 
(see Table 17 and Figure 20)  
 
Threshold 30 Best first Set     
Method Specificity Sensitivity CCR MCC AUC 
SVM rbf 0.164 0.875 0.519 0.590 0.786 
SVM polynomial 0.137 0.835 0.486 0.546 0.786 
Multilayer Perceptron 0.329 0.686 0.508 0.715 0.746 
  Correlation Set       
Method Specificity Sensitivity CCR MCC AUC 
SVM rbf 0.205 0.818 0.512 0.586 0.755 
SVM polynomial 0.110 0.871 0.490 0.496 0.767 
Multilayer Perceptron 0.301 0.719 0.510 0.655 0.757 
 CART Set         
Method Specificity Sensitivity CCR MCC AUC 
SVM rbf 0.205 0.871 0.538 0.579 0.780 
SVM polynomial 0.110 0.875 0.492 0.479 0.773 
Multilayer Perceptron 0.205 0.637 0.421 0.681 0.774 
 
Table 17 - Performance of numeric models is shown after recoding into classification scale. We applied 
cut-off values from initially set ordinal classes. For performance measurement only positive class (! 80 
%Abs) and negative class (" 30 %Abs) was used. Compounds classified as unknown were omitted. 
The corrected classification rate (CCR), Matthews correlation coefficient (MCC), specificity, sensitivity 
and area under the ROC curve (AUC) are indicated for each model. Best results for coefficients are 
given in boldface for all reduced feature sets: best first feature selection (BFS), linear correlation 
analysis (CFS) and decision tree splitting criteria (DTIS). 
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Figure 20 - ROC curves are shown of best recoded models according to highest achieved corrected 
classification rates (CCR) and Matthews correlation coefficients (MCC). Multilayer perceptron on best 
first feature set (BFS) (1), linear correlation analysis set (CFS) (2) and decision tree-splitting criteria 
(DTIS) (3). Support vector machines with rbf kernel on BFS (4), CFS (5) and DTIS (6). 
 
For each model, optimal thresholds were selected by determining the one with the highest Youden 
index (J). Instances were recoded into the two-class case according to these thresholds. Models and 
their performance after recoding are summarized in Table 18. The SVM model with the rbf kernel was 
most precise (CCR: 0.72; MCC: 0.47, using the BFS subset), outperforming the MP model. 
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  Best first Set         
Method Thopt  Specificity Sensitivity CCR MCC 
SVM rbf 82.0 0.541 0.836 0.689 0.398 
SVM polynomial 79.6 0.613 0.842 0.727 0.464 
Multilayer Perceptron 78.3 0.723 0.739 0.731 0.443 
      
  Correlation Set       
Method Thopt Specificity Sensitivity CCR MCC 
SVM rbf 78.9 0.574 0.842 0.708 0.430 
SVM polynomial 78.0 0.526 0.901 0.714 0.471 
Multilayer Perceptron 68.4 0.538 0.896 0.717 0.468 
      
 CART Set         
Method Thopt Specificity Sensitivity CCR MCC 
SVM rbf 83.9 0.570 0.809 0.689 0.391 
SVM polynomial 83.4 0.602 0.754 0.678 0.358 
Multilayer Perceptron 72.3 0.619 0.840 0.729 0.461 
 
Table 18 - Optimal cut points for thresholds were determined using the maximization of the Youden 
indices in receiver operating characteristics analysis. Specificity, sensitivity, CCR and MCC for all 
models are indicated at the optimal threshold (Thopt). The best results are given in boldface for all 
reduced feature sets: best first feature selection (BFS), linear correlation analysis (CFS) and decision 
tree splitting criteria (DTIS). 
 
Discussion 
Dataset 
Our dataset of 458 substances covers a broad range of small molecule drugs as indicated by the high 
value of dissimilarity within the descriptor space employed. The distribution of absorption ratios is 
bimodal with a small peak at the low end of the spectrum and a larger one for highly absorbed 
molecules (Figure 16). This reflects the desire to bring to market orally administrable drugs. Models 
based on this dataset should therefore best be applied in late-stage drug development. Even though 
the dataset is unbalanced, the sensitivity of our models is not impaired. 
 
Wang et al. [232] proposed to use drug subsets with similar pharmacological targets when modeling 
human intestinal absorption. While this approach may be of use in late-stage optimization, we feel that 
general physiological features cannot be deduced when examining such restricted data sets. 
 
Our models intentionally disregard mechanistic minutiae of intestinal absorption (e.g., transcellular 
versus paracellular pathways) as we are predicting the final endpoint of human intestinal absorption 
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and not specific pathways. Members of our group have shown the validity of this approach for even 
more complex endpoints.[233] Furthermore, the original data source does not provide sufficient 
information on the specific absorption kinetics and metabolism on the level of the intestinal epithelium.  
 
Feature Selection 
All feature sets include descriptors of PSA. Palm et al. demonstrated its correlation with human 
intestinal absorption and the CACO-2 cell model.[234] In models of Winiwarter et al. [235], polar 
surface area (PSA) was emphasized as one of the most important parameters to predict drug 
permeability. However, it was reported that an excellent sigmoidal relationship with high correlation 
could be established between the absorbed fraction after oral drug administration to humans and 
PSA.[236] In line with other groups [237, 238] we clearly disapprove of this approach. As a single 
feature, PSA is not a reliable criterion to distinguish poorly absorbed from well-absorbed compounds. 
Seven descriptors of the cPSA set appear in the BFS set of features. It is important to note that while 
all of these concern charge analysis, they are distinctly different. Nonetheless, we performed an 
additional analysis and found low intercorrelation between these features (ravg 0.59 ± 0.06 SEM). 
Highest rsig (0.90) is seen for dPSA3 and fNSA2, both of which are derived from central descriptors of 
the cPSA set. Specifically, fNSA2 puts charge into relation with molecular topology while dPSA3 
weighs positive against negative charge contributions. Therefore, both contribute distinct molecular 
information to the models and hence have not been removed from the final dataset. Additionally, any 
intercorrelation is penalized by cross-validation and does not introduce an overfitting bias. 
 
According to current understanding, the feature selection paradigms singled out descriptors of 
lipophilicity, charge (e.g., aPol), hydrogen bonding descriptors, and molecular weight (as selected in 
CART DTI trees). These features are already known from studies of human jejunal permeability 
(LogPeff) [18, 235] and deconvolution studies of human absorption rate constants.[239] Zhao et al. 
further demonstrated that hydrogen bonding is the rate-limiting step in absorption kinetics.[240] 
 
Repeated inclusion of gravitational Indices (CHAID, BFS, CFS), moments of inertia (BFS), length over 
breadth (CFS), and longest aliphatic chain (BFS, CART) indicate the importance of molecular mass 
distribution and geometry in modeling oral absorption. This seems reasonable as smaller molecules 
have better passive permeation capability than compounds with long aliphatic motifs. Moreover, BCUT 
descriptors [241] were selected by two paradigms (CHAID, BFS). These features are defined as 
eigenvalues of modified connectivity matrices with frequent application in drug discovery [242]. Their 
discriminatory power for aqueous solubility is well known [243] and therefore confirms the importance 
of this physicochemical property in absorption kinetics. 
 
Best first feature reduction and linear correlation are two commonly used means of reducing 
dimensionality of the descriptor space. The use of features selected from DTI models learned from the 
same data is rather unusual. We consider this a valid approach in that the feature set provides a 
mechanistical theory, which the models created a posteriori seek to verify. There is no unreasonable 
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flow or leakage of information into the learning process (as in an overfitting bias) compared to reducing 
features using the other paradigms. 
 
Individual Models 
The DTI algorithms provided the strongest models (Table 15). Other paradigms, such as SVM 
classifiers, showed far weaker performance. These observations are in line with other studies.[177, 
233] DTI often outperforms other machine learning methods when moderately sized and skewed 
datasets are used. Table 19 gives a summary of recent modeling attempts. Comparable performance 
is achieved only by work based on DTI and Gaussian kernels such as Obrezanova et al. [244] who, 
however, fail to cross-validate their models. In terms of accuracy, our models (DTI) are only rivaled by 
work by Shen [245], which, again is not cross-validated. Remarkably, many studies choose not to 
employ cross-validation, resulting in accuracy measures which overestimate their power in unseen 
data. Hou et al. [246] reported very strong models in a comparable context using SVM. Predictions 
achieved MCC of up to 0.89. Their dataset, however, had been artificially expanded by extrapolating 
%Abs values from bioavailability data. Moreover, the inclusion of redundant descriptors may have lead 
to overfitting, as has been reported previously [238].  
 
It is worth noting that the PSA descriptors of CDK also contain the fragment-based method (tPSA) 
introduced by Ertl et al..[247] Inclusion of different PSA paradigms does not introduce redundancy. The 
method established by Ertl et al. considers molecule fragments, which might only be exposed to the 
environment when drugs are dissolved in the aqueous intestinal lumen. Other implementations focus 
on charge and total molecular surface area. 
 
On reduced features, Naive Bayes and Bayesian nets performed well. Their impressive results seem 
at first glance surprising, especially as these paradigms assume independence of variable. Although 
this is rarely given in real world data, dependence can be minimized by eliminating redundant and 
therefore non-independent features. It can be argued that with the splitting of data into test and training 
sets, the independence bias is not equally distributed over both sets. Predictions of unseen data 
should then be interpreted with caution.[218] This assumption holds less well in the case of randomly 
performed cross-validation. The quality measures presented here might therefore give a more realistic 
estimate of the predictive power. Provided that the compound of interest fits the chemical space 
analyzed in this study, Naive Bayes models should classify it correctly. 
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Work N CV Paradigm R2 RSME CCR MCC Acc Sens. Spec. 
Zhao et al., 
2001[248] 241 No Regression 0.74 14 - - - 0.95 0.72 
Niwa et al., 
2003[249] 86 No 
ANN (general 
regression) - 22.8 
- 
- - - - 
Niwa et al., 
2003[249] 86 No 
ANN 
(probabilistic) - - 0.75 0.612 80% 1 0.5 
Bai et al., 
2004[250] 1260 No DTI (CART) - - - - 
79 - 
86% - - 
Liu  et al., 
2005[251] 
169 Yes 
SVM 
(gaussian 
kernel) 
0.73 14.08 - - - 0.98 0.66 
Jones et al., 
2005[252] 241 No Kernel - 22% - - - 0.9 0.46 
Deconinck et 
al.,2005[253] 141 Yes DTI (CART) - - - - 65% 0.89 0 
Iyer et al., 
2006[254] 
188 No 
Membrane-
Interaction 
QSAR 
0.68 - - - - - - 
Hou et al., 
2007[238] 455 No 
Genetic 
programming - - - 0.836 - 1 0.64 
Yan et al., 
2008[255] 552 No PLS 0.83 18.18 - - - - - 
Yan et al., 
2008[255] 552 No 
SVM (rbf 
kernel) 0.89 16.53 - - - - - 
Reynolds et al., 
2009[256] 567 No 
Nonlinear 
regression 0.84 35 - - - - - 
Obrezanova et 
al., 2010[244] 260 No Kernel - - - - 91% - - 
Obrezanova et 
al., 2010[244] 
260 No 
DTI 
(unspecified 
algorithm) 
- - - - 85% - - 
Shen et al., 
2010[245] 578 No 
SVM 
(polynomial) - - 0.928 0.909 98% 0.998 0.859 
Shen et al., 
2010[245] 578 No SVM (rbf) - - 0.948 0.932 98% 0.998 0.897 
Guerra et al., 
2010[257] 202 Yes ANN - - - - 73% - - 
Suenderhauf et 
al., 2010 458 Yes DTI (CHAID) - - 0.883 0.752 92% 0.944 0.882 
Suenderhauf et 
al., 2010 458 Yes DTI (CART) - - 0.843 0.698 91% 0.947 0.740 
Suenderhauf et 
al., 2010 458 Yes 
ANN 
(numeric) 0.6 25.823 - - - - - 
Suenderhauf et 
al., 2010 458 Yes 
ANN 
(recoded) - - 0.717 0.468 79% 0.896 0.538 
 
Table 19 - Representative models for human intestinal absorption are summarized. Indicating size of 
dataset used (n), the use of cross-validation (CV), paradigm and algorithm used and performance 
estimates (coefficient of determination [R2], root mean squared error [RMSE], corrected classification 
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rate [CCR], Matthews correlation coefficient [MCC], accuracy [Acc], sensitivity and specificity). 
Accuracy was calculated as true hits (true positives and true negatives) divided by n. 
 
The numeric models presented here exhibit low predictive power as visualized in Figure 19. This might 
be caused by the bimodal distribution of the dataset. The clustering of compounds around low and high 
levels of absorption reflects the two major galenic classes of drug: orally and intravenously 
administered compounds. Hence, the instance space is not entirely covered (Figure 16). Regression 
models are likely to perform badly on such data. Indeed, the achieved R2 values range from 0.544 to 
0.600, confirming that linear regression models are a completely inappropriate method type for the 
present dataset. This holds even in the case where compounds are grouped together (such that a 
group has similar activities), because of the linear model's constant slope. It would be more 
appropriate to perform binning of instances into two classes and analyze them by classification. 
Because focusing on two classes can improve numeric models, we stress the importance of choosing 
appropriate algorithms for the dataset at hand. 
 
It also should be noted that we succeeded in producing models of high accuracy (up to 92% with DTI) 
without specifically incorporating the influence of efflux transporters such as P-gp. This indicates that 
these are not major influencing factors. The poorer performance of numerical models therefore seems 
to be intrinsic to the paradigms. 
 
Numeric vs. Classification 
Comparison of classification and numeric models is not straightforward. Numeric measures of 
accuracy are RMSE or R2. In a classification system, confusion matrices and corresponding quality 
measures (CCR, MCC) are used. Both model types may therefore not be compared directly. In an 
attempt to do so indirectly, we translated numeric predictions into a classification scale. As expected, 
performance of numeric models was worse compared to genuine classification. We analyzed 
predictions with ROC graphs (Figure 20) to estimate predictive power for the well-absorbed class. 
Models achieved a reasonable sensitivity, which is reflected in high AUC values (Table 17). In other 
words, numerical models tended to generally overestimate absorption ratios. By determining optimal 
cut-off values using the best Youden Index, we markedly improved models in terms of specificity. 
Treated in this fashion, we state that numeric and classification models perform comparatively strong 
(Table 15, Table 18) 
 
Conclusion 
While intestinal absorption of drugs in humans is mostly governed by passive diffusion, it is potentially 
influenced by several other factors. Our models can be seen as a combined endpoint analysis as they 
disregard, among other aspects, the location of absorption and specifics of administration (e.g., 
galenics, counterions). Performance, however, is not impeded by these generalizations. The dataset 
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comprises the entire range of absorption ratios and has a great chemical diversity in the descriptor 
space employed. 
 
Although we used differing approaches to reduce features, certain descriptors were present in all sets. 
Descriptors of charge and lipophilicity reflect the current understanding of drug absorption in humans. 
Our models show the importance of molecular shape and complexity on absorption. Small size, little 
branching, and equal distribution of mass (as represented by descriptors of the moments of inertia) 
seem to be of advantage in oral absorption. 
 
The advantages of computational methods in the prediction of oral absorption have been described 
previously, e.g., Norinder et al.[15] In clinical practice, drugs fall into just two categories with little 
overlap: those which are orally administrable and those for which other routes of administration have to 
be taken (for example intravenous injection or topical application). Therefore, specific numerical 
values, such as absorption ratios are often considered to be of less importance than classification. 
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Abstract 
Drug penetration into the central nervous system is dependent on a molecule’s ability to cross the 
blood brain barrier (BBB). Limited passive diffusion and active efflux and influx systems account for the 
complexity of this highly regulated process. It was our aim establishing models of drug permeation 
including both active and passive transport systems. 
 
We collected a database of 163 compounds where information on the in vivo surface permeability 
product (LogPS) in rats was available. We used the DRAGON toolkit and the Chemical Development 
Kit (CDK) to calculate physicochemical descriptors. Decision trees were induced on both descriptor 
sets. We were able to establish models with corrected classification rates (CCR) of 90.9% - 93.9%. An 
Ant colony optimization (ACO) based binary classifier was used to search for the most predictive 
chemical substructures. The best model yielded a CCR of 89%. 
 
Decision trees revealed descriptors of lipophilicity (partition coefficient) and charge (polar surface 
area), which were also described in models of passive diffusion. However, measures of molecular 
geometry and connectivity could be related to an active drug transport component.  
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Introduction 
See Section 3.2.1.2. 
Development of new central nervous system (CNS) active drugs is hampered by limited brain 
permeation. As invasive methods have proven themselves to be ineffective and risky for patients, the 
systemic application is the preferred route for drug administration into the brain.[28, 29] Hence, blood 
brain barrier (BBB) permeability is a feature absolutely mandatory for any drug which targets the CNS. 
It is desirable to have estimates on a compounds behavior on level of the BBB as early as possible in 
the drug development process.  
 
The process of passive brain permeation is well characterized and accurate computational models to 
predict molecule behavior exist.[33-36] Major physicochemical determinants are lipophilicity, molecular 
weight, and measures of molecular polarity.[32] However, such expert-based rules do not accurately 
reflect the complexity of interactions as they disregard the biochemical processes mediated by 
transport proteins.[37]  
 
Computational models to discriminate substrates, inhibitors, and inducers of P-glycoprotein (P-gp) 
have successfully been established.[258] It is tempting from a mechanistic point of view to join the 
various models for passive diffusion and active transport to predict brain penetration in general. 
However, every model suffers from a varying degree of uncertainty which accumulates the more of 
them are concatenated. To avoid such shortcomings, it is more efficient to generate a single model of 
a complex phenomenon rather than sequentially apply model after model. Members of our group have 
shown the feasibility and validity of this approach.[259, 260] 
 
We applied modern machine learning algorithms to predict this highly complex endpoint. We 
assembled 163 in vivo BBB permeability-surface area (PS) product (LogPS) experiments from 
literature. LogPS values are usually calculated from internal carotid artery perfusion studies in rats. 
This procedure is considered superior to other methods like blood/brain partition measurement at 
steady state (LogBB), as it lacks systemic distribution effects, which distort brain penetration 
substantially.[51] The majority of high quality data found in literature was gathered in rats. We decided 
to omit data acquired in other species to avoid interspecies variability and reduce noise in our models.  
 
Materials & Methods!
Dataset 
We assembled a dataset of 163 small molecules from literature where information on in vivo BBB 
permeability-surface area (PS) product, usually given as its logarithm (LogPS), was available.[51, 261-
273] Besides wild type animal data, we found also LogPS values from transgenic rats. Single 
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transporter knockout animals are particularly useful when active transport mechanisms are studied. 
However for the present work we exclusively used data from wild type animals, as we aimed to model 
brain penetration entirely under physiological conditions (i.e. including also active transport). 
 
The paradigms used in the present study were classification algorithms. We therefore aimed to split 
data in two classes, according to cut-off values published literature.[274, 275] LogPS values >= -2 
were judged as readily penetrating the brain and received the label "CNSp+" (n = 70), while measures 
<= -3 were labeled "CNSp-" (n = 61). To increase discriminatory power of our models, values between 
-2.1 and -2.9 were exempt from classification learning (n = 32). The final dataset used consisted 
therefore of 131 compounds. 
 
Structural information was retrieved from the National Library of Health database PubChem 
(http://pubchem.ncbi.nlm.nih.gov/). For salts, we removed the counterion prior to further 
considerations. Conversion to three-dimensional structure representation was achieved by using 
lowest energy conformers within the Ghemical force field.[229] 
 
Physicochemical descriptors 
See Section 4.2 and 4.6.3. 
 
Fingerprints 
See Section 4.1.3. 
 
Machine learning techniques 
Decision tree induction 
See Section 4.3.1. 
CHAID and CART were grown to a maximum depth of 3 and 5 nodes, respectively. We set minimum 
cases for parent nodes to 10 instances and allowed 5 cases in the child nodes. 
 
Ant colony optimization 
Ant colony optimization is a natural computing paradigm introduced by Dorigo et al.[224] The algorithm 
uses an abstraction of ants foraging behavior to select meaningful features. Higher-dimensional QSAR 
studies, e.g., ligand docking, routinely apply ACO alongside other optimization paradigms. With a few 
modifications, ACO can be used as a feature selector, i.e. to identify attributes that carry information on 
the endpoint of interest. For this study, we applied a variant of ACO algorithm recently published by our 
group (Section 5.5). 
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Cross-validation 
See Section 4.6. 
 
Chemical Similarity 
See Section 3.3.2. 
 
Quality measures 
See Section 4.5. 
 
Software used 
See Section 4.6.3. 
 
Results!
Chemical Similarity 
The Tanimoto coefficient for our dataset (n = 131) was 0.282. This great dissimilarity indicates that the 
data span a reasonable chemical space. 
 
DTI performance 
Decision trees using CHAID algorithm trained with Dragon descriptors yielded the best results (Figure 
21). This tree classified compounds with a CCR of 93.9% (MCC: 87.9%).  
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Figure 21 - Chi-squared automatic interaction detector (CHAID) was trained on the whole feature set 
provided by DRAGON toolkit (n= 4885). The resulting model performed with a corrected classification 
rate of 93.9%. "CNSp+" indicates good permeation and "CNSp-" stands for bad brain permeation. 
 
Features were topological polar surface area (tPSA[NO]) derived from polar fragments (i.e., oxygen 
and nitrogen), the Balaban Y Index (Y-Index), the distance of lipophilic pharmacophore groups 
(CATS2D 02 LL), 3DMoRSE descriptor weighted by polarizability (Mor27p), and spectral mean 
absolute deviation from the edge adjacency matrix, weighted by bond order (SpMAD EA [bo]). When 
trained with CDK descriptors, the paradigm performed slightly worse, achieving a CCR of 90.9% 
(MCC: 81.7%) (Figure 22). 
    Projects 
 
- 84 - 
 
 
Figure 22 - The tree built by Chi-squared automatic interaction detector (CHAID) on CDK descriptors 
(n= 81) is shown. The cross-validated model achieved a corrected classification rate of 90.9%. When a 
molecule reaches a leave indicating "CNSp+" it is judged to exhibit good brain permeation. When 
"CNSp-" is reached, the molecule will not pass the BBB. 
 
Splitting criteria were partition coefficient (aLogP), charge weighted partial positive surface area 
divided by total molecular surface area (fPSA), hydrogen bond acceptor count (hBondAcceptors), and 
rotatable bonds count (rotatable bonds). Models created with CART paradigm could not match the 
performance of CHAID. Trained on DRAGON and CDK feature sets it yielded a CCR of 90.8% (MCC: 
81.6%) and CCR of 89.8% (MCC: 79.9%), respectively. Trees are summarized in Figure 24 and Figure 
26. 
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Figure 23 - Classification and regression tree (CART) on DRAGON descriptors (n= 4885). The 
corrected classification rate was 90.8%. 
 
When trained with Dragon descriptors, CART used the amount of van der Waals volume having 
polarizability over one (P_VSA_p2), three-dimensional (3D) autocorrelation weighted for polarizability 
(TDB05p), and 3D-MoRSE descriptor, weighted by ionization potential (Mor10s).  Partition coefficient 
(aLogP), topological polar surface area (tPSA), and highest eigenvalue weighted for the lowest atom in 
the Burden matrix (BCUTS) were chosen. Table 20 gives a comprehensive summary of model 
performance. Features used for classification are given in Table 21. 
 
 DRAGON CDK 
 CHAID CART CHAID CART 
CCR 93.9 90.8 90.9 89.8 
MCC 87.7 81.6 81.7 79.9 
Spec 93.4 90.2 91.8 86.7 
Sens 94.3 91.4 90 92.9 
 
Table 20 - Performance of chi squared automatic interaction detector (CHAID) and classification and 
regression tree (CART) on Chemical Development Kit (CDK) and DRAGON descriptors is 
summarized. Corrected classification rate (CCR), Matthews correlation coefficient (MCC), Specificity 
(Spec), and Sensitivity (Sens) are given. All models presented were cross-validated and quality 
measures indicate a realistic performance estimate for unseen data. 
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Figure 24 - We summarized the result of classification and regression tree (CART) on CDK descriptors 
(n= 81). The predictive power of the cross-validated model was 89.8%. 
Descriptor 
sets Paradigm Splitting criteria Comment 
DRAGON CHAID tPSA(NO) 
Topological polar surface area (only considering Nitrogen 
and Oxygen) 
  Yindex Balaban Y index 
  CATS2D_02_LL CATS2D descriptor lipophillic-lipophillic at lag 02 
  Mor27p 
3D-MoRSE descriptor, weighted by polarizability (signal 
27) 
  SpMAD_EA(bo) 
Spectral mean absolute deviation from the edge 
adjacency matrix, weighted by bond order 
 CART P_VSA_p_2 P_VSA-like descriptor, weighted on polarizability (bin2) 
  TDB05p 
3D topological distance based descriptors- lag 5 weighted 
by polarizability 
  Mor10s 3D-MoRSE descriptor, weighted by I-state (signal 10) 
CDK CART aLogP Partition coefficient as defined by Ghose-Crippen 
  BCUTS 
The number of highest eigenvalue, weighted for the 
lowest atom 
  tPSA Topological polar surface area 
 CHAID aLogP Partition coefficient as defined by Ghose-Crippen 
  fPSA3 
Charge weighted partial negative surface area/ total 
molecular surface area 
  hBondAcceptors Hydrogen bond acceptor count 
  rotatable bonds Rotatable bonds count 
Table 21 - Features revealed by DTI to predict brain permeation are shown. Descriptor sets, paradigm, 
and its selected criteria as well as a short explanation of the descriptor is given. 
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ACO performance 
The best performing subset of fingerprints revealed by ACO is summarized in Table 22. This subset of 
chemical substructures performed with a CCR of 82% (MCC: 64%). Figure 27 shows the ROC curve 
and cutoff point (circle). The corresponding area under the curve (AUC) was 0.89. 
 
Figure 25 - The ROC curve is depicted corresponding to the best fingerprint set revealed by ant colony 
optimization (ACO). Cut off value is indicated by red circle. Fingerprints were selected from the 
MACCS key set (n= 166). This subset consisted of nine fingerprints and achieved a corrected 
classification rate of 82%. 
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Table 22 - The fingerprints selected from the MACCS keys are given with their internal number (No), 
SMART code, and a short explanation of the substructure. In the sample structure, A stands for any 
atom, X for a heteroatom, and R any molecular rest. 
No Sample Structure SMARTS Descripton
23 !"#$%!"&$'%!"($)%!"($ Nitogen connected to carbon atom, which is 
connected to two Oxigen 
atoms.
36 !"*&+$ Any heterocycle containing 
a sulfur atom.
60 !"*&$,!"($ Oxigen and Sulfur connected by a double 
bond.
82 -%!./0$%!1"&21"*21/3 Any atom connected to CH2, which is itself connected to a heteroatom 
with at least one hydrogen 
atom.
122 -%!"#$'%-)%- Any atom connected to Nitrogen. Nitrogen has to 
be connected with any two 
additional atoms.
130 !1"&21"*$%!1"&21"*$ Two heteroatoms connected 
to each other.
145 -*%-%-%-%-%-%* Six ring structure, occuring twice in molecule (They do 
not have to be directly 
connented).
150 -14-4-14- One intramolecular chirality 
centre. 
156 !"#$%-'%-)%- Nitrogen connected to any 
three atoms.
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Discussion 
Dataset 
The low level of chemical similarity (Tanimoto coefficient = 0.282) reflects the broad chemical space 
covered by our dataset. We restricted the present dataset to results of experiment in rats. For this 
reason, our dataset seems at first glance smaller compared to other work published in the field. We 
feel that artificially expanding datasets by mixing data from different species would introduce noise into 
deduced models. Moreover, we only used results from experiments conducted in wild type animals in 
order to not intentionally exclude any actively transported compounds. Active transport plays a major 
role in BBB permeation and can alter pharmacokinetics of a drug substantially.[276] Moreover, one can 
hardly assure purity of a dataset including only passively transported molecules. The characterization 
of active transport mechanisms is still an ongoing topic of research and active transport mediated by 
yet unknown transporters could remain undetected when saturation occurs at very low concentrations.  
 
In the past, it was criticized that binning in CNS positive and CNS negative substances referred to 
presence or absence of pharmacological CNS activity, respectively.[277] We met these justified 
concerns in our considerations. Pharmacological activity is a qualitative and inadequate measure for 
brain permeation capacity and it is advisable to use a quantitative permeability measure like LogPS for 
classification instead. In the present study, the distinction in positively and negatively classified 
molecules refers to compounds with LogPS values <=-2mg/ml/s and >=-3mg/ml/s, respectively. 
 
Decision tree models 
One of the main advantages of DTI is the human-readable output they produce. Our models did not 
only predict this highly combined endpoint with excellent performance, but also gave insights into the 
biological processes involved. Interestingly, some features revealed were already used in models of 
passive brain permeation. Descriptors of lipophilicity and charge are frequently used to predict 
membrane permeation. It is therefore not surprising that three out of four paradigms selected partition 
coefficient (aLogP), the distance of lipophilic pharmacophore groups (CATS2D 02 LL) and/or polar 
surface area (PSA) as splitting criteria.  
 
When we compared trees using CDK descriptors, we found that both paradigms set a much lower 
threshold for splitting on aLogP than earlier defined rules do.[33, 278-280] This could be an indication 
for active transport involvement. Recent studies refer to increasing lipophilicity as a major rate-limiting 
feature for P-gp interactions and played a predominant role in DTI models predicting P-gp inhibitors 
and substrates.[258, 281] We could therefore not confirm the opinion that high lipophilicity would be 
generally associated with good brain permeation.[179] While we found that it was clearly an important 
feature to split data on, aLogP unfolded its predictive power for the present endpoint only in 
combination with other descriptors. 
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Polar surface area was present in virtually all models. Other groups observed a corresponding role of 
this feature in CNS penetration.[179] Generally, our models revealed that polar molecules (PSA) were 
associated with bad BBB permeation. The cutoff value for classifications varied substantially between 
our models, but generally spoken higher molecular polarity hindered passage into the hydrophobic 
milieu of the brain endothelial cells. The tree grown by CHAID with Dragon descriptors used tPSA as 
the root splitting criterion. Although earlier work implies that PSA values over 60-90 Å2 are generally 
associated with bad brain permeation, the paradigm detected in combination with connectivity 
measures positive instances.[278, 282, 283] This is in line with other work, where high capacity for 
polar interaction and low connectivity were crucial features of P-gp substrates.[258, 284] 
 
We observed that CHAID attributed good BBB permeation for compounds with less than four hydrogen 
bond acceptors. This is an interesting finding as it is generally agreed that hydrogen bond acceptors 
are less confining for passive diffusion than donors are. Additionally, thresholds to classify were set at 
much higher levels (usually around 8 or 10) than our model suggests. However, we can see parallels 
to other work, where high hydrogen bond basicity was associated with P-gp substrates.[285] 
Accordingly, Norinder and Haeberlein reported that compounds exhibiting less than five nitrogen and 
oxygen ([O+N]) entities would readily enter the brain.[286] This threshold corresponds with the cutoff 
value set in our model. 
 
In the CDK CHAID tree, an increase in rotatable bonds was associated with bad brain permeability. 
Interestingly, these findings were contrasting to observations of Iyer at al., who stated that increasing 
molecular flexibility was associated with an increasing permeation. They argued that the number of 
rotatable bonds were proportional to molecular weigh. Consecutively, an increase in rotatable bonds 
would clandestinely refer to a relationship of molecular weight and brain permeation. We found a rather 
low correlation between these two descriptors (R2 = 0.74) (Figure 26) in our present study and feel that 
mass, although to a certain extent present, did not contribute substantially to our classification. 
Figure 26 - Scatterplot matrix of intercorrelation molecular weight and rotatable bonds count is shown. 
The coefficient of determination (R2) was 0.74. 
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Remarkably, although the whole feature set was at disposal for training, none of the paradigms 
selected explicitly molecular weight to classify. This finding is in accordance to the opinion of Abraham 
and co-workers, who stated a less significant role of the descriptor in predicting brain penetration as 
certain rules of thumb imply.[287] Diminished permeation capacity with increasing number of rotatable 
bonds could also refer to potential conformational bulkiness of a molecule. Rotatable bonds are 
defined as any single bond not involved in a ring structure or connected to a non-terminal heavy atom. 
In fact, a high number of rotational bonds implied that an extended conformation could roll up into 
spherical shape. In other words, a molecule could potentially permeate the BBB worse than its 
molecular weight would indicate owing to a bulky shape. The number of rotatable bonds would then 
add additional information to models by taking also account of geometrical features rather than simply 
considering molecular mass. The importance of geometry in predicting brain penetration was 
substantiated by other DTIs. Our strongest model (CHAID trained on DRAGON descriptors) included 
edge adjacency matrix indices (SpMAD EA[bo]) to give information on molecular connectivity. The 
three-dimensional (3D) topological autocorrelation (TDB 05 p, weighted for polarizability) selected by 
CART represents the information gain from comparing topological and Euclidian distances of atoms in 
a molecule. Again, this descriptor refers to molecular conformation, as folded chains will have much 
lower values than stretched ones.[288] Spectral indices like the mass weighted Burden matrix 
(BCUTS) refer to molecular topology and complexity. Moreover, both DTI paradigms selected 3D-
MoRSE descriptors from DRAGON features. These autocorrelation descriptors consider the three-
dimensional molecular representation based on electron diffraction patterns. Schuur and co-workers 
pointed out their use as a measure for mass distribution and branching of a molecule.[289] Although 
different weighting schemes were used (polarizability for CHAID and intrinsic state for CART), both 
trees associated lower values with good permeation. 
 
Fragment based approach 
The fingerprints selected by binary ACO classification reconfirmed our findings from descriptor based 
machine learning. The repeated inclusion of ring features indicates a strong contribution of lipophilicity, 
which is involved in passive and active transport processes across the BBB. Heteroatoms were 
present in seven out of nine fingerprints, of which four included explicitly nitrogen and/or oxygen 
atoms. This could relate, in analogy to our findings using DTI, to hydrogen bonding capacity and 
polarity of a molecule. However an interesting structural feature was fingerprint No. 150, which refers 
to anticlockwise chirality. To our knowledge stereoselectivity has not yet been used to predict brain 
penetration capacity. However, in vivo studies confirm involvement of stereoselectivity of drug uptake 
on the BBB.[290, 291]  
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Conclusions 
Our decision trees reconfirmed the involvement of lipophilicity, size, and charge in predicting brain 
penetration. Additionally, we shed light on features such as molecular geometry, connectivity, and 
stereochemistry, which are less commonly used in the field. 
 
One could argue that the data underlying our models was derived from rodents and might not 
accurately reflect the situation in humans. Due to ethical constraints LogPS measurements in man are 
not feasible. There is little data from intra-operative microdialysis experiments conducted in patients 
who underwent neurosurgery. Hence, these reports do most likely reflect pathophysiological conditions 
and are therefore inapt to model the healthy BBB.  
 
Rats are commonly used as an animal model to conduct pharmacokinetic experiments. However, 
performing in vivo perfusion studies is time consuming, costly and requires experience. In addition, 
these experiments are highly invasive and stand in contrast to general attempts to reduce animal tests. 
Our models are suitable to predict drug brain permeation in wild type rats and could therefore 
contribute also to save animal numbers. 
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Abstract 
It is commonly agreed that breastfeeding is highly beneficial for mother and child. However, maternal 
medication intake can impose a risk for the baby as many drugs appear in mother milk. Despite its 
social, economic, and medical impact, safety of drug intake in nursing is still a relatively unexplored 
field. We aimed to computationally model drug passage into mother milk. The work presented here is a 
novel approach to holistically assess active and passive transport processes in the mammary gland 
epithelium. 
 
We assembled a dataset of small molecule drugs (n=90) and used the DRAGON toolkit and the 
Chemical Development Kit (CDK) to generate physicochemical descriptors. From these feature sets 
decision trees were grown. Performance in models using DRAGON features was outstanding and 
achieved corrected classification rates of 85.3% - 95.3%. Prominent splitting criteria were descriptors 
of molecular size, branching, charge and geometry. A fragment-based analysis revealed structural 
elements referring to polarity and to involvement of an active transport component. 
 
We consistently observed strong predictive power in all of our models, which underlines the viability of 
the present dataset. Descriptor and fragment based models shed light on the molecular requirements 
to identify safe drugs in nursing. The classifiers presented here will ease decision making in clinical 
settings or drug design even if no experimental data are available. 
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Introduction 
See Section 3.2.1.3. 
Drugs accumulating in mother milk are likely to become increasingly available to the baby. Considering 
the immature metabolism and drug clearance of the baby, serum levels could rise above therapeutic 
concentrations and cause side effects. Therefore, models including actively transported structures, 
which could lead to drug accumulation, are of substantial importance, both in drug development and 
safety monitoring in the clinical setting. 
 
Materials & Methods 
Dataset 
We assembled a dataset of 90 compounds for which information on human breast milk excretion 
profiles was available. The initial dataset was based on 162 marketed small molecule drugs from the 
therapeutic drug database.[230] The source supplied either qualitative (e.g., descriptive) or quantitative 
(numeric data) information on endpoints. We therefore classified compounds accordingly to Table 23 
as excreted (BM+, n = 40) or non-excreted (BM-, n= 50) drugs.  
 
Class label Qualitative label from source Quantitative label from source n 
BM+ Accumulation Milk levels > maternal blood levels  40 
 Same/ greater/ higher than maternal blood levels 
Milk levels 1-40x higher than 
maternal blood level  
 Therapeutic concentrations, Freely diffusing 
Milk/maternal blood ratio 1.5 or 
8.5:1  
 Clinically significant/ extensively secreted   
BM- Traces, minimally, negligible, not secreted <= 1% of maternal blood level 50 
  Very/ extremely low/ small quantities     
 
Table 23 - Class label assignment was performed as shown. The source supplied information on drug 
presence in mother milk either qualitatively (e.g., nominal quantification) or quantitatively (e.g., 
milk/plasma ratios). Due to varying detection techniques, maternal drug concentrations were measured 
either in plasma, serum or blood. For reasons of readability, we refer to these different values as 
maternal blood levels. We denoted compounds passing into breast milk as BM+ (n = 40) and non-
permeating molecules as BM- (n=50). 
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Compounds not meeting these requirements were exempt from learning, for the sake of classifier 
quality. We did not exclude any compounds which are known substrates of active transport and/or are 
known to accumulate in milk.  
 
The data source contained generic names. Corresponding structures were retrieved from the National 
Library of Health database, PubChem.[292] As the paradigms used cannot handle disconnected 
structures, we removed counterions form salts prior to their consideration.  
 
Descriptors 
See Section 4.2 and 4.6.3. 
To derive descriptors from chemical structure we used the commercial DRAGON toolkit. To ease 
reproducibility of our models we also applied descriptors calculated with the open source CDK 
software. 
 
Chemical fingerprints 
See Section 4.1.3. 
To get insight into structural requirements for safe drugs in nursing, we performed a fragment-based 
analysis. 
 
Decision tree induction 
See Section 4.3.1. 
In this study, we set maximum tree depth to five nodes for CART, and to three nodes for CHAID, 
respectively. We allowed a minimum of 10 instances in the parent and 5 cases in the child node.  
 
Ant colony optimization 
See Section 5.5. 
 
Chemical Space 
We assessed the chemical space spanned by our dataset calculating the Tanimoto coefficient 
spanned by the MACCS keys using the Open Babel toolkit and in-house software.[293] Keys of every 
molecule were compared to the remaining set. The resulting similarities were then averaged over the 
whole dataset (n=90) to receive an overall similarity value.  
Quality measure 
See Section 4.5. 
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Cross-validation 
See Section 4.6.2. 
 
Software used 
See Section 4.6.3.  
In-house software was available for ACO (Section 5.5.). 
 
Results 
Chemical Space 
We calculated an overall similarity of 0.333 for our dataset using Tanimoto coefficient. This is a low 
level of similarity and represents a reasonable chemical space on which to base machine learning. 
Models created will most likely interpolate well for future small molecule drugs.  
 
Performance of machine learning methods 
Both DTI paradigms achieved the strongest models when trained on DRAGON descriptors. 
Classification and regression tree (CART) produced the best model in our study, achieving a CCR of 
95.3% (MCC: 91%) closely followed by Chi-squared interaction detector (CHAID), which performed 
with a CCR of 92.5% (MCC: 87.1%). Figure 27 and Figure 28 show the corresponding trees.  
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Figure 27 - We show the CART built on DRAGON features. The tree predicted with CCR of 95.3% 
(MCC: 91%). SpDIAM_AEA(dm) is the spectral diameter from augmented edge adjacency (AEA) 
matrix, weighted by dipole moment. Mor28s stands for the MoRSE3D descriptors at lag 28, weighted 
by I-state. MATS7i and GATS7i are 2D autocorrelation matrices at lag 7 weighted by their ionization 
potential (i), defined by Moran and Geary, respectively. BM+ and BM- denote permeating and not 
permeating compounds, respectively. 
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Figure 28 - The CHAID tree built on DRAGON descriptors is shown. The paradigm achieved a 
performance of CCR: 92.5% (MCC: 87.1%). First splitting criterion was R4s, the R autocorrelation at 
lag 4 weighted by intrinsic state from the GETAWAY descriptors. Eig07_AEA(bo) is a descriptor of the 
edge adjacency indices. It stands for the eigenvalue number 7 from the augmented edge adjacency 
matrix weighted by bond order. MATS7e and GATS6m are both 2D autocorrelations, defined by Moran 
and Geary. MATS was weighted for electronegativity and GATS was weighted for mass. BM+ indicates 
permeating and BM- not permeating compounds. 
 
Performance in these models was outstanding, but to a certain extent at expense of interpretability. 
When we trained the paradigms on CDK features, more intuitive features were chosen.  
 
    Projects 
 
- 100 - 
 
Figure 29 - When CART performed on CDK features the depicted tree was grown. Splitting criteria 
were gravitational Index 4, Kier Hall kappa shape index, molecular weight, and molar refractivity. The 
paradigm achieved a performance of CCR: 85.3% (MCC: 70.2%). BM+ stands for permeating 
molecules and BM- for not permeating ones. 
 
However, predictions of CART performed with CCR of 85.3% (MCC: 70.2%)(Figure 29) and CHAID 
with CCR of 85% (MCC: 70.7%)(Figure 30). Table 24 summarizes DTI performance on all feature sets. 
 
Descriptors Paradigm CCR(%) MCC(%) SENS SPEC 
DRAGON CHAID 92.5 87.1 1 85 
 CART 95.3 91 98 92.5 
CDK CHAID 85 70.7 80 90 
 CART 
85.3 70.2 92.5 78 
 
Table 24 - We present the performance of DTI on DRAGON and CDK descriptors. Corrected 
classification rate (CCR) and Matthews correlation coefficient (MCC) for all DTI models are given. 
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CART tree trained on DRAGON features achieved the best performance (indicated in bolt face). 
Sensitivity and specificity are given as SENS and SPEC, respectively. 
 
 
Figure 30 - We present the tree grown with CHAID on CDK descriptors. The paradigm selected 
gravitational index four, relative positive charge (rPCG), partial positive surface area multiplied by total 
positive charge on the molecule (pPSA2), and the difference of pPSA2 divided by molecular surface 
and partial negative surface area multiplied by total negative charge on the molecule (dPSA2). RPCG, 
pPSA2, and dPSA2 belong to the charged polar surface areas descriptors (cPSA). CHAID achieved a 
performance of CCR: 85% (MCC: 70.7%). BM+ indicates permeating and BM- not permeating drugs. 
 
Our analysis of structural requirements for safe drugs in nursing revealed 10 relevant fingerprints which 
are listed in Table 25. The molecular fragments performed with a CCR of 83% (MCC: 66%) and an 
area under the curve (AUC) of 0.85. The corresponding ROC curve is depicted in Figure 31. 
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Figure 31 - The ROC curve achieved of best-performing ACO model is shown. The 10 fingerprints from 
the MACCS keys performed with a CCR of 83% (MCC: 66.2%). The area under the curve (AUC) was 
0.85. The cutoff point taken as maximum Youden’s J is indicated by a circle. 
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No Sample Structure SMARTS Description 
51 
 
[#6]~[#16]~[#8] Carbon bound sulfoxide. 
82 
 
*~[CH2]~[!#6;!#1;!H0 
Methylene connected to a heteroatom 
with at least one hydrogen atom and to 
an additional molecule. 
97 
 
[#7]~*~*~*~[#8] Nitrogen connected to oxygen via any three atoms. 
122 
 
*~[#7](~*)~* 
Any atom connected to nitrogen. 
Nitrogen has to be connected with any 
two additional atoms. 
139 
 
[O;!H0] Oxygen with at least one hydrogen (e.g., hydroxy group). 
149 
 
[C;H3,H4] More than one methyl group. 
153 
 
[!#6;!#1]~[CH2]~* Heteroatom with methylene group, connected to a rest. 
159 
 
[#8] More than one oxygen atom. 
162 
 
a Aromatic atom.  
163 
 
*1~*~*~*~*~*~1 Six-membered ring structure, occurring twice in molecule. 
 
Table 25 - The 10 best performing MACCS Keys selected by ACO are shown. We give the number 
(No) in the fingerprint set, a sample structure, the corresponding SMART keys, and a short explanation 
of the chemical fragment. 
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Discussion 
Our dataset exhibited a reasonable dissimilarity to interpolate for existing and future small molecule 
drugs. This is an advantage, if safety estimates are needed and no experimental data are available. In 
terms of size, our dataset might be considered modest compared to others. However, division in test 
and training sets dramatically reduces the effective size of data used for creating models. We 
overcame this problem by cross-validating our models, thus using the whole chemical space available. 
Additionally, k-fold cross-validation resulted in a realistic performance estimate as the data subsets 
were randomly composed. Therefore, we considered our models in terms of size competitive with other 
models using holdout validation. 
 
We felt that a numeric prediction approach would not be sensible due to the inherent fuzziness in 
reporting quantities of compounds detected in mother milk. We therefore decided to restore 
discriminatory power by partitioning compounds into two classes. 
 
Classifiers trained with DRAGON descriptors achieved excellent performance. However one could 
argue that the selected splitting criteria are not easily interpretable and traceability of trees is 
hampered to a certain extent. Although the CDK trees could not hold with the strong performance 
given in DRAGON based models, they yielded more intuitive features. Interestingly, these splitting 
criteria did largely reflect our current knowledge of the process. 
 
Typically, molecular size and weight substantially determine the membrane permeation capacity. While 
small compounds readily undergo passive diffusion, bulky ones will be sterically hindered. An earlier 
study by Meskin and co-workers revealed a negative correlation of molecular weight and milk plasma 
ratios.[294] We could reconfirm his observation in our CART model trained with CDK descriptors, 
where lower values were associated with well-permeating compounds. 
 
Additionally, CART classified drugs exhibiting molar refractivity over the critical threshold as 
permeating drugs (BM+). Molar refractivity refers to molecular shape and compactness. Tightly packed 
compounds would more readily permeate through membranes than highly branching ones. 
Gravitational index 4 considers the mass distribution related to intramolecular distances accounting for 
the bulk cohesiveness. Information on molecular graph complexity gave topological shape descriptors 
of second order (Kappa shape Index, Kier 2) included by CART. Other groups confirmed the role of 
molecular density and complexity in the permeation capacity.[178, 295] 
 
Lipophilicity plays a delicate role in determining permeability. It is certainly a prerequisite for membrane 
interactions and permeation into milk. However, in maternal circulation, high lipophilicity hampers 
solubility and enhances serum protein binding, counteracting a compound's distribution and eligibility to 
be secreted. None of our models selected partition coefficient (LogP), although some seminal work 
accounted for the descriptors dominant role in estimating drug diffusion into breast milk.[63, 296] In 
these studies, the number of features was restricted by an expert-based preselection. We agree with 
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Agatonovic and co-workers, who stated that with higher dimensional descriptors at hand, machine 
learning paradigms can select more refined measures of lipophilicity than LogP.[295]  
 
Molecular polarity played a key role in models trained with CDK descriptors. Polarity refers to a 
compounds hydrophilic potential and can be seen as an indirect measure for lipophilicity. Namely, 
charged polar surface area descriptors were prominent splitting criteria in the CHAID tree. We 
observed a certain tendency in compounds with low polarity (i.e., more lipophilic drugs) to better 
permeate into mother milk. However, thresholds set in our models were subtle and reflected the narrow 
scope of this attribute. 
 
All splitting criteria selected from the DRAGON set relied on weighted matrices. Weighting schemes 
are used to encode chemical information on bonds or molecules that is not contained in a molecular 
graph. SpDiam_AEA(dm) and Eig07_AEA(bo) belong to the edge adjacency indices, where spectral 
diameter and eigenvalue of the augmented edge adjacency (AEA) matrix are considered. Bond 
matrices based on the chemical graph theory encode information on intramolecular connectivity. The 
weighting schemes considered bond order (bo) and dipole moment (dm). The importance of 
connectivity and molecular polarity corresponds with our findings from CDK descriptors. 
 
Spatial autocorrelation descriptors, such as Moran's (MATS) and Geary’s (GATS) autocorrelation were 
chosen by both paradigms. Autocorrelation descriptors evaluate a certain atomic property for every 
atom in the molecule. Both features selected by CART used molecular ionization potential (i) as 
weighting property. The involvement of ionization could refer to an ion-trapping effect as breast milk 
exhibits a lower pH than human plasma. Electronegativity (e) and molecular mass (m) were the 
weighting schemes selected by CHAID. Observations from CDK learned trees confirmed involvement 
of charge and mass in predicting BM-/BM+ compounds. Two features were weighted by intrinsic state. 
Namely, these were R4s from the GETAWAY descriptor containing information on molecular branching 
and Mor28s from the 3D MoRSE descriptors which encodes three-dimensional information based on 
electron diffraction.[297, 298] Intrinsic state gives information on the electrotopological state of a 
molecule. 
 
Our fragment-based approach gave information on structural requirements for safe drugs, e.g., poorly 
permeating compounds. The repeated selection of amides, oxygen, and hydroxy groups indicates 
involvement of hydrogen bonding capacity and molecular polarity. Other strongly polarizing groups, 
such as sulfoxyde are likely to oxydize amino acids, e.g., cysteine, at the binding site of transporters 
through irreversible addition of a thiol group.  
 
Interestingly, fingerprint fragments revealed by ACO included six-membered rings and aromaticity. We 
found these features also in typical substrates of BCRP such as chemotherapeutics (e.g., 
mitoxantrone), antivirals (e.g., zidovudine), and antibiotics (e.g., ciprofloxacin).[299] However, there is 
evidence that the mammary gland epithelium expresses a multitude of transport proteins including 
other ABC transporters such as P-gp (MDR1).[300] In contrast to BCRP, studies indicate an apical to 
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basolateral transport, which would counteract drug accumulation in breast milk.[104] As both proteins 
share certain substrates, the complexity of molecular interplay may be potentiated. In earlier models of 
metabolic enzymes and P-gp, constitutional and connectivity measures played key roles to predict 
substrates.[177] Thus, we were not surprised to find parallels between our results and those from other 
models of these transporters.  
 
Conclusions 
Excretion of drugs into breast milk remains poorly understood. Beside passive diffusion form plasma to 
milk, other transport mechanisms exist for various compounds, as evidenced by the emergence of 
further transport proteins that play a role in mother milk composition. Excretion and reabsorption 
processes additionally confound the issue. Therefore, our approach to predict breast milk excretion 
beyond separation into active and passive processes seems sensible. Although our models do not 
compensate for careful assessment of single biological mechanisms involved, they are able to predict 
the drug presence in human breast milk.  
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Abstract 
Multidrug resistance protein 2 (MRP2) plays an important role in drug clearance and efflux. As both, 
the functional loss and overexpression were associated with pharmacokinetics alteration of several 
drugs, knowledge on structural and physicochemical requirements for MRP2 drug interaction is 
desirable. We performed a computational analysis based on a small molecule datasets from literature 
providing information on MRP2 inhibitors (n = 277), inducers (n= 122) and substrates (n= 76). 
 
Decision trees were induced and resulting models predicted inhibitors and inducers with a corrected 
classification rate (CCR) of 87.3 - 87.6%, 84 - 90.9%, respectively. Our tree models used descriptors of 
charge and molecular complexity along with connectivity measures to predict MRP2 inhibitors and 
inducers. 
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Introduction 
See Section 3.2.3.1. 
Despite the clinical implications of MRP2 on drug excretion, knowledge on requirements for MRP2 
interaction is mostly restricted to results of single compound analysis. Quantitative structure activity 
relationship (QSAR) analysis is ideally suited to summarize these data to get more generalized 
information on physicochemical properties involved. Moreover these techniques enable 
implementation of fast and accurate screening techniques for future drug development. Computational 
methods have already been successfully applied to model drug behavior of other ABC transporters, 
such as P-gp and BCRP.[258, 299, 301] It was our intention to contribute to the ongoing discussion on 
the chemical requirement for MRP2 interaction, by presenting a decision tree approach to predict this 
highly complex endpoint. The production of easily interpretable rules is certainly an advantage of 
decision tree induction. They can easily be implemented to apply them on unseen compounds to 
predict MRP2 inhibitors, inducers and substrates.  
 
Materials & Methods  
Data sets 
We assembled three datasets of small molecules from published literature. The dataset concerning 
MRP2 inducing compounds consisted of 122 entities. We found 52 inducers and labeled them as  
“MRPind+”. All molecules that were explicitly found to not induce MRP2 expression received the labeled 
“MRPind-”.  
 
We collected a set of 277 compounds where information of their inhibitory function on MRP2 was 
available. We found 146 Inhibitors (label = “MRP2inh+”) and 131 non-inhibitors (label= “MRP2inh-”). The 
data set for MRP2 substrates consisted of 77 molecules, of which only 10 were explicit non-substrates.  
 
Descriptors  
See Section 4.2.  
 
Decision Tree Induction  
See Section 4.3.1 
We used classification and regression trees (CART) to induce trees for the current study.[204] A prior 
feature reduction was not needed as decision trees perform implicitly by themselves a feature 
selection. To grow trees we restricted splitting in parent nodes to a minimum of five instances and in 
child nodes to a minimum of two cases. CART was grown to a maximum depth of five levels.  
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Quality measures 
See Section 4.5. 
 
Cross-validation 
See Section 4.6.2. 
 
Software 
See Section 4.6.3. 
 
Results  
MRP2 Inducers: 
The best performing trees for MRP2 inducers were created on DRAGON features (CCR: 90.9%). The 
paradigm produced models with 83.5% CCR on CDK features. Figure 32 shows the corresponding 
tree. 
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Figure 32 - Classification and regression tree (CART) trained on DRAGON features. The paradigm 
achieved a corrected classification rate (CCR) of 90.9%. Splitting criteria were eigenvalue of the 
augmented adjacency matrix weighted for dipole moment (Eig02_AEA[dm]), Schultz molecular 
topological index by valence vertex degrees (SMTIV), Balaban like index from the Barysz matrix 
weighted by polarizability (J_Dz[p]), spectral moment from the Barysz matrix weighted by 
ionization(SM1_Dz[i]), mass weighted largest Burden eigenvalues (SpMax_B[m]), number of six 
membered rings (nR06), molecular electrotopological variation (DELS), mass weighted Burden matrix 
(SpMAD_B[m]), bond order weighted spectral moment of the augmented adjacency matrix 
(SM02_AEA[bo]). MRP2ind+ indicates MRP2 inducers while MRP2ind- indicates non-inducers. 
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Figure 33 - Decision tree induced on CDK features is shown. The tree achieved a correct classification 
rate of 83.5%. Features selected were polarizability weighted BCUTS, gravitational Index four, relative 
positive charge (rPCG), molar refractivity, charge weighted partial positive surface area (pPSA3), bond 
count, moment of inertia on the z-axis, and relative sum of solvent accessible surface areas of atoms 
with absolute value of partial charges less than 0.2 (rHSA). MRP2ind+ and MRP2ind- indicates MRP2 
inducers and non-inducers, respectively. 
 
MRP2 Inhibitors: 
The best model for MRP2 inhibitors was produced with the CART paradigm on DRAGON features, 
yielding a CCR of 87.6% (Figure 34). The corresponding tree using CDK features predicted the 
endpoint with 87.3% CCR (Figure 35).  
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Figure 34 - The best decision tree predicting MRP2 inhibitors on DRAGON features with corrected 
classification rate (CCR) of 87.6% is shown. Splitting criteria were Hosoya like index form the chi 
matrix (Ho_X), dipole moment weighted eigenvalue of the edge adjacency matrix (Eig03_EA[dm]), 
distance/detour ring index of order 9 (D/Dtr09), pharmacophore pair distance of hydrogen donors and 
lipophilic groups (CATS2D_07_DL), edge degree weighted eigenvalue of the augmented adjacency 
matrix (Eig14_AEA[ed]), squared Moriguchi octanol water partitioning coefficient (sLogP2), bond order 
weighted leading eigenvalue of the augmented adjacency matrix (SpMax_AEA[bo]), polarizability 
weighted Balaban like index from the Barysz matrix (J_Dz[p]), sum of Sanderson electronegativity 
(Se), double bound oxygen count (O-058), average van der Waals volume weighted Wiener-like index 
from the Barysz matrix (WiA_Dz[v]), average vertex sum of the chi-matrix (AVS_X). MRP2inh- and 
MRP2inh+ indicates non-inhibitor and inhibitor, respectively. 
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Figure 35 - Classification and regression tree trained on CDK features is shown. MRP2 inhibitors and 
non-inhibitors are indicated as MRP2inh+ and MRP2inh-, respectively. Features selected include 
moment of inertia in the z-axis, charge weighted partial positive surface area (pPSA3), partition 
coefficient (aLogP), aromatic atom count, the sum of the absolute difference between atomic 
polarizabilities of all bonded atoms in the molecule (bPol), charge weighted partial positive surface 
area (wPSA3) and partial negative surface area (wNSA2) multiplied by molecular surface, partial 
negative surface area multiplied by total negative charge (pNSA2), Wiener polarity number (Wiener 
polarity num.), gravitational index one and four (grav. Index 1, grav. Index 4), relative sum of solvent 
accessible surface areas of atoms with absolute value of partial charges less than 0.2 (rHSA), charge 
weighted partial negative surface area divided by total surface (fNSA3), and relative negative charge 
(rNCS). The paradigm performed with a corrected classification rate (CCR) of 87.3%. 
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Performance of CART predicting MRP2 inhibitors and inducers on both feature sets is summarized in 
Table 26. 
 
Dataset Feature Set CCR (%) MCC (%) SENS (%) SPEC (%) 
MRP2 Inducers CDK 83.5 66.8 94.2 72.9 
 DRAGON 90.9 83.4 84.6 97.1 
MRP2 Inhibitors CDK 87.3 76.0 95.2 79.4 
 DRAGON 87.6 76.8 95.9 79.4 
 
Table 26 - A summary of the 10-fold cross-validates decision trees on MRP2 inducers and inhibitors is 
given. Trees were trained on DRAGON and CDK features.  Corrected classification rate (CCR), 
Matthews correlation coefficient (MCC), sensitivity (Sens), and specificity (Spec) are indicated. Best 
models are highlighted in bold letters. 
 
MRP2 Substrates: 
Our dataset of MRP2 substrates was strongly skewed, in a way that only 10 compounds were judged 
to be non-substrates. The number of these negative compounds would be by far to small to make 
adequate assumptions on their chemical requirements. Although our decision trees could discriminate 
between these unbalanced groups, interpretability was severely reduced because of the small class 
size (data not shown). 
 
Discussion  
We presented three new datasets assembled form literature for MRP2 inhibitors, inducers, and 
substrates. The data consisted only of experiments conducted on human MRP2. Compared to other 
transporters, reports on MRP2 drug interaction were relatively rare in literature. Ideally, one would 
create a database on a high-throughput screening. However, these are still missing for MRP2. This 
might be due to the highly interactive character of transporter and enzyme interplay on level of the 
polarized cell. The establishment of a potent in vitro essay, such as MRP2 expressing polarized cells, 
is a challenging endeavor. Interestingly, relevant directed transport occurs only in presence of 
coexpressed basolateral uptake transport.[302, 303] Moreover, there is evidence that minimal 
mutations in MRP2 lead to broader substrate specificity and activity.[131, 304, 305] Further analysis of 
single nucleotide polymorphisms will hopefully lead to more specific essays for substrate testing. 
Another issue, which is hard to address is the saturation capacity of the transporter. The experimental 
data published is mostly restricted to a careful analysis of single compounds, which holds that 
information. However, for the present study, we decided to use a simplified view by binning 
compounds in positive or negative classes, regarding their activity. This procedure would allow for 
models with higher discriminatory power, as it would compensate for differences in experimental 
settings and show a reduced vulnerability for overfitting. 
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For inhibitors and inducers we assembled well balanced datasets, in terms of positive compounds not 
outweighing positive ones. They readily qualified for computational analysis. This did not hold for our 
MRP2 substrate dataset. Although we assembled 66 substrate compounds, only 10 molecules were 
reported to be explicitly not substrates of MRP2. We feel that non- transported compounds suffer from 
a positive publication bias, despite their impact for drug development. Although our decision trees 
could discriminate between these unbalanced groups, interpretability was severely reduced (data not 
shown). The computational analysis led most likely to a projection of the dataset instead of the 
effective requirements for MRP2 substrates.  
 
As discussed before, adequate essays for MRP2 substrates involve a multitude of factors such as 
influx transporters and probably also metabolic enzymes, which transform parent compounds. The 
proximity and interaction with phase I and II enzymes underlines this assumption. Structures with high 
lipophilicity and charge are typically metabolized by cytochromes.[177] Such compounds could likely 
be prone to prior metabolism before undergoing secretion by MRP2. Hence, it would be tempting to 
assess every metabolism and transport step by a single model and then concatenate these to predict 
general drug excretion. We feel that such an approach would introduce error accumulation, as every 
single model suffers from an individual degree of uncertainty. Several studies showed that for creation 
of robust and noise resistant computational models, simplification to end- and starting point is a valid 
and beneficial procedure.[259, 260]  
 
Decision trees of MRP2 inducers and inhibitors were highly accurate in discriminating active and 
inactive compounds. The best model for inhibitors was achieved on DRAGON features, yielding 
predictions of 87.6% accuracy (Table 26). Inducers were predicted with 90.9% accuracy. This is a 
remarkable performance as all models were cross-validated. Our models for inhibitors outperformed 
recent modeling attempts by Zhang et al. and Pedersen et al., who reported an accuracy of 77% and 
72%, respectively.[306, 307] In both studies, no cross-validation was applied. 
 
To our knowledge, MRP2 shares many inhibitors and inducers with other ABC transporters like P-gp or 
BCRP. Certain resemblance of the splitting criteria revealed by our trees with earlier studies 
concerning P-gp modeling does therefore not surprise. A computational analysis of P-gp interactions 
revealed an involvement of lipophilicity and aromaticity to discriminate inhibitors form non-
inhibitors.[258] A study of BCRP inhibition used exclusively lipophilicity and polarizability to 
discriminate inhibitory compounds.[308] We are therefore not surprised to find these features in both 
trees for MRP2 inhibitors. While in models of P-gp inhibitors ring bonds played a dominant role,[258] 
MRP2 inhibitors seemed to be more dependent on charge distribution, reflected by repeated selection 
of cPSA descriptors. Interestingly, our findings reconfirmed a recent study of Pedersen at al., where 
they state a correlation of lipophilicity, polarity, and aromaticity with MRP2 inhibitors. [307] A relatively 
unusual feature to classify inhibitors on, is the molecular mass distribution, quantified by gravitational 
indices. Trees trained on CDK features selected the first and the fourth index for discrimination. These 
indices could be seen as a refined measure for molecular mass introduction. Additionally, the 
descriptor holds information on molecular connectedness and geometry. Although not commonly used 
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to study ABC transporters, gravitational indices and moment of inertia have been used to model 
cytochrome P450 (CYP) inhibitors.[177] This could be an indication of the transporter's interplay with 
phase one enzymes like CYPs. However, we found also a links to hepatotoxicity prediction studies. 
Drugs associated with toxicity were generally more lipophilic and charged than safe compounds. [259] 
 
MRP2 inducers were generally compacter and bulkier molecules than non-inducers were and showed 
a tendency for higher polarity. However, we could not generally associate smaller size with inducer 
activity as proposed by Pedersen.[307] Our CDK features tree indicated a rather fine discrimination, 
where additional features such as charge distribution and molecular interconnectedness are taken into 
account. In the tree built with DRAGON descriptors, we saw a tendency of inducers exhibiting lower 
numbers of six-ring structures, which indicated that they are less lipophilic than non-inducers. We 
stress that the splitting criterion cannot be interpreted in isolation, as charge weighted connectivity is a 
dominant factor in this tree. 
 
Interestingly, we found in consistency with a comparable study of P-gp,[258] that decision trees for 
inhibitors were more complex and deeper than those for inducers. This could reflect the multitude of 
possible drug interactions leading to transporter inhibition. While it was argued that MRP2 inducers 
would bind on one of the transporter’s two binding sites, the example of P-gp teaches us that 
transporter inhibition can involve far more complex mechanisms. 
 
Conclusion 
We were able to present three datasets concerning MRP2 inhibitors, inducers and substrates of 
reasonable size to apply computational methods on them. The models produced predicted their 
endpoint with high discriminatory power. Although the establishment of HTS screening for MRP2 could 
improve standardization and quantity of data available, we feel that decision trees can substantially 
contribute to extrude information even out of inhomogeneous data. An advantage of DTI is their rule-
based output, which can easily be implemented without any specialized software. In this way, our 
models will, besides their contribution to our knowledge on MRP2 interaction, also serve as sensitive 
screening tools in drug development and toxicity screening. 
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Abstract 
Chemical fingerprints encode the presence or absence of molecular features and are available in many 
large databases. Using a variation of the Ant Colony Optimization (ACO) paradigm, we describe a 
binary classifier based on feature selection from fingerprints. We discuss the algorithm and possible 
cross-validation procedures. As a real-world example, we use our algorithm to analyze a Plasmodium 
falciparum inhibition assay and contrast its performance with other machine learning paradigms in use 
today (decision tree induction, random forests, support vector machines, artificial neural networks). Our 
algorithm matches established paradigms in predictive power, yet supplies the medicinal chemist and 
basic researcher with easily interpretable results. Furthermore, models generated with our paradigm 
are easy to implement and can complement virtual screenings by additionally exploiting the pre-
calculated fingerprint information. 
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Introduction 
Chemical fingerprints, which are in essence hashes calculated from molecular structures, are 
frequently used in large chemical database.[309] These fixed-length strings encode a variety of 
molecular properties, oftentimes the presence or absence of a substructural motif.[310, 311] Using 
fingerprints, it is possible to quantify chemical similarity, restrict searches to a number of promising 
candidates, and so on.[312, 313] A variety of distance measures exist to determine proximity between 
two molecules and also to define clusters of similar structures.[309, 314] 
 
According to the similarity principle, molecules with closely related structures are likely to exhibit the 
same activity.[315] While similarity may be defined as small distance from a selected point (e.g., a 
centroid in clustering), one may also construct a plane of separation within the attribute space to 
distinguish one type of molecule from another. A typical example of this approach are support vector 
machines,[316] and these have been successfully employed in many quantitative structure-activity 
relationship (QSAR) studies.[317] 
 
Statistical models often rely on a number of physicochemical descriptors, which are rarely available in 
chemical databases. Screening an entire database therefore requires retrieving the complete set of 
structures and subsequently calculating these properties. On the other hand, fingerprints already 
contain many properties calculated upon insertion into the database. A classification scheme based on 
fingerprints could therefore save data traffic and computing power. 
 
Such a classifier would need to find a subset of attributes present in a list of desirable molecules and 
absent in a list of negative controls. This feature selection is essentially an optimization problem. In 
recent years, the field of natural computing has produced intriguing heuristics for optimizations in 
engineering and the natural sciences. Ant Colony Optimization (ACO), a paradigm introduced in the 
1990s,[224] has drawn a special amount of attention. Real-world ants are abstracted as agents able to 
traverse a graph while they deposit a pheromone whose intensity decays over time. An ant scurrying 
about the graph at random until it finds a food source initiates the process. It then returns to the 
starting point in a more or less direct trajectory. Other ants explore the graph and weigh their choices 
of route by previously deposited pheromones. Eventually, shorter (i.e., more efficient) paths will 
extrude a more intense signal and become points of convergence.  
 
Here, we propose a binary classifier that uses an ACO variant to select relevant molecular fragments. 
Modifications of ACO have been proposed previously for variable selection and reduction of 
dimensionality.[318] They have also found application in the field of drug discovery, where they, 
however, were used in ensemble prediction settings (as feature reduction prior to e.g., linear 
regression [319, 320] or support vector machines [320] QSAR/QSPR studies of anti-HIV activity and 
human serum albumin binding activity, respectively). ACO is also often employed (along with other 
optimization paradigms) in protein ligand-docking studies.[321] While ACO has been applied to 
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molecular binary classification (e.g., as an estimator of splitting criteria in decision tree induction),[322] 
we are not aware of its solitary use in fragment analysis. 
 
The variant described by us can be visualized with the ant colony at the center and various single 
fingerprint flags as the vertices of edges of equal length radiating from the center, i.e. a complete 
bipartite graph S1,n where n is the number of fingerprint flags (Figure 36). From this, the method 
compiles a subset of flags that are associated with a given label or activity. 
 
 
Figure 36 - Sample graphical depiction of the ant colony feature selection problem for twelve different 
attributes. Edges are of equal length, with the colony at the center (*). 
 
Theory 
Fingerprints 
For a molecule A, a fingerprint F with n elements takes the form of an attribute vector FA  [309] 
 
 
 
The fingerprints used in this context are dichotomous (or binary), i.e. each element fxA corresponds to a 
bit with encodes the presence (ON) or absence (OFF) of a feature within the molecule A. 
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Classification problem 
The problem can be stated as follows: given a total of n positions in a set F of fingerprints bits, find the 
subset S of magnitude m (m<n, S ! F) so that the subset of features Q (Q ! F) present in all active 
compounds has maximum specificity and sensitivity compared to the set of inactive compounds. 
Initially, a fixed number na of ants, each with the ability to select m features, explore the feature space 
at random, and return to the nest. This random exploration is implemented by assigning a random 
amount of pheromone ! (range 0 to 1) to each feature at the start of a run. Here, a heuristic fitness 
function H rates each ant’s performance, and ants are ranked by quality of their subset. The best k (k < 
na) ants are selected and deposit a constant amount ! of pheromone on the edges connecting 
members of their subset to the nest. The other ants are ignored. All n edges are allowed to evaporate 
their pheromone trails by a constant linear term d, and a new cycle is initiated. Again, na ants are 
created. Each ant now generates a random number ri for each i of the n edges connected to the nest 
(0 " rn " 1) and ranks their attractiveness by choosing those with a maximal value for the term 
 
! 
ai = ri" i  
 
where !i is the intensity of the pheromone signal on edge i, and ri the random weight. With the 
introduction of the random term, exploration of other combinations is encouraged. Over a given 
number of cycles, information-rich features are reinforced and increasingly become part of subsets 
until ants will almost uniformly choose these same features (Figure 37). Chart 1 further illustrates the 
proposed method. 
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Chart 1 - Pseudocode representation of learning algorithm. 
KeyLength: length of fingerprint key in bits 
m: number of features in ant memory 
n: number of ants to create per cycle 
k: number of ants to keep per cycle, where k <= n 
Pheromones: list of length KeyLength containing pheromone intensities associated with keys 
 
Initialize Pheromones with random floating point values from the range [0, 1] 
 
repeat for a given number of cycles 
 repeat for each of n ants 
  copy Pheromones to Pheromones’ 
  multiply every position in Pheromones’ with random floating point number from the 
   range [0, 1] 
  find m positions in Pheromones’ with highest value 
  compute fitness H and store with ant 
 end repeat 
 
 select k ants with highest H and repeat for each of m features in ant memory add constant 
  pheromone amount ! to corresponding value in Pheromones 
 
 for each position in Pheromones subtract constant linear evaporation rate 
end repeat 
 
Output: the list of pheromone intensities Pheromones  
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Figure 37 - Visualization of evolution of a solution over a number of cycles as produced by the software 
written for this study. Initially, many different attributes are being explored until several strong attributes 
are converged upon (indicated by intensity of pheromone trail). 
 
Heuristic fitness function H 
The heuristic fitness function H used in this study first finds the cardinality ci of the intersection Ii of the 
subset S of features being evaluated and the entire set of features Mi (Mi ! F) of each molecule i in a 
training dataset such that !
 
Depending on the original parameterization of the ant agents, ci will take on values between 0 and 
cardinality of S. The fitness function determines ci for every instance in the training set and group 
instances by this value. Sensitivity and specificity of S for active molecules can be ranked by the area 
under the curve (AUC) of receiver operating characteristic (ROC) curves, as ci as a cut-off value 
increases. This AUC is also the return value of H(S) for a subset S. A pseudocode representation is 
given in Chart 2. 
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Chart 2 - Pseudocode representation of heuristic fitness function H. 
 
Statement of models 
The ROC curves are used further to determine the cut-off point with optimal sensitivity and specificity. 
The Youden index [323] J given as  
 
J = Sensitivity + Specificity – 1 
 
is maximal for this point (Section 4.5.3). A model built in this fashion can therefore be stated as the set 
of features indicative of activity and the minimum number of features required to qualify as active. A 
model P built with m features and cut-off point at p features takes the form of 
 
P = {{x1, x2, …, xm}, p} 
 
As an illustration, consider a sample model M trained from a set of 100 possible binary keys to select 
the 10 keys associated with a given activity. This might look as follows: 
 
M = { { 4, 12, 15, 23, 38, 42, 61, 89, 90, 95 }, 3 } 
 
For an instance to be classified as active, 3 or more of the 10 features would need to be present in its 
key vector, e.g., a molecule with a vector  
 
Mol1 = { 10, 12, 19, 20, 23, 38, 49, 50, 67, 70, 82, 83, 100 } 
 
would classify as active (as the intersection with the key vector in model M has a cardinality of 3).  
 
TrainingData: training data with binary labels and fingerprint keys 
AntMemory: set of m keys 
 
repeat for each instance in TrainingData 
 compute hits (i.e. ci) as the number of keys present in both the instance and AntMemory 
 sort and divide instances in TrainingData by hits 
 continuously combining groups of instances ordered by value of hits, compute true and  
  false positive rates for all instances as coordinates 
 calculate the area under the curve formed by these points 
end repeat 
 
Output: area under the curve 
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Cross-validation procedure 
To avoid overfitting (i.e., creating overly complex models with very high predictive accuracy on training 
data by extracting too many parameters from the known data at the expense of not being able to 
predict unseen compounds), we used k-fold cross-validation (CV). Here, a data set is randomly 
recombined into k subsets (here k=10).[324] Of these, k-1 are re-combined to make up a training set 
which is tested against the remaining subset. This process is repeated k times until all instances have 
served as training and test data, thereby making sure that no classes are left out. Sets were 
permutated using the Fisher-Yates-Shuffle algorithm as detailed by Knuth.[325] 
 
We evaluated three different ways of combining the different models: averaging of pheromone weights 
in every fold (averaged model), selection of most frequently employed attributes (frequency model), 
and combination of attributes most frequently selected by elite ants (elite ants model), i.e. the single 
best performing ant within a run. For averaging, the pheromone weights associated with each of the n 
attributes are normalized to a range (0, 1). Next, all of the k pheromones for a given attribute are 
summed up. The result is a list of n combined pheromone weights ranging from 0 to k, allowing them to 
be ranked. Attributes of the highest rank are selected and make up the final model. For the frequency 
model, the highest-ranking attribute of each fold is selected. In order to create the elite ants model, the 
software stores the single best performing ant of each fold. The corresponding feature sets are 
combined in the same manner as in the frequency model. 
 
Performance measures 
See Section 4.5. 
 
Plasmodium falciparum growth inhibitor assay 
Dataset and preparation 
Models were learned from data of a high-throughput SYBR Green proliferation assay of P. falciparum 
(Pf) infected red blood cells published by Plouffe et al.[326] The data was retrieved from PubChem 
(http://pubchem.ncbi.nlm.nih.gov/) and contains a total of 1,272 compounds (201 active, 349 inactive, 
and 722 inconclusive). We omitted compounds labeled as inconclusive, as well as those for which not 
every CDK descriptor could be calculated (n=3). We removed disconnected small fragments such as 
counterions prior to any calculation in analogy to McGregor and Pallai.[310] 
 
We evaluated three fingerprint keys (MACCS (MDL), STANDARD, EXTENDED) available in the latest 
stable Chemical Development Kit (Version 1.2.7).[327] The 166 bit MDL key [310] was used in the final 
model as it is the best documented of the three and has been optimized to allow for clustering of 
bioactive substances in the context of drug discovery. The concept of fingerprint darkness refers to the 
fraction of bits set to ON, i.e. we consider fingerprints with more bits set to ON as darker. The 
characteristics of the three different keys evaluated are given in Table 27. 
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Key Class mean% max% min% sd% 
MACCS negative 29.7 49.4 4.8 7.8 
 positive 24.1 49.4 1.2 9.2 
 total 26.1 49.4 1.2 9.1 
Standard negative 9.9 49.9 0.1 8.3 
 positive 17.1 60.1 0.8 9.6 
 total 12.5 60.1 0.1 9.4 
Extended negative 10.2 51.4 0.1 8.4 
 positive 17.6 59.7 0.8 9.6 
 total 12.9 59.7 0.1 9.6 
 
Table 27 - Mean fingerprint darkness (number of bits set over total number of bits), with minimum 
(min%), maximum (max%) percentages and standard deviation in percent (sd%) of the 166 bit MACCS 
key and the 1024 bit standard and extended keysets. 
 
Of these, the MACCS 166 bit key shows the greatest darkness (26.1%), implying that it is capable of 
reflecting the most features with the least computational effort. 
 
Training of models 
We let the classifier learn over 100 cycles with to produce models of with a magnitude of 10. Ants 
deposited a pheromone amount ! = 0.1 which evaporated by d = 0.05 within cycles. We performed 100 
runs using the three different modes of cross-validation outlined above. This amounted to a total of 300 
models. For comparison, we created models with a decision tree induction algorithm (J4.8, a C4.5 
variant), random forests (RF) of ten trees with five attributes each,[328] support vector machines 
(SVM) using a polynomial kernel function, and artificial neural networks (ANN) with a single hidden 
layer. In line with other current studies, models were learned in a 10-fold cross-validated context.[260, 
329] The numerical attributes used in this process were the 1D and 2D descriptors (n = 27) available in 
the CDK (molecular weight, calculated partitioning coefficient (LogP), topological polar surface area, 
BCUT metrics, fragment complexity, atom and bond counts of aromatic and of all atoms, hydrogen 
bond donor and acceptor counts, Kier-Hall shape indices, Petitjean number, number of rotatable 
bonds, atomic polarizability, length of largest chain and largest aliphatic chain, as well as length of 
largest " chain).[330] 
 
Model performance 
The classification results of the best performing models for each mode of cross-validation are shown in 
Table 28. All three CV procedures achieve comparable CCRs of 0.84 to 0.87 - values that match those 
of the other paradigms implemented. An elite ant model achieved the highest CCR (0.87). Its 
associated ROC curve has a high area under the curve of 0.91 and is given in Figure 38. It is readily 
apparent from Table 29, which presents the substructural motifs selected by the model, that the binary 
ACO classifier retrieves fragments with a mechanistical relevance. 
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 TP TN FN FP CCR MCC Accuracy 
Elite ACO Model (Run 36) 171 307 29 40 0.87 0.73 0.87 
Frequency ACO Model (Run 17) 169 294 31 53 0.85 0.68 0.85 
Averaged ACO Model (Run 16) 162 303 38 44 0.84 0.68 0.85 
J48 156 313 44 34 0.84 0.69 0.86 
RF 155 316 45 31 0.84 0.70 0.86 
SVM 157 317 43 30 0.85 0.71 0.87 
ANN 161 296 39 51 0.83 0.65 0.84 
 
Table 28 - Results of binary ant colony optimization (ACO) classification using three different cross-
validation paradigms and comparison with established machine learning paradigms. The data consists 
of 547 instances (positive: 200, negative: 347). J48: decision tree induction, RF: random forests, SVM: 
support vector machines, ANN: artificial neural networks. Performance is measured as corrected 
classification rate (CCR), Matthews correlation coefficient (MCC), and accuracy. 
 
Figure 38 - Receiver operating characteristic curve for the best performing classification model in this 
study (area under the curve = 0.91). The circle denotes the cut-off point from which on instances are 
classified as positive. 
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Index Depiction SMARTS Comment 
25 
 
[#7]~[#6](~[#7])~[#7] trisamino / imino 
methylene. 
49 
 
[!+0] presence of charge. 
75 
 
*!@[#7]@* interposition of nitrogen. 
86 
 
[C;H2,H3][!#6;!#1][C;H2,H3] carbon – heteroatom – 
carbon chain. 
124  
[!#6;!#1]~[!#6;!#1] two connected 
heteroatoms. 
127 
 
*@*!@[#8] oxygen connected to any 
ring system via a single 
bond. 
137 
 
[!C;!c;R] any heterocycle. 
140 
 
[#8] presence of oxygen. 
144 
 
*!:*:*!:* aromatic ring substituted 
in ortho-position by two 
non-aromatic substituents. 
161 
 
[#7] presence of nitrogen. 
 
Table 29 - Fingerprint keys associated with a Plasmodium falciparum growth inhibition as determined 
by binary ant colony optimization classification. Substructural motifs are given with their position 
(index), SMILES arbitrary target specification (SMARTS) along with an image and an explanation. 
 
For instance, the presence of nitrogen and oxygen atoms in different frameworks (keys 25, 75, 127, 
140, and 161) is characteristic of drug-like molecules (hydrogen bonding capacity) as well as important 
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for successfully overcoming cellular membranes. They are also present in molecules which exert 
oxidative stress, to which P. falciparum is very sensitive. The prevalence of both nitrogen and oxygen 
are high in small molecule drugs. Of course, some rare examples exist which contain neither 
(noteworthy members of this class are lindane and mitotane, two chemotherapeutic agents) and many 
molecules contain exclusively one these atom species (e.g., nitrogen in amitryptiline, selegeline, and 
memantine, and oxygen in ivermectin, digoxin, and cholecalciferol). This shows how the substructures 
identified by the paradigm need to be interpreted together. For example, nitrogen appears in other 
keys (keys 25 (trisamino / imino methylene) and 75). Presence of one of these more complex 
substructures therefore automatically increases the score and, by consequence, the likelihood of 
positive classification. In the same vein, molecules lacking keys 25 or 75 can improve their score by 
offering other hydrogen binding sites, e.g., oxygen (keys 140 and 127), thereby increasing their drug-
likeness. 
 
A key enzyme in the life cycle of Pf, the cysteine protease Falcipain-2 (FP-2) that degrades 
hemoglobin (Hb), can be inhibited by certain epoxysuccinates and aziridinyl substituents in quinone 
rings (perceived, amongst others, by keys 86 and 137) have been shown to enhance antiplasmodial 
activity by inhibiting Pf glutathion reductase.[331] The life cycle of Pf is particularly vulnerable during 
the erythrocytic stage as its metabolism is largely anaerobic and hence sensitive to oxidative stress. 
 
Conclusions 
We investigated whether binary classification of molecular activity using a variation of the ACO 
paradigm could become a valid alternative to other ML classification methodologies. Analysis of the Pf 
inhibition assay by Plouffe et al. shows the high degrees of accuracy achieved by our models and their 
competitiveness with established ML methods.[326] 
 
The different modes of CV produce similarly powerful classifiers. From Table 28 it is evident that these 
models stem from different runs, i.e. the choice of CV influences the final performance, and no final 
ranking can be made between these modes. Therefore, we consider it advisable to calculate all three 
to maximally exploit the information extracted by the learning process. 
 
The information provided to the binary ACO learning algorithm was in essence a list of the presence or 
absence of substructural motifs or fragments, i.e. two-dimensional structural information. We, 
therefore, explicitly learned the alternative ML methods from two-dimensional descriptors as well to 
ensure a level playing field. Arguably, one might see better performance of the established ML 
methods with a different choice of descriptors. Conversely, other fingerprint keys could improve the 
results of binary ACO classification. 
 
We chose MACCS over the other available fingerprint keys in CDK because of its length (166 bits vs. 
1024 bits for Standard and Extended) and its high ratio of keys set to on. Notably, the molecules 
tagged as negative have a higher fingerprint darkness than the positive instances, i.e., the inactive 
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compounds are actually captured better than the active ones. When one learns a model to distinguish 
active compounds by presence of certain features from such a data set, it is apparent that the 
algorithm cannot simply associate fingerprint darkness of a compound with activity. 
 
The substructures encoded in the MACCS fingerprint are oftentimes ambiguous or very general, and 
features selected by our algorithm can overlap (e.g., keys 25 and 161). Still, models perform well and 
robustly in a cross-validated setting. This indicates that the subsets of keys are more than the sum of 
their parts, i.e. the individual contribution of a key must be seen in the context of the entire subset. 
Also, a feature that is recognized by several keys is amplified (or deemed more important) in the 
perception of the classifier. 
 
Binary ACO models can benefit the drug discovery process in two principle ways. First, the models 
provide an explicit fragment analysis directly accessible to human interpretation. Medicinal chemists 
can use them as guides for further development. Secondly, models can be applied directly to existing 
databases without any further calculations if both use the same fingerprinting scheme. This is in 
contrast to more elaborate numerical methods (e.g., SVM or ANN) where a) a number of 
physicochemical descriptors need to be computed, and b) the software implementation of the classifier 
itself is complex. In fact, binary ACO models learned from fingerprints could be implemented as native 
database queries. 
 
Of the learning paradigms employed in this study, decision tree induction took the least time to 
produce models. This, of course, does not consider the time required for calculating descriptors, 
performing intercorrelation analysis, and checking for missing values. Support vector machines had the 
most time-intensive learning process. For SVM, we are not considering the tedious process of 
optimizing learning parameters. Similar considerations, of course, have also to be made when applying 
the binary ACO algorithm. Proper choice of the model size, m, influences not only the interpretability 
and performance on unseen data, but also the time required to learn models. The number of cycles 
being spent on learning contributes directly to the computational expense. In summing up, the 
proposed algorithm ranks with SVMs in terms of time consumption for learning. A more thorough 
profiling does not seem called for, as the learning paradigms differ in practice in the amount of data 
preparation and optimization they require.  
 
In the future, this algorithm could be extended to numerical predictions, i.e. the learning process could 
correlate number of keys present with the degree of activity. Additionally, instead of merely identifying 
keys contributing to activity, a variant of the algorithm proposed here might single out detrimental 
features and incorporate them in the predictions. 
 
Software used 
See Section 4.6.3.  
Feature selection was performed using in-house software.  
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6 Conclusion and outlook 
It was the aim of the present thesis to assess drug transport across several physiological barriers using 
computational methods. As these barriers are found on different sites in the body such as the intestinal 
wall, the CNS, and the lactating breast epithelium, they vary in their characteristics and degree of 
tightness. However, all of them are able to alter drug distribution and pharmacokinetics. Generally, one 
could use in vitro methods to gain information on pharmacokinetics on the cellular level. However, 
these models are limited as they do not reflect complexity of the living system. Therefore, 
pharmacokinetic studies are ideally performed in vivo. Both methods can be time consuming and 
expensive, which does not meet the requirements for fast screening of chemical libraries. Meeting the 
demand for efficient ways to assess thousands of compounds for their pharmacokinetic behavior, in 
silico methods were developed to predict several relevant endpoints. The information content, which 
these models hold in turn shed new light on the processes involved. In the present thesis, it could 
indeed be shown that pharmacokinetic modeling can be applied to different barriers: 
 
In the first study, robust and accurate models were presented to predict human intestinal absorption. 
Emphasis was put on comparing different feature sets and performance of various machine learning 
paradigms. Although a variety of approaches was used, models revealed uniformly well-known 
features, such as measures of charge and lipophilicity, but also descriptors which are less commonly 
used to model human intestinal absorption, such as structural symmetry.  
 
Models for drug brain penetration reconfirmed the importance of well-known physicochemical features 
from other models, such as lipophilicity, size, and charge. However, substructure analysis and decision 
trees added new perspectives for predicting brain penetration, such as the involvement of 
stereochemistry. The underlying data were based on experimental LogPS values retrieved from rats. 
Although LogPS data of mice were available, they were not included into the present models to avoid 
bias due to relevant effects in different species. Ideally, a prediction for drug brain penetration would be 
based on data retrieved in humans. Hopefully, such data could be acquired in the future with non-
invasive techniques. 
 
Data preparation for the models dealing with prediction of drug permeation from maternal plasma into 
breast milk was a challenging endeavor. The data underlying these models was retrieved from 
literature, where information was available from nursing mothers. However, the quantities of drug 
retrieved in breast milk were often reported in an ambiguous manner. In order to produce meaningful 
and predictive models, numerous drugs with ambiguous endpoints had to be excluded from learning. 
Although it would be desirable to have a bigger data source of numeric data, models created on these 
imprecise endpoints performed with exceptional accuracy. Breast milk varies in nutrient composition 
regarding proteins and fat content during the lactating period. It is most likely that this change in 
composition would also have impacts on drug permeation. Future studies might address this issue by 
establishing models for single lactating periods.  
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In the study of MRP2 substrates, inducers and inhibitors, three new datasets retrieved from literature. 
Decision tree models of inducer and inhibitors data, as well as the substructure search for substrates, 
revealed insights in the requirements for MRP2 interaction. However, for these endpoints no gold 
standard for experimental settings and data acquisition has yet been defined. The complexity of influx, 
metabolic enzyme, and MRP2 interplay hampered the development of robust in vitro models, which 
would qualify for high-throughput screening. While the cross-validated models presented here 
performed strongly, models based on uniformly acquired data would probably yield even more 
information.  
 
In our last project, an ant colony optimization algorithm was presented to perform fragment based 
feature selection. The paradigm was tested on the highly combined endpoint of predicting drugs with 
antimalarial activity. The chemical fingerprints selected gave direct information on structural 
requirements for drug activity, without distinguishing different action mechanisms. By implementing an 
extension for numerical predictions, fingerprints could be correlated with different levels of activity.  The 
paradigm could be additionally enhanced to make statements on structural requirements for inactive 
compounds.  
 
The accuracy and performance the models presented here is encouraging and shows that 
pharmacokinetic endpoints can be successfully assessed by computational methods. The adaption of 
new machine learning techniques and advances in data acquisition will therefore offer additional 
perspectives for in silico methods. 
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7.3 Supporting information Project 5.1  
 
%Abs Ordinal Class SMILES 
2 FALSE CC1OC(OC2C(O)C(O)C(OC3C(O)C(O)C(O)OC3CO)OC2CO)C(O)C(O)C1NC4C=C(CO)C(O)C(O)C4O 
50 UNKNOWN CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(=O)C 
90 TRUE CC(=O)CC(c1ccc(cc1)[N+](=O)[O-])c2c(O)c3ccccc3oc2=O 
95 TRUE CC(=O)Nc1ccc(O)cc1 
99 TRUE CC(=O)Nc1nnc(s1)S(=O)(=O)N 
90 TRUE CC(=O)NC(CS)C(=O)O 
90 TRUE Cc1cnc(c[n+]1[O-])C(=O)O 
90 TRUE COc1cc(C)c(C=CC(=CC=CC(=CC(=O)O)C)C)c(C)c1C 
17 FALSE Nc1nc(O)c2ncn(COCCO)c2n1 
85 TRUE CC(C)(C)NCC(O)c1ccc(O)c(CO)c1 
0 FALSE OCC=C1C[N+]2(CC=C)CCC3(C2CC1C4=CN5C6C(=CN7C43)C8CC9C6(CC[N+]9(CC=C)CC8=CCO)c%10ccccc5%10)c%11ccccc7%11 
1 FALSE NCCCC(O)(P(=O)(O)O)P(=O)(O)O 
100 TRUE CC(C)CCCC(C)C1CCC2C(=CC=C3CC(O)CC(O)C3=C)CCCC12C 
80 TRUE O=c1[nH]cnc2[nH]ncc12 
90 TRUE Fc1ccc(cc1)C(N2CCN(CC2)c3nc(NCC=C)nc(NCC=C)n3)c4ccc(F)cc4 
90 TRUE NC1(CC2CC3CC(C2)C1)C3 
10 FALSE CC1(C)SC2C(N=CN3CCCCCC3)C(=O)N2C1C(=O)O 
50 UNKNOWN NC(=N)NC(=O)c1nc(Cl)c(N)nc1N 
100 TRUE CCC1(CCC(=O)NC1=O)c2ccc(N)cc2 
50 UNKNOWN CCCCc1oc2ccccc2c1C(=O)c3cc(I)c(OCCN(CC)CC)c(I)c3 
95 TRUE CN(C)CCC=C1c2ccccc2CCc3ccccc13 
70 UNKNOWN CCOC(=O)C1=C(COCCN)NC(=C(C1c2ccccc2Cl)C(=O)OC)C 
95 TRUE Clc1ccc2Oc3ccccc3N=C(N4CCNCC4)c2c1 
90 TRUE CC1(C)SC2C(NC(=O)C(N)c3ccc(O)cc3)C(=O)N2C1C(=O)O 
35 UNKNOWN CC1(C)SC2C(NC(=O)C(N)c3ccccc3)C(=O)N2C1C(=O)O 
100 TRUE CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N 
80 TRUE CC(=O)Oc1ccccc1C(=O)O 
90 TRUE COc1ccc(CCN2CCC(CC2)Nc3nc4ccccc4n3Cc5ccc(F)cc5)cc1 
44 UNKNOWN CC(C)NCC(O)COc1ccc(CC(=O)N)cc1 
95 TRUE CN1C2CCC1CC(C2)OC(=O)C(CO)c3ccccc3 
23 FALSE CC(=O)OCC1OC(S)C(OC(=O)C)C(OC(=O)C)C1OC(=O)C 
90 TRUE CN1CCC(=C2c3ccccc3CCc4cccnc24)CC1 
87 TRUE Cn1cnc([N+](=O)[O-])c1Sc2[nH]cnc3ncnc23 
37 UNKNOWN CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC3OC(C)CC(C3O)N(C)C)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O 
0 FALSE CC1(C)SC2C(NC(=O)C(NC(=O)N3CCNC3=O)c4ccccc4)C(=O)N2C1C(=O)O 
1 FALSE CC1C(NC(=O)C(=NOC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O 
95 TRUE NCC(CC(=O)O)c1ccc(Cl)cc1 
37 UNKNOWN CCOC(=O)C(CCc1ccccc1)NC2CCc3ccccc3N(CC(=O)O)C2=O 
100 TRUE NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F 
100 TRUE CC(=O)Nc1ccc(OC(=O)c2ccccc2OC(=O)C)cc1 
70 UNKNOWN NC(CO)C(=O)NNCc1ccc(O)c(O)c1O 
100 TRUE CNCCc1ccccn1 
85 TRUE CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1 
100 TRUE CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O 
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95 TRUE CNCCCCOc1ccccc1Cc2ccccc2 
100 TRUE OC(CCN1CCCCC1)(C2CC3CC2C=C3)c4ccccc4 
90 TRUE CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1 
35 UNKNOWN CC(C)CC1N2C(=O)C(NC(=O)C3CN(C)C4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(OC2(O)C7CCCN7C1=O)C(C)C 
50 UNKNOWN CN(C)CCC(c1ccc(Br)cc1)c2ccccn2 
100 TRUE CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(O1)C(=O)CO 
80 TRUE CCCCNc1cc(cc(c1Oc2ccccc2)S(=O)(=O)N)C(=O)O 
95 TRUE CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1 
100 TRUE O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)c4ncccn4 
95 TRUE Cn1cnc2n(C)c(=O)n(C)c(=O)c12 
100 TRUE CC(CCCC(C)(C)O)C1CCC2C(=CC=C3CC(O)CC(O)C3=C)CCCC12C 
72 UNKNOWN CC(CS)C(=O)N1CCCC1C(=O)O 
80 TRUE NC(=O)N1c2ccccc2C=Cc3ccccc13 
90 TRUE CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC43C)C(=O)O)OC(=O)CCC(=O)O 
60 UNKNOWN CC(Cc1ccc(O)c(O)c1)(NN)C(=O)O 
95 TRUE CCOC(=O)n1ccn(C)c1=S 
95 TRUE CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12 
80 TRUE COc1ccccc1OCCNCC(O)COc2cccc3[nH]c4ccccc4c23 
60 UNKNOWN Nc1nc(cs1)C(=NOCC(=O)O)C(=O)NC2C3SCC(=C(N3C2=O)C(=O)O)C=C 
0 FALSE CON=C(C(=O)NC1C2SCC(=C(N2C1=O)C(=O)O)CSc3nc(C)c(CC(=O)O)s3)c4csc(N)n4 
0 FALSE COC1(NC(=O)Cc2cccs2)C3SCC(=C(N3C1=O)C(=O)O)COC(=O)N 
50 UNKNOWN COCC1=C(N2C(SC1)C(NC(=O)C(=NOC)c3csc(N)n3)C2=O)C(=O)OC(C)OC(=O)OC(C)C 
94 TRUE CC=CC1=C(N2C(SC1)C(NC(=O)C(N)c3ccc(O)cc3)C2=O)C(=O)O 
0 FALSE CON=C(C(=O)NC1C2SCC=C(N2C1=O)C(=O)O)c3csc(N)n3 
55 UNKNOWN CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(=O)C 
90 TRUE CC1=C(N2C(SC1)C(NC(=O)C(N)c3ccccc3)C2=O)C(=O)O 
100 TRUE OC(=O)COCCN1CCN(CC1)C(c2ccccc2)c3ccc(Cl)cc3 
100 TRUE CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C 
95 TRUE C[N+](C)(C)CC(=O)[O-] 
95 TRUE OC(O)C(Cl)(Cl)Cl 
85 TRUE OCC(NC(=O)C(Cl)Cl)C(O)c1ccc(cc1)[N+](=O)[O-] 
95 TRUE CNC1=Nc2ccc(Cl)cc2C(=[N+]([O-])C1)c3ccccc3 
100 TRUE CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12 
20 FALSE NS(=O)(=O)c1cc2c(N=CNS2(=O)=O)cc1Cl 
80 TRUE CN(C)CCC(c1ccc(Cl)cc1)c2ccccn2 
96 TRUE CN(C)CCCN1c2ccccc2Sc3ccc(Cl)cc13 
100 TRUE CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1 
60 UNKNOWN CN(C)C1C2CC3C(=C(O)C2(O)C(=O)C(=C1O)C(=O)N)C(=O)c4c(O)ccc(Cl)c4C3(C)O 
65 UNKNOWN NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc32 
60 UNKNOWN CCOC(=O)C(CCc1ccccc1)NC2CCCN3CCCC(N3C2=O)C(=O)O 
90 TRUE CNC(=NC#N)NCCSCc1nc[nH]c1C 
95 TRUE CCn1nc(C(=O)O)c(=O)c2cc3OCOc3cc12 
99 TRUE CC(C)(Oc1ccc(cc1)C2CC2(Cl)Cl)C(=O)O 
77 UNKNOWN OC(=O)c1cn(C2CC2)c3cc(N4CCNCC4)c(F)cc3c1=O 
95 TRUE COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c3cc(Cl)c(N)cc3OC 
100 TRUE CN(C)CCCC1(OCc2cc(C#N)ccc21)c3ccc(F)cc3 
100 TRUE CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC3OC(C)CC(C3O)N(C)C)C(C)(CC(C)C(=O)C(C)C(O)C1(C)O)OC 
75 UNKNOWN OCC=C1OC2CC(=O)N2C1C(=O)O 
95 TRUE CN1C(=O)CC(=O)N(c2ccccc2)c3cc(Cl)ccc13 
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95 TRUE CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1 
95 TRUE Cc1ncsc1CCCl 
95 TRUE CN(C)CCCN1c2ccccc2CCc3ccc(Cl)cc13 
80 TRUE [O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1 
100 TRUE Clc1cccc(Cl)c1N=C2NCCN2 
100 TRUE CC1CCCC(C)N1NC(=O)c2ccc(Cl)c(c2)S(=O)(=O)N 
93 TRUE CN1CCN(CC1)C2=Nc3cc(Cl)ccc3Nc4ccccc24 
90 TRUE Coc1ccc2CC3C4C=CC(O)C5Oc1c2C54CCN3C 
100 TRUE COc1cc2CCC(NC(=O)C)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC 
95 TRUE CC(=O)OCC(=O)C1(O)CCC2C3CCC4=CC(=O)CCC4(C)C3C(=O)CC21C 
1 FALSE OC(COc1cccc2oc(cc(=O)c12)C(=O)O)COc3cccc4oc(cc(=O)c34)C(=O)O 
75 UNKNOWN ClCCN(CCCl)P1(=O)NCCCO1 
100 TRUE NC1CONC1=O 
40 UNKNOWN 
CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C
)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)
C1=O)C(C)C 
95 TRUE CC(=O)OC1(CCC2C3C=C(Cl)C4=CC(=O)C5CC5C4(C)C3CCC21C)C(=O)C 
80 TRUE [O-][N+](=O)c1ccc(cc1)c2ccc(C=NN3CC(=O)NC3=O)o2 
90 TRUE Nc1ccc(cc1)S(=O)(=O)c2ccc(N)cc2 
0 FALSE Coc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)C 
90 TRUE CNCCCN1c2ccccc2CCc3ccccc13 
70 UNKNOWN CCC12CC(=C)C3C(CCC4=CCCCC34)C2CCC1(O)C#C 
83 TRUE CCNC(C)Cc1cccc(c1)C(F)(F)F 
100 TRUE CN1CCC23C4Oc5c3c(CC1C2C=CC4OC(=O)C)ccc5OC(=O)C 
100 TRUE CN1C(=O)CN=C(c2ccccc2)c3cc(Cl)ccc13 
90 TRUE CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 
90 TRUE OC(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl 
30 FALSE OCC1CCC(O1)n2cnc3c(O)ncnc23 
90 TRUE CCN(CC)C(=O)N1CCN(CC1)C 
90 TRUE CCC(=C(CC)c1ccc(O)cc1)c2ccc(O)cc2 
90 TRUE OC(=O)c1cc(ccc1O)c2ccc(F)cc2F 
90 TRUE CC1OC(CC(O)C1O)OC2C(C)OC(CC2O)OC3C(C)OC(CC3O)OC4CCC5(C)C(CCC6C5CCC7(C)C(CCC67O)C8=CC(=O)OC8)C4 
80 TRUE CC1OC(CC(O)C1O)OC2C(C)OC(CC2O)OC3C(C)OC(CC3O)OC4CCC5(C)C(CCC6C5CC(O)C7(C)C(CCC67O)C8=CC(=O)OC8)C4 
97 TRUE COc1ccc2CC3C4CCC(O)C5Oc1c2C54CCN3C 
90 TRUE CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1 
90 TRUE Coc1ccc(cc1)C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(=O)C 
90 TRUE CN(C)CCOC(c1ccccc1)c2ccccc2 
3 FALSE OP(=O)([O-])C(Cl)(Cl)P(=O)(O)[O-] 
95 TRUE CC(C)N(CCC(C(=O)N)(c1ccccc1)c2ccccn2)C(C)C 
80 TRUE CCN(CC)C(=S)SSC(=S)N(CC)CC 
78 UNKNOWN O=C(OC1CC2CC3CC(C1)N2CC3=O)c4c[nH]c5ccccc45 
93 TRUE Clc1ccc2n(C3CCN(CCCn4c(=O)[nH]c5ccccc45)CC3)c(=O)[nH]c2c1 
0 FALSE NCCc1ccc(O)c(O)c1 
95 TRUE CN(C)CCC=C1c2ccccc2CSc3ccccc13 
65 UNKNOWN Coc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4COc5ccccc5O4 
100 TRUE CN(C)CCC=C1c2ccccc2COc3ccccc13 
93 TRUE CC1C2C(O)C3C(N(C)C)C(=C(C(=O)N)C(=O)C3(O)C(=C2C(=O)c4c(O)cccc14)O)O 
55 UNKNOWN NCCCC(N)(C(F)F)C(=O)O 
60 UNKNOWN CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N2CCCC2C(=O)O 
80 TRUE CSc1ccc(cc1)C(=O)c2[nH]c(=O)[nH]c2C 
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100 TRUE CNC(C)C(O)c1ccccc1 
0 FALSE CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O 
90 TRUE CCC(=C)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl 
80 TRUE CCC(CO)NCCNC(CC)CO 
90 TRUE CCc1cc(ccn1)C(=S)N 
100 TRUE CCC1(C)CC(=O)NC1=O 
5 FALSE CC(O)(P(=O)(O)O)P(=O)(O)O 
73 UNKNOWN CCc1cccc2c3CCOC(CC)(CC(=O)O)c3[nH]c12 
40 UNKNOWN CCOC(=O)C=C(C)C=CC=C(C)C=Cc1c(C)cc(OC)c(C)c1C 
73 UNKNOWN CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(=O)C 
40 UNKNOWN NC(=Nc1nc(CSCCC(=NS(=O)(=O)N)N)cs1)N 
90 TRUE NC(=O)OCC(COC(=O)N)c1ccccc1 
100 TRUE CCOC(=O)C1=C(C)NC(=C(C1c2cccc(Cl)c2Cl)C(=O)OC)C 
80 TRUE OC(=O)CCC(=O)c1ccc(cc1)c2ccccc2 
95 TRUE CCNC(C)Cc1cccc(c1)C(F)(F)F 
75 UNKNOWN CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2 
85 TRUE CC(C(=O)O)c1cccc(Oc2ccccc2)c1 
100 TRUE CC(C)(C)NC(=O)C1CCC2C3CCC4NC(=O)C=CC4(C)C3CCC12C 
95 TRUE FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2 
80 TRUE Cc1onc(c1C(=O)NC2C3SC(C)(C)C(N3C2=O)C(=O)O)c4c(F)cccc4Cl 
90 TRUE OC(Cn1cncn1)(Cn2cncn2)c3ccc(F)cc3F 
100 TRUE Nc1nc(=O)[nH]cc1F 
75 UNKNOWN Nc1nc(F)nc2n(cnc12)C3OC(COP(=O)(O)O)C(O)C3O 
95 TRUE CC(=O)OCC(=O)C1(O)CCC2C3CCC4=CC(=O)CCC4(C)C3(F)C(O)CC21C 
95 TRUE CCOC(=O)c1ncn-2c1CN(C)C(=O)c3cc(F)ccc32 
95 TRUE Fc1ccc(cc1)C(N2CCN(CC=Cc3ccccc3)CC2)c4ccc(F)cc4 
80 TRUE CC1(C)OC2CC3C4CC(F)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(O1)C(=O)CO 
28 FALSE Fc1c[nH]c(=O)[nH]c1=O 
95 TRUE CNCCC(Oc1ccc(cc1)C(F)(F)F)c2ccccc2 
100 TRUE OCCN1CCN(CCC=C2c3ccccc3Sc4ccc(cc24)C(F)(F)F)CC1 
100 TRUE CCC(CC)CCN1C(=O)CN=C(C2CCCCC2F)c3cc(Cl)ccc13 
95 TRUE CC(C(=O)O)c1ccc(c(F)c1)c2ccccc2 
90 TRUE CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(c1)C(F)(F)F 
20 FALSE CCC(=O)OC1(C(C)CC2C3CC(F)C4=CC(=O)C=CC4(C)C3(F)C(O)CC21C)C(=O)SCF 
95 TRUE CC(C)n1c(C=CC(O)CC(O)CC(=O)O)c(c2ccc(F)cc2)c3ccccc13 
90 TRUE COCCCCC(=NOCCN)c1ccc(cc1)C(F)(F)F 
75 UNKNOWN Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)C(=O)O)cnc2[nH]1 
65 UNKNOWN Coc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1 
20 FALSE OC(=O)P(=O)(O)O 
50 UNKNOWN CC1OC1P(=O)(O)O 
34 UNKNOWN CCC(=O)OC(OP(=O)(CCCCc1ccccc1)CC(=O)N2CC(CC2C(=O)O)C3CCCCC3)C(C)C 
65 UNKNOWN NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl 
100 TRUE CC1C(O)CCC2(C)C1CCC3(C)C2C(O)CC4C(=C(CCC=C(C)C)C(=O)O)C(CC43C)OC(=O)C 
60 UNKNOWN NCC1(CC(=O)O)CCCCC1 
90 TRUE Coc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC 
5 FALSE Nc1nc(O)c2ncn(COC(CO)CO)c2n1 
100 TRUE Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1 
100 TRUE CCC12CCC3C(CCC4=CC(=O)CCC34)C2C=CC1(O)C#C 
60 UNKNOWN CCC12C=CC3=C4CCC(=O)C=C4CCC3C2CCC1(O)C#C 
98 TRUE Cc1ccc(cc1)S(=O)(=O)NC(=O)NC2C(O)C3(C)CCC2C3(C)C 
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100 TRUE Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3 
95 TRUE COc1ccc2c(c1)C(=O)N(CCc3ccc(cc3)S(=O)(=O)NC(=O)NC4CCCCC4)C(=O)C2(C)C 
95 TRUE COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3 
17.5 FALSE C[N+]1(C)CCC(C1)OC(=O)C(O)(C2CCCC2)c3ccccc3 
95 TRUE COCCOc1cnc(NS(=O)(=O)c2ccccc2)nc1 
100 TRUE CN1C2CCCC1CC(C2)NC(=O)c3nn(C)c4ccccc34 
100 TRUE OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3 
100 TRUE Nnc1nncc2ccccc12 
70 UNKNOWN NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl 
90 TRUE CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 
90 TRUE CCCCCC(=O)OC1(CCC2C3CCC4=CC(=O)CCC4(C)C3CCC21C)C(=O)C 
95 TRUE CC(C)Cc1ccc(cc1)C(C)C(=O)O 
82 TRUE CCCCCCCN(CC)CCCC(O)c1ccc(NS(=O)(=O)C)cc1 
30 FALSE CC1OC(CC(N)C1O)OC2CC(O)(Cc3c(O)c4C(=O)c5ccccc5C(=O)c4c(O)c23)C(=O)C 
0 FALSE OCC1OC(CC1O)n2cc(I)c(=O)[nH]c2=O 
16 FALSE CC#CCC(C)C(O)C=CC1C(O)CC2CC(=CCCCC(=O)O)CC12 
5 FALSE CC(O)C1C2CC(=C(N2C1=O)C(=O)O)SCCNC=N 
90 TRUE CN(C)CCCN1c2ccccc2CCc3ccccc13 
19 FALSE CC(C)(C)NC(=O)C1CN(Cc2cccnc2)CCN1CC(O)CC(Cc3ccccc3)C(=O)NC4C(O)Cc5ccccc45 
100 TRUE COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)O)c2c1 
95 TRUE NNC(=O)c1ccncc1 
85 TRUE CC(C)NCC(O)c1ccc(O)c(O)c1 
90 TRUE CC(=CC=CC(=CC(=O)O)C)C=CC1=C(C)CCCC1(C)C 
90 TRUE COC(=O)C1=C(C)NC(=C(C1c2cccc3nonc23)C(=O)OC(C)C)C 
85 TRUE CCC(C)n1ncn(c2ccc(cc2)N3CCN(CC3)c4ccc(OCC5COC(Cn6cncn6)(O5)c7ccc(Cl)cc7Cl)cc4)c1=O 
60 UNKNOWN COC1CC(OC2C(C)OC(CC2OC)OC3C(C)C=CC=C4COC5C(O)C(=CC(C(=O)OC(C)CC6(CCC(C)CO6)OC(C)CC=C3C)C54O)C)OC(C)C1O 
100 TRUE Fc1ccc(cc1)C(=O)C2CCN(CCn3c(=O)[nH]c4ccccc4c3=O)CC2 
100 TRUE CN1C(=O)CN2C(=O)C=C(C)OC2(c3ccccc3)c4cc(Cl)ccc14 
90 TRUE CC(C(=O)O)c1cccc(c1)C(=O)c2ccccc2 
95 TRUE OC(=O)C1CCn2c(ccc12)C(=O)c3ccccc3 
90 TRUE CN1CCC(=C2c3ccsc3C(=O)Cc4ccccc24)CC1 
95 TRUE CCOC(=O)C1=C(C)NC(=C(C1c2ccccc2C=CC(=O)OC(C)(C)C)C(=O)OCC)C 
2 FALSE OCC1OC(O)(CO)C(O)C1OC2OC(CO)C(O)C(O)C2O 
98 TRUE Nc1nnc(c(N)n1)c2cccc(Cl)c2Cl 
85 TRUE Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F 
95 TRUE C1CN2CC(N=C2S1)c3ccccc3 
100 TRUE CC(C)(C)NCC(O)COc1cccc2C(=O)CCCc12 
95 TRUE CCN(CC)CC(=O)Nc1c(C)cccc1C 
25 FALSE NCCCCC(NC(CCc1ccccc1)C(=O)O)C(=O)N2CCCC2C(=O)O 
100 TRUE CCN(CC)C(=O)NC1CN(C)C2Cc3c[nH]c4cccc(C2=C1)c34 
75 UNKNOWN OC(=O)C(=O)Nc1cc(C#N)cc(NC(=O)C(=O)O)c1Cl 
98 TRUE Ccn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12 
65 UNKNOWN CN(C)C(=O)C(CCN1CCC(O)(CC1)c2ccc(Cl)cc2)(c3ccccc3)c4ccccc4 
90 TRUE CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc4cccnc24)CC1 
90 TRUE OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O 
66 UNKNOWN CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)c3ccccc3c4nnn[nH]4 
95 TRUE CNCCCC1(CCC2c3ccccc31)c4ccccc24 
7.5 FALSE COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c3ccccc3 
90 TRUE CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc2ccc(OC)cc2 
90 TRUE Cc1cccc(Nc2ccccc2C(=O)O)c1C 
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77.5 UNKNOWN OC(C1CCCCN1)c2cc(nc3c(cccc23)C(F)(F)F)C(F)(F)F 
100 TRUE CC(=O)OC1(CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC21C)C(=O)C 
100 TRUE CCOC(=O)C1(CCN(C)CC1)c2ccccc2 
100 TRUE CCC1(CCCCN(C)C1)c2cccc(O)c2 
0 FALSE CC(O)C1C2C(C)C(=C(N2C1=O)C(=O)O)SC3CNC(C3)C(=O)N(C)C 
90 TRUE COc1ccc2C3CCC4(C)C(CCC4(O)C#C)C3CCc2c1 
55 UNKNOWN CN(C)C(=N)NC(=N)N 
95 TRUE Cn1cc[nH]c1=S 
95 TRUE CC(CO)NC(=O)C1CN(C)C2Cc3cn(C)c4cccc(C2=C1)c34 
80 TRUE COC(=O)C(C1CCCCN1)c2ccccc2 
90 TRUE CC1CC2C3CCC(O)(C(=O)COC(=O)CCC(=O)O)C3(C)CC(O)C2C4(C)C=CC(=O)C=C14 
100 TRUE CCC(CO)NC(=O)C1CN(C)C2Cc3cn(C)c4cccc(C2=C1)c34 
90 TRUE CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC 
64 UNKNOWN CC1Nc2cc(Cl)c(cc2C(=O)N1c3ccccc3C)S(=O)(=O)N 
95 TRUE COCCc1ccc(OCC(O)CNC(C)C)cc1 
95 TRUE Cc1ncc([N+](=O)[O-])n1CCO 
0 FALSE CC1(C)SC2C(NC(=O)C(NC(=O)N3CCN(C3=O)S(=O)(=O)C)c4ccccc4)C(=O)N2C1C(=O)O 
70 UNKNOWN CN1CCN2C(C1)c3ccccc3Cc4ccccc24 
100 TRUE COCC(=O)OC1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc4cc(F)ccc4C1C(C)C 
20 FALSE Clc1ccc(COC(Cn2ccnc2)c3ccc(Cl)cc3Cl)c(Cl)c1 
100 TRUE Cc1ncc2CN=C(c3ccccc3F)c4cc(Cl)ccc4-n12 
90.6 TRUE CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(CC21C)c5ccc(cc5)N(C)C 
82.5 TRUE CC1=NC(=O)C(C=C1c2ccncc2)C#N 
100 TRUE CN(C)C1C2CC3Cc4c(ccc(O)c4C(=O)C3=C(O)C2(O)C(=O)C(=C1O)C(=O)N)N(C)C 
100 TRUE Nc1cc(nc(N)[n+]1[O-])N2CCCCC2 
88 TRUE CCCCC(C)(O)CC=CC1C(O)CC(=O)C1CCCCCCC(=O)OC 
95 TRUE Clc1ccc(cc1)C(=O)NCCN2CCOCC2 
100 TRUE CCOC(=O)N=c1c[n+]([n-]o1)N2CCOCC2 
95 TRUE CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN4CCOCC4)c2c1 
37.5 UNKNOWN CN1CCC23C4Oc5c3c(CC1C2C=CC4O)ccc5O 
0 FALSE COC1(NC(=O)C(C(=O)O)c2ccc(O)cc2)C3OCC(=C(N3C1=O)C(=O)O)CSc4nnnn4C 
80 TRUE COc1ccc2cc(CCC(=O)C)ccc2c1 
30 FALSE CC(C)(C)NCC(O)COc1cccc2CC(O)C(O)Cc12 
92.5 TRUE CCN(CC)CCOC(=O)C(CC1CCCO1)Cc2cccc3ccccc23 
100 TRUE OC1CCC2(O)C3Cc4ccc(O)c5OC1C2(CCN3CC6CCC6)c54 
90 TRUE CCn1cc(C(=O)O)c(=O)c2ccc(C)nc12 
95 TRUE Oc1ccc2CC3N(CC=C)CCC4(C5Oc1c24)C3(O)CCC5=O 
100 TRUE Oc1ccc2CC3N(CC4CC4)CCC5(C6Oc1c25)C3(O)CCC6=O 
100 TRUE Coc1ccc2cc(ccc2c1)C(C)C(=O)O 
2.5 FALSE CCCc1c2oc(cc(=O)c2cc3c(=O)cc(C(=O)O)n(CC)c13)C(=O)O 
99 TRUE CCc1nn(CCCN2CCN(CC2)c3cccc(Cl)c3)c(=O)n1CCOc4ccccc4 
97.5 TRUE CN1CCOC(c2ccccc2)c3ccccc3C1 
5 FALSE NCC1OC(OC2C(N)CC(N)C(O)C2O)C(N)C(O)C1O 
1.5 FALSE CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C 
95 TRUE COC(=O)C1=C(C)NC(=C(C1c2cccc(c2)[N+](=O)[O-])C(=O)OCCN(C)Cc3ccccc3)C 
100 TRUE [O-][N+](=O)OCCNC(=O)c1cccnc1 
100 TRUE CN1CCCC1c2cccnc2 
90 TRUE COC(=O)C1=C(C)NC(=C(C1c2ccccc2[N+](=O)[O-])C(=O)OC)C 
53 UNKNOWN COCCOC(=O)C1=C(C)NC(=C(C1c2cccc(c2)[N+](=O)[O-])C(=O)OC(C)C)C 
100 TRUE COC(=O)C1=C(C)NC(=C(C1c2ccccc2[N+](=O)[O-])C(=O)OCC(C)C)C 
    Appendix 
 
- 162 - 
95 TRUE [O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3)c2c1 
95 TRUE [O-][N+](=O)c1ccc(C=NN2CC(=O)NC2=O)o1 
70 UNKNOWN CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1 
100 TRUE CCC12CCC3C(CCC4=CC(=NO)CCC34)C2CCC1(OC(=O)C)C#C 
100 TRUE CNCCC=C1c2ccccc2CCc3ccccc13 
100 TRUE CC1COc2c(N3CCN(C)CC3)c(F)cc4c(=O)c(cn1c24)C(=O)O 
3 FALSE OC(=O)c1cc(N=Nc2ccc(O)c(c2)C(=O)O)ccc1O 
65 UNKNOWN COc1ccc2[nH]c(nc2c1)S(=O)Cc3ncc(C)c(OC)c3C 
59 UNKNOWN Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C 
100 TRUE CN(C)CCOC(c1ccccc1)c2ccccc2C 
5 FALSE CC1OC(OC2CC(O)C3(CO)C4C(O)CC5(C)C(CCC5(O)C4CCC3(O)C2)C6=CC(=O)OC6)C(O)C(O)C1O 
98 TRUE OC1N=C(c2ccccc2)c3cc(Cl)ccc3NC1=O 
16 FALSE CC[N+]1(C)C2CC(CC1C3OC32)OC(=O)C(CO)c4ccccc4 
100 TRUE CC(C)NCC(O)COc1ccccc1OCC=C 
100 TRUE CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2 
60 UNKNOWN CN(C)C1C2C(O)C3C(=C(O)C2(O)C(=O)C(=C1O)C(=O)N)C(=O)c4c(O)cccc4C3(C)O 
0 FALSE CC(=O)OC1C(CC2C3CCC4CC(OC(=O)C)C(CC4(C)C3CCC12C)[N+]5(C)CCCCC5)[N+]6(C)CCCCC6 
77 UNKNOWN COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC 
90 TRUE COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC 
100 TRUE Fc1ccc(cc1)C2CCNCC2COc3ccc4OCOc4c3 
100 TRUE CC(C)(C)NCC(C)(O)COc1ccccc1C2CCCC2 
40 UNKNOWN CC(C)(S)C(N)C(=O)O 
30 FALSE CC1(C)SC2C(NC(=O)Cc3ccccc3)C(=O)N2C1C(=O)O 
0 FALSE NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(=N)N)cc1 
100 TRUE CC1C2Cc3ccc(O)cc3C1(C)CCN2CC=C(C)C 
100 TRUE CCCC(C)C1(CC)C(=O)NC(=O)NC1=O 
95 TRUE CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O 
60 UNKNOWN CCCN1CC(CSC)CC2C1Cc3c[nH]c4cccc2c34 
95 TRUE CCCC(NC(C)C(=O)N1C(CC2CCCCC21)C(=O)O)C(=O)OCC 
100 TRUE OCCN1CCN(CCCN2c3ccccc3Sc4ccc(Cl)cc24)CC1 
100 TRUE O=C1C(C(=O)c2ccccc12)c3ccccc3 
90 TRUE CCC1(C(=O)NC(=O)NC1=O)c2ccccc2 
12 FALSE CCOC(=O)C1(CCN(CCC(O)c2ccccc2)CC1)c3ccccc3 
25 FALSE CC(COc1ccccc1)N(CCCl)Cc2ccccc2 
95 TRUE CCC(c1ccccc1)c2c(O)c3ccccc3oc2=O 
95 TRUE CCCCC1C(=O)N(N(C1=O)c2ccccc2)c3ccccc3 
90 TRUE CC(N)C(O)c1ccccc1 
90 TRUE O=C1NC(=O)C(N1)(c2ccccc2)c3ccccc3 
70 UNKNOWN Fc1ccc(cc1)C(CCCN2CCC(CC2)n3c(=O)[nH]c4ccccc34)c5ccc(F)cc5 
90 TRUE CC(C)NCC(O)COc1cccc2[nH]ccc12 
25 FALSE CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc4cccnc24)CC1 
86 TRUE NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc3ccccc3)C(=O)O 
100 TRUE CN1C(=C(O)c2ccccc2S1(=O)=O)C(=O)Nc3ccccn3 
80 TRUE CN1CCC(=C2c3ccsc3CCc4ccccc24)CC1 
100 TRUE CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(=O)(=O)N 
30 FALSE C[n+]1ccccc1C=NO 
34 UNKNOWN CCC(C)C(=O)OC1CC(O)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C12 
90 TRUE O=C(C1CCCCC1)N2CC3N(CCc4ccccc34)C(=O)C2 
57 UNKNOWN COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)c4ccco4 
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75 UNKNOWN CCC1(C(=O)NCNC1=O)c2ccccc2 
100 TRUE CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(=O)O 
82.5 TRUE CCN(CC)CCNC(=O)c1ccc(N)cc1 
95 TRUE CNNCc1ccc(cc1)C(=O)NC(C)C 
100 TRUE OC(CCN1CCCC1)(C2CCCCC2)c3ccccc3 
90 TRUE CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1 
80 TRUE CC(CN1c2ccccc2Sc3ccccc13)N(C)C 
95 TRUE CCCNCC(O)COc1ccccc1C(=O)CCc2ccccc2 
10 FALSE CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc3ccccc13)C(C)C 
95 TRUE CCC(=O)OC(Cc1ccccc1)(C(C)CN(C)C)c2ccccc2 
95 TRUE CC(C)NCC(O)COc1cccc2ccccc12 
62.5 UNKNOWN CCCc1cc(=O)[nH]c(=S)[nH]1 
95 TRUE CNCCCC1c2ccccc2C=Cc3ccccc13 
4 FALSE OC(=O)c1cc2ccccc2c(Cc3c(O)c(cc4ccccc34)C(=O)O)c1O 
100 TRUE NC(=O)c1cnccn1 
100 TRUE CCCN1CC(CC2Cc3c(O)cccc3CC21)NS(=O)(=O)N(CC)CC 
60 UNKNOWN CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N2Cc3ccccc3CC2C(=O)O 
63 UNKNOWN Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4 
60 UNKNOWN CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N2C(CC3CCCC32)C(=O)O 
50 UNKNOWN CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1 
80 TRUE CC(=CCO)C=CC=C(C)C=CC1=C(C)CCCC1(C)C 
50 UNKNOWN COC1C=COC2(C)Oc3c(C2=O)c4C5=NC6(CCN(CC(C)C)CC6)NC5=C(NC(=O)C(=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)C(=O)c4c(O)c3C 
60 UNKNOWN Nc1nc2ccc(OC(F)(F)F)cc2s1 
97 TRUE Cc1nc2CCCCn2c(=O)c1CCN3CCC(CC3)c4noc5cc(F)ccc45 
95 TRUE CC(NCCc1ccc(O)cc1)C(O)c2ccc(O)cc2 
95 TRUE CCCN(CCC)CCc1cccc2NC(=O)Cc21 
75 UNKNOWN OC(=O)c1ccccc1O 
30 FALSE CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(O)C(Cc3ccccc3)NC(=O)C(CC(=O)N)NC(=O)c4ccc5ccccc5n4 
10 FALSE CCCC[N+]1(C)C2CC(CC1C3OC32)OC(=O)C(CO)c4ccccc4 
100 TRUE CC(Cc1ccccc1)N(C)CC#C 
5 FALSE OCC1OC(Oc2cccc3C(C4c5cccc(OC6OC(CO)C(O)C(O)C6O)c5C(=O)c7c(O)cc(cc47)C(=O)O)c8cccc(O)c8C(=O)c23)C(O)C(O)C1O 
100 TRUE CC(C)NCC(O)c1ccc(NS(=O)(=O)C)cc1 
82 TRUE Cc1cn(C2OC(CO)C=C2)c(=O)[nH]c1=O 
0 FALSE CN(N=O)C(=O)NC1C(O)OC(CO)C(O)C1O 
100 TRUE Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2 
95 TRUE Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1 
85 TRUE Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1 
25 FALSE OC(=O)c1cc(N=Nc2ccc(cc2)S(=O)(=O)Nc3ccccn3)ccc1O 
90 TRUE CC1=C(CC(=O)O)c2cc(F)ccc2C1=Cc3ccc(cc3)S(=O)C 
32.5 UNKNOWN CCN1CCCC1CNC(=O)c2cc(ccc2OC)S(=O)(=O)N 
100 TRUE CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1 
0 FALSE 
Cc1ccc(cc1NC(=O)c2cccc(NC(=O)Nc3cccc(c3)C(=O)Nc4cc(ccc4C)C(=O)Nc5ccc(c6cc(cc(c56)S(=
O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)c2)C(=O)Nc7ccc(c8cc(cc(c78)S(=O)(=O)O)S(=O)(=O)O)S(=O)
(=O)O 
95 TRUE Nc1c2CCCCc2nc3ccccc13 
95 TRUE CN1C(=O)C(O)N=C(c2ccccc2)c3cc(Cl)ccc13 
100 TRUE CN1C(C(=O)Nc2ccccn2)C(=O)c3sccc3S1(=O)=O 
95 TRUE COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4 
80 TRUE CN(CC=CC#CC(C)(C)C)Cc1cccc2ccccc12 
100 TRUE CC(C)(C)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4 
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95 TRUE COc1cc2CCN3CC(CC(C)C)C(=O)CC3c2cc1OC 
90 TRUE c1nc(cs1)c2nc3ccccc3[nH]2 
34 UNKNOWN Nc1nc2[nH]cnc2c(=S)[nH]1 
60 UNKNOWN CSc1ccc2Sc3ccccc3N(CCC4CCCCN4C)c2c1 
90 TRUE CC1CC2=C(CCC(=O)C2)C3CCC4(C)C(CCC4(O)C#C)C13 
0 FALSE CC1(C)SC2C(NC(=O)C(C(=O)O)c3ccsc3)C(=O)N2C1C(=O)O 
80 TRUE Clc1ccccc1CN2CCc3sccc3C2 
100 TRUE CC(C)(C)NCC(O)COc1nsnc1N2CCOCC2 
100 TRUE CCS(=O)(=O)CCn1c(C)ncc1[N+](=O)[O-] 
0 FALSE NCC1OC(OC2C(N)CC(N)C(OC3OC(CO)C(O)C(N)C3O)C2O)C(N)CC1O 
100 TRUE CC(N)C(=O)Nc1c(C)cccc1C 
90 TRUE C(C1=NCCN1)c2ccccc2 
95 TRUE CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1 
99 TRUE Cc1ccc(cc1)C(=O)c2ccc(CC(=O)O)n2C 
66 UNKNOWN COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(=O)O 
50 UNKNOWN NCC1CCC(CC1)C(=O)O 
100 TRUE Clc1cccc(c1)N2CCN(CCCn3nc4ccccn4c3=O)CC2 
85 TRUE Cc1nnc2CN=C(c3ccccc3Cl)c4cc(Cl)ccc4-n12 
100 TRUE CN1CCN(CCCN2c3ccccc3Sc4ccc(cc24)C(F)(F)F)CC1 
100 TRUE OC(CCN1CCCCC1)(C2CCCCC2)c3ccccc3 
95 TRUE COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC 
80 TRUE CC(CN(C)C)CN1c2ccccc2CCc3ccccc13 
53 UNKNOWN Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O 
95 TRUE CCCC(CCC)C(=O)O 
0 FALSE 
CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(O)C6NC(=O)C(NC(=O)C4NC(=O)
C(CC(=O)N)NC1=O)c7ccc(O)c(c7)-
c8c(O)cc(O)cc8C(NC6=O)C(=O)O)c3OC9OC(CO)C(O)C(O)C9OC%10CC(C)(N)C(O)C(C)O%10)c
(Cl)c2 
92 TRUE COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2 
90 TRUE COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC 
80 TRUE NC(CCC(=O)O)C=C 
95 TRUE CC(=O)CC(C1C(=O)Oc2ccccc2C1=O)c3ccccc3 
73 UNKNOWN Cc1cccc(C)c1NC(=O)c2cc(c(Cl)cc2O)S(=O)(=O)N 
85 TRUE Nc1ccn(C2CCC(CO)O2)c(=O)n1 
95 TRUE CN(C)C(=O)Cc1c(nc2ccc(C)cn12)c3ccc(C)cc3 
95 TRUE CN1CCN(CC1)C(=O)OC2N(C(=O)c3nccnc23)c4ccc(Cl)cn4 
95 TRUE CN(C)CCOC1=Cc2ccccc2Sc3ccc(Cl)cc13 
92 TRUE CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4 
90 TRUE CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C 
100 TRUE C(C1C(C(C(C(O1)O)O)O)O)O 
95 TRUE CCN(CC)C(C)C(=O)C1=CC=CC=C1 
10 FALSE C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-] 
100 TRUE CCO 
100 TRUE CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O 
100 TRUE C(C(C(C(C(=O)CO)O)O)O)O 
100 TRUE CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O 
0 FALSE CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I 
0 FALSE C1=C(C(=C(C(=C1I)I)NC(=O)COCCOCCOCC(=O)NC2=C(C(=CC(=C2I)I)I)C(=O)O)C(=O)O)I 
90 TRUE C1C(C2C(O1)C(CO2)O[N+](=O)[O-])O[N+](=O)[O-] 
100 TRUE C1C(C2C(O1)C(CO2)O[N+](=O)[O-])O 
0 FALSE CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=
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O)C6CCC(=O)N6 
10 FALSE C[N+](C)(C)CC(CC(=O)[O-])O 
100 TRUE CCC12CCC3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34 
57 UNKNOWN C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)CC(C(=O)O)N 
90 TRUE C1CC(=C(N2C1C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)Cl 
76 UNKNOWN C(CS(=O)(=O)[O-])S 
90 TRUE C1=CC(=CN=C1)C(=O)[O-] 
0 FALSE CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O 
90 TRUE CCCC1=NC=CC(=C1)C(=S)N 
95 TRUE CC(C(C1=CC=CC=C1)O)NC 
15 FALSE C[N+]1=CC=CC(=C1)OC(=O)N(C)C 
80 TRUE COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O 
30 FALSE COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC 
45 UNKNOWN C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N 
1 FALSE C(C1C(C(C(C(O1)OC2(C(C(C(O2)OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-] 
2 FALSE 
C1C2C(=O)NC(C3=CC(=CC(=C3)O)OC4=C(C=CC(=C4)C(C(=O)N2)N)O)C(=O)NC5C6=CC(=C(C
(=C6)OC7=C(C=C(C=C7)C(C8C(=O)NC(C9=CC(=CC(=C9C2=C(C=CC(=C2)C(C(=O)N8)NC5=O)
O)O)O)C(=O)O)O)Cl)O)OC2=C(C=C1C=C2)Cl 
0 FALSE 
C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=
O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=
O)NCC(=O)N 
95 TRUE CN1C2=C(C(=O)N(C1=O)C)NC=N2 
80 TRUE CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C 
100 TRUE CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C 
0 FALSE C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)CO)O)O 
70 UNKNOWN CC1=C2C(=C(C(=C1C)OC(=O)C)C)CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C 
95 TRUE C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO 
 
7.4 Supporting information Project 5.5 
CID Outcome SMILES 
24867529 Active COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@H]3C[C@H]4CCN3C[C@H]4C=C)O 
11957564 Active C1CCC(CC1)[Si](CCCN2CCCCC2)(C3=CC=C(C=C3)F)O 
3068143 Active CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC 
24867531 Active COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@H]4CCN3C[C@H]4C=C)O 
2733504 Active C1=CC=C2C(=C1)C3=CC=CC=C3[I+]2 
6239 Active CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC 
11957453 Active C[N+](C)(CCC(=O)CC[N+](C)(C)C1=CC=C(C=C1)CC=C)C2=CC=C(C=C2)CC=C 
6604151 Active C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N 
9853645 Active CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C 
11957525 Active C1=CC(=C(C=C1CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N)Cl)Cl 
10440396 Active C[N+](C)(CCCCCC[N+](C)(C)CCCN1C(=O)C2=CC=CC3=C2C(=CC=C3)C1=O)CCCN4C(=O)C5=CC=CC6=C5C(=CC=C6)C4=O 
824226 Active C1=CC(=CC=C1C2=NC3=C(N2)C=C(C=C3)C4=NC5=C(N4)C=C(C=C5)N)N 
184822 Active CCCNC[C@@H](COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O 
60703 Active C1CN(CCC1CC2=CC=C(C=C2)F)CC(C3=CC=C(C=C3)Cl)O 
36708 Active CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O 
2812 Active C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4 
24867458 Active CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCCC3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C 
11957606 Active CC[N+](CC)(CC)COC1=CC=C(C=C1)/C=C/C2=CC=CC=C2 
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5326739 Active C1=CC=C2C(=C1)C(=C(N2)C3=C4C=CC=CC4=NC3=O)NO 
5280754 Active 
CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)
N(C(C(=O)N(C(C(=O)N1)C(C(C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(
C)C)CC(C)C)C)C 
126941 Active CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O 
107656 Active CC1=C(C(=C2CCC(OC2=C1C)(C)CN3CCN(CC3)C4=NC(=NC(=C4)N5CCCC5)N6CCCC6)C)O 
51082 Active C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO 
5614 Active CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C=C(C#N)C#N 
4477 Active C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O 
3213 Active CC1=C2C(=C(C3=C1C=CN=C3)C)C4=CC=CC=C4N2 
11957726 Active CCCN(CCC)[C@@H]1CCC2=C(C=CC(=C2C1)O)F 
11957700 Active CCC1=CC=CC=C1OC[C@H](CN[C@H]2CCC3=CC=CC=C3C2)O 
11957587 Active 
CC[C@@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H]
(/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H
]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C 
11957499 Active C[C@@H]1CC[C@]2([C@@H](C[C@H]([C@H](O2)[C@H](C)C(=O)C3=CC=CN3)C)C)O[C@@H]1CC4=NC5=C(O4)C=CC(=C5C(=O)O)NC 
10236521 Active CCCN(CCC)[C@H]1CCC2=C(C=CC(=C2C1)O)F 
4605800 Active C1CC2=C3C(=CC=C2)N(S(=O)(=O)N3C1)CCN4CCC(=CC4)C5=CNC6=C5C=CC(=C6)F 
42890 Active C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O 
24195776 Active CCCN1CCC2=CC=CC3=C2C1CC4=C3C(=C(C=C4)O)O 
11957469 Active C[C@H]1CCC/C=C/C2C[C@@H](C[C@]2(C/C=C/C(=O)O1)O)O 
5329255 Active C1=CC(=C(C=C1/C=C(/C(=O)NCCCNC(=O)/C(=C/C2=CC(=C(C=C2)O)O)/C#N)\C#N)O)O 
1318 Active C1=CC2=C(C3=C(C=CC=N3)C=C2)N=C1 
73334 Active CCNC(=O)N1CCN(CC1)CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F 
24867476 Active CC(C)C[C@H]1C(=O)N2CCCC2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O 
148673 Active COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42 
5770 Active CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC 
24867499 Active C=CCN1CCC2=CC=CC3=C2C1CC4=C3C(=C(C=C4)O)O 
24867538 Active C[C@]12CC=C3C([C@@H]1CC[C@@H]2C(=O)CN4CCN(CC4)C5=NC(=NC(=C5)N6CCCC6)N7CCCC7)CCC8=CC(=O)C=C[C@@]83C 
11957693 Active COC1=CC=C(C=C1)CCCOC2=C(C=CC(=C2)CCN3C=CN=C3)OC 
11957671 Active CCCN(CCC1=CC=CC=C1)C2CCC3=C(C2)C=CC=C3O 
443390 Active COC1=C(C=C2C(=C1)CCN2C(=O)NC3=CC(=CC(=C3)C4=CN=CC=C4)F)C(F)(F)F 
441276 Active 
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@](C3[C@@H]([C@@](C2(C)C)(C[C@@H
]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C
7)(CO4)OC(=O)C)O)C)OC(=O)C 
107759 Active COC1=CC=CC=C1CNCCCCCCNCCCCCCCCNCCCCCCNCC2=CC=CC=C2OC 
64927 Active CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl 
65341 Active CCCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(CC)CC 
122215 Active CCCCCCCCCC[Si](C)(C)CCC(=O)NC(CC1=CC=C(C=C1)C)C2=CC=CC=C2 
16759248 Active CCCCN1C2CCC1CC(C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F 
5702010 Active CN1CCC2=CC=CC3=C2C1CC4=C3C(=C(C=C4)O)O 
9951033 Active C1[C@H](O[C@H](C2=C1C(=C(C=C2)O)O)CN)C34CC5CC(C3)CC(C5)C4 
10649 Active CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C 
24867491 Active C[C@@]1(C(=O)N2[C@H](C(=O)N3CCCC3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C 
41114 Active CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC 
10047903 Active CC(COC1=CC=C(C=C1)/C=C/C2=CC=CC=C2)[N+](C)(C)C 
441325 Active CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I 
62978 Active COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC 
11957656 Active C=CCN1C2[C@]3([C@]4(C5=C(C2)C=CC(=C5O[C@@H]4/C(=N/N=C\6/[C@H]7OC8=C(C=CC9=C8[C@]72[C@](C(C9)N(CC2)CC=C)(CC6)O)O)/CC3)O)CC1)O 
24360 Active CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O 
9874535 Active COC1=CC(=CC(=C1OC)OC)C2=C(N(C(=O)C3=C2C=CC(=C3)OCC4=CC=CC=N4)C5=CC=C(C
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=C5)N)C(=O)OC 
5702295 Active C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N 
5287844 Active C1=CC2=C(/C(=C/3\C4=C(C=C(C=C4)Br)NC3=O)/N=C2C=C1)NO 
71420 Active CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4 
68635 Active C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6 
54900 Active C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O 
443600 Active CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO 
11957578 Active CC(C)C1=C2C[C@](CCC2=CC(=C1)F)(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)C5CC5 
6435335 Active CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N 
11957719 Active CC[C@@]12C=CCN3[C@@H]1[C@]4(CC3)C([C@]([C@@H]2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)[C@]6(CC7CC(CN(C7)CCC8=C6NC9=CC=CC=C89)(CC)O)C(=O)OC)OC)C 
11957677 Active CCCCCCCCCC(=O)NC(CN1CCOCC1)[C@@H](C2=CC=CC=C2)O 
104895 Active CCCCCCC(C)(C)C1=CC(=C(C=C1)[C@@H]2C[C@@H](CC[C@H]2CCCO)O)O 
11957588 Active C1=CC(=CC=C1C(C2=CC=C(C=C2)F)OCCCC3=CN=CN3)F 
1730 Active C1=CC(=CC=C1C(=O)O)[Hg]Cl 
24867482 Active C[C@]1(CCCC(C1)C(C)(C)NC(=O)CBr)NCC(COC2=CC=CC=C2CC=C)O 
5282483 Active C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO 
3060974 Active CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2C)OC)OC)C 
203135 Active CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=C(C=C4)Cl 
173603 Active CCCN1CCC2=C3C1CC4=C(C3=CC(=C2)O)C(=C(C=C4)O)O 
60662 Active CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F 
11957481 Active CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O 
5280343 Active C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O 
10921 Active C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C 
2544 Active CC1(C2CCC(C1(C)C(=O)O)O2)C(=O)O 
10321498 Active CCN(CC)C(=O)C1=CC=C(C=C1)[C@H](C2=CC(=CC=C2)OC)N3C[C@@H](N(C[C@H]3C)CC=C)C 
5281847 Active CC1=C(C(=C(C(=C1O)C(=O)C)O)CC2=C(C3=C(C(=C2O)C(=O)/C=C/C4=CC=CC=C4)OC(C=C3)(C)C)O)O 
176157 Active CCCN(CC1CC1)C2=NC(=NC(=C2Cl)NC3=C(C=C(C=C3Cl)Cl)Cl)C 
11497466 Active CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)N5CCN(CC5)C 
9951825 Active C1=CC=C(C(=C1)N)S/C(=C(\C(=C(/SC2=CC=CC=C2N)\N)\C#N)/C#N)/N 
3108 Active C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO 
2545 Active CC12C3CCC(C1(C(=O)OC2=O)C)O3 
24867460 Active CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5(C4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C 
11957716 Active C[C@]12CCC3C([C@@H]1CC[C@]2(C#N)O)CCC4=CC5=NC6=NC7=CC=CC=C7N6C=C5C[C@]34C 
11957542 Active CC(C)C[C@@H](C(=O)NCCCCN=C(N)N)NC(=O)C1C(O1)C(=O)O 
5283454 Active CCCCCCCC/C=C\CCCCCCCC(=O)NCCO 
24867497 Active C[C@@H]1C2[C@@H]([C@H]3C(C(=O)/C(=C(/N)\O)/C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O 
10098248 Active CC(C)(C)NC(=O)C1CN(CCN1C(=O)OCC2=CC=CC=C2)C3=NC4=CC(=C(C=C4C(=N3)N)OC)OC 
5405 Active CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O 
4748 Active C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO 
3396 Active C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F 
24867511 Active CC(C)C1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=O)/C(=C(/N)\O)/C1=O)O)O)O)N(C)C 
9852041 Active CC1=NC=CC(=C1)CN2C(=C(C3=C(C2=O)C(=NC=C3)OCC4=NC=CC=N4)C5=CC(=C(C(=C5)OC)OC)OC)C(=O)OC 
67356 Active C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO 
29976 Active COC1=CC(=CC(=C1OC)OC)C(=O)OCCC[NH+]2CCC[NH+](CC2)CCCOC(=O)C3=CC(=C(C(=C3)OC)OC)OC 
24867479 Active CC(C)(C)[C@@]1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@@H]2C1)O 
16362 Active C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F 
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4712 Active C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)[N+](=O)[O-] 
1967 Active CC1=C(C(=O)C(=C(C1=O)C)CCCCC#CCCCC#CCO)C 
11957714 Active CC[C@@]12C=CCN3[C@@H]1[C@]4(CC3)C([C@]([C@@H]2OC(=O)C)(C(=O)OC)O)N(C5=CC(=C(C=C45)[C@]6(CC7CC(CN(C7)CCC8=C6NC9=CC=CC=C89)(CC)O)C(=O)OC)OC)C=O 
11957662 Active C1=CC(=CC(=C1)CCSC(=N)N)CCSC(=N)N 
11957527 Active C[C@@H]1OC[C@@H]2[C@@](O1)(C[C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O 
11647992 Active C1CN(CCC1(C2=CC(=CC=C2)C(F)(F)F)O)CCCC(=O)C3=CC=C(C=C3)F 
3559 Active C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F 
5312137 Active CN(C)S(=O)(=O)C1=CC\2=C(C=C1)NC(=O)/C2=C\C3=CC4=C(N3)CCCC4 
262093 Active C1=CC=C2C(=C1)C(=O)C(=C(C2=O)SCCO)SCCO 
11957570 Active CCCN(CCC)[C@@H]1CCC2=C(C1)C(=CC=C2)O 
11957495 Active CCN1C=NC2=C1N=C(N=C2NC3=CC(=CC=C3)Cl)N[C@@H]4CCCC[C@@H]4N 
6603857 Active CN(C)C1=NC=C2C(=C1)C(=NC=N2)NC3=CC4=C(C=C3)N(N=C4)CC5=CC=CC=C5 
5282407 Active C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F 
66368 Active CC(C)NCC(COC1=CC=CC=C1CC=C)O 
9868848 Active CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCC3CCCN3C 
3038495 Active COC1=CC=CC=C1N2CCN(CC2)CCCCNC(=O)C3=CC4=CC=CC=C4C=C3 
517348 Active C1CCN(C1)C(=S)[S-] 
104920 Active C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F 
72430 Active CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C=O)NC(=O)OCC2=CC=CC=C2 
62969 Active CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC 
5546 Active C1=CC=C(C=C1)C2=NC3=C(N=C2N)N=C(N=C3N)N 
11957577 Active C[C@@H](CN1CCC2=C1C=C(C=C2)Br)N 
644274 Active C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)N3C=C[N+](=C3)CC(C4=C(C=C(C=C4)Cl)Cl)OCC5=C(C=C(C=C5)Cl)Cl)Cl 
3151 Active C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O 
11957697 Active CN1CCC2=C(C(=C(C=C2C(C1)C3=CC(=CC=C3)Cl)O)O)Cl 
6603792 Active C1CCC(C1)N2C=C(C3=C2N=CN=C3N)C4=CC=C(C=C4)OC5=CC=CC=C5 
5487525 Active CC(C)(C)C1=CC(=C/C(=C(/N)\S)/C#N)C=C(C1=O)C(C)(C)C 
135348 Active C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O 
132496 Active CCCCCCN(CCCCCC)C(=O)CC1=C(NC2=CC=CC=C21)C3=CC=C(C=C3)F 
119442 Active CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC 
91505 Active CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O 
66366 Active CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O 
3957 Active CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1 
24867500 Active CN(C)C1[C@@H]2CC3[C@@H](C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=O)/C(=C(\N)/O)/C1=O)O)O)O)Cl)O 
11957722 Active CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C 
11957605 Active C1CN2CCC1C(C2C(C3=CC=CC=C3)C4=CC=CC=C4)NCC5=CC=CC=C5I 
5282408 Active CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1 
71587 Active C1CN(CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CCO 
11957579 Active CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3 
6604029 Active C1=C(C=C(C(=C1O)O)O)/C(=C(\C=C(C#N)C#N)/N)/C#N 
5702062 Active CC(=O)O 
62882 Active CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O 
6014 Active CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C 
2051 Active COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC 
11957725 Active C1CCN(CC1)CC2=CC(=CC=C2)OCCCNC3=NC4=CC=CC=C4S3 
11957483 Active C=CCN1CCC2=C(C(=C(C=C2[C@H](C1)C3=CC=CC=C3)O)O)Br 
9909521 Active C=CCN1CCC2=C(C(=C(C=C2C(C1)C3=CC=CC=C3)O)O)Cl 
4519262 Active CC(C)C1=CC2=C(C=C1)N(C(=C2SC(C)(C)C)CC(C)(C)C(=O)[O-])CC3=CC=C(C=C3)Cl 
238053 Active CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4 
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71401 Active C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl 
28693 Active CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5 
24867540 Active CCCCCCCC(=O)O[C@@H]1[C@H](C(=C2C1[C@@](C[C@H]([C@]3([C@H]2OC(=O)[C@@]3(C)O)O)OC(=O)CCC)(C)OC(=O)C)C)OC(=O)/C(=C\C)/C 
11957658 Active CS(=O)(=O)O 
11957596 Active CN([C@@H]1CCCC[C@@H]1N2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl 
719408 Active C1=CC=C(C=C1)NC(=S)NC2=NC=CS2 
73314 Active CC(C)CN(C)C1=NC(=C(N=C1Cl)C(=O)N=C(N)N)N 
66064 Active CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F 
6240 Active CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl 
5578 Active COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N 
11957590 Active CC1=C2CCCC2=C(C=C1)OCC(C(C)NC(C)C)O 
11957508 Active C1CN(C=CC1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F 
11957471 Active CN(C)CC/C=C/1\C2=C(C=C(C=C2)Cl)SC3=CC=CC=C31 
11417991 Active C1CN(CCC1OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)CCCl 
9604979 Active CS(=O)(=O)O 
6604176 Active CC1=C(C2=C3N1[C@@H](COC3=CC=C2)CN4CCOCC4)C(=O)C5=CC=CC6=CC=CC=C65 
13770 Active CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1 
11957553 Active C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=CC=C3)C4=CC=CC=C4 
11538542 Active CCOC(=O)C1=C(N(C(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)CC#C)C 
10008573 Active CN1C=C(N=C1C2=CC=C(C=C2)OCC(CNCCOC3=CC(=C(C=C3)O)C(=O)N)O)C(F)(F)F 
5289419 Active COC1=CC\2=C(C=C1)NC(=O)/C2=C\C3=CN=CN3 
5288209 Active CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)NC2=CC=C(C=C2)O)/C)/C 
5281032 Active CN1CCN(CC1)CCCN2C3=C(SC4=CC=CC=C24)C=CC(=C3)Cl 
4350931 Active CN1CCC2=CC=CC=C2CC3=C(CC1)C4=CC=CC=C4N3 
133633 Active C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CC3=CNC4=CC=CC=C43 
66062 Active CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC 
62878 Active C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4 
60839 Active CCC1=CC(=CC=C1)N(C)C(=NC2=CC=CC3=CC=CC=C32)N 
3885 Active CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C 
24867502 Active CN1CCC2=C3C1CC4=C(C3=CC(=C2)O)C(=C(C=C4)O)O 
11957699 Active C1CN(C2=CC=CC=C21)C(=O)C(CC3=CC(=C(C=C3)O)O)C#N 
11957600 Active C1C[C@@H]([C@@H](NC1)C2=CC=CC=C2)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F 
11957569 Active C1CN=C(N1)N(CC2=CC=C(C=C2)F)C3=C(C=CC=C3Cl)Cl 
11226716 Active CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)N4CCC5=C4C=C6C(=C5)OCC67CCN(CC7)C 
10314472 Active CN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl 
9601084 Active C=CCN1CC[C@]23[C@@H]4/C(=N/NC(=O)C5=CC=CC=C5)/CC[C@]2([C@H]1CC6=C3C(=C(C=C6)O)O4)O 
6438352 Active CN1CCN(CC1)C2=NC3=C(C=CC(=C3)C(F)(F)F)N4C2=CC=C4 
3014059 Active C[N+]1(CCC(CC1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3)C 
2733525 Active CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3 
456201 Active CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl 
68546 Active COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC 
68539 Active CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl 
9279 Active CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C 
1794 Active C1CCCN(CC1)C2=NC(=C(N=C2Cl)C(=O)N=C(N)N)N 
24867541 Inactive 
C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4
C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)NC7C8=CC(
=C(C=C8)O)C9=C(C=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=
O)C(=O)O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O 
24867536 Inactive 
C1=CC(=C[N+](=C1)[C@H]2C(C([C@@H](O2)COP(=O)([O-
])OP(=O)(O)OC[C@@H]3[C@@H]([C@H]([C@@H](O3)N4C=NC5=C4N=CN=C5N)OP(=O)(O)[
O-])O)O)O)C(=S)N 
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24867535 Inactive CC([C@H]([C@H]1CNC2=C(N1)C(=O)N=C(N2)N)O)O 
24867530 Inactive C1=CC=C(C(=C1)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])C(=O)[O-] 
24867525 Inactive C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)O)N)O[C@@H]3[C@H]([C@H]([C@H](O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N 
24867522 Inactive CC(=C)[C@@H]1C2[C@@H]3[C@@]4([C@](C1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C 
24867518 Inactive C1C=CN(C=C1C(=O)N)C2C(C(C(O2)COP(=O)([O-])OP(=O)([O-])OC[C@@H]3[C@@H]([C@H]([C@@H](O3)N4C=NC5=C4N=CN=C5N)OP(=O)([O-])[O-])O)O)O 
24867514 Inactive CSC1=NC2=C(C(=N1)N)N=CN2[C@H]3[C@@H]([C@H]([C@H](O3)COP(=O)([O-])OP(=O)([O-])[O-])O)O 
24867513 Inactive CN1CCC[C@H]1C2=CN=CC=C2 
24867509 Inactive [Li+] 
24867503 Inactive CCNC(=O)[C@@H]1[C@@H]([C@H]([C@@H](O1)N2C=NC3=C2N=CN=C3N)O)O 
24867493 Inactive C[C@]12CCC3C([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)[O-])C 
24867492 Inactive CC[C@@H](C)C1CN[C@@H]([C@H]1CC(=O)O)C(=O)O 
24867487 Inactive CCNC(=O)[C@@H]1[C@@H]([C@H]([C@@H](O1)N2C=NC3=C2N=C(N=C3N)NCCC4=CC=C(C=C4)CCC(=O)O)O)O 
24867481 Inactive CCCC 
24867470 Inactive C1=CN2[C@H]3[C@H]([C@H]([C@H](O3)CO)O)OC2=NC1=N 
24867469 Inactive C[C@]12CCC3C([C@@H]1CC[C@@H]2O)CCC4[C@@]3(CC[C@H](C4)O)C 
24867466 Inactive CNC(=O)[C@@H]1[C@@H]([C@H]([C@@H](O1)N2C=NC3=C2N=CN=C3N)O)O 
24867465 Inactive CC1(O[C@@H]2[C@H](C(O[C@@H]2O1)[C@@H](CO)O)OCCCN(C)C)C 
24848913 Inactive CC(=NCCCC(C(=O)O)N)N 
23682212 Inactive CC(=O)[C@H]1CCC2[C@@]1(CCC3C2CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)[O-])C)C 
23681235 Inactive C1CC(C(C2=CC=CC=C2C1)O)CC(=O)[O-] 
23681234 Inactive C1=CC(=CC=C1C(/C=C/C(=O)[O-])O)Cl 
23681233 Inactive CCCCCN(CCCCC)C(=O)C(CCC(=O)[O-])NC(=O)C1=CC(=C(C=C1)Cl)Cl 
23681059 Inactive C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)[O-] 
23679632 Inactive C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3 
23676659 Inactive CCCCCC(CCCC(=O)[O-])O 
23668244 Inactive COC1=C(C=CC(=C1)C(CO)O)OS(=O)(=O)[O-] 
23663954 Inactive C1=CC(=CN=C1)CC2=CC3=C(C=C2)OC(=C3)C(=O)[O-] 
16760703 Inactive CCCC(CCC)C(=O)[O-] 
16759251 Inactive CC(=O)NCCC(=O)C1=C(C=CC(=C1)OC)CN=O 
16757702 Inactive C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C 
16219752 Inactive COC(=O)C(CCCN=C(N)N[N+](=O)[O-])N 
13830713 Inactive CNC1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@H]([C@H](O3)CO)O)O 
12997925 Inactive C1=CC=C(C=C1)NC2=NC=NC3=C2N=CN3[C@H]4[C@@H]([C@H]([C@H](O4)CO)O)O 
12906333 Inactive C[N+]1(C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)C 
11957723 Inactive C[C@]12CCC3C(C1CC[C@@H]2NCCCCCCN4C(=O)C=CC4=O)CCC5=C3C=CC(=C5)OC 
11957708 Inactive CN(C)CCCCSC(=N)N 
11957705 Inactive CCN(CC)CCOC(=O)C1=CC(=C(C=C1OC)N)Cl 
11957702 Inactive CC1C2=C(C(=O)N(C1=O)C)N=CN2 
11957691 Inactive C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OP(=O)(NC(CC(C)C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)[O-])[O-])O)O)O 
11957681 Inactive CNC1=CC(=NC(=N1)NC)NS(=O)(=O)C2=CC=C(C=C2)N 
11957668 Inactive CCCN1CCO[C@H]2[C@H]1COC3=C2C=C(C=C3)O 
11957663 Inactive C1C[C@H]([C@H](NC1)C(=O)O)C(=O)O 
11957648 Inactive C[N+](C)(C)CCC(=O)C1=CC=CC2=CC=CC=C21 
11957647 Inactive CC1=CC=C(C=C1)C(=O)O[C@H]([C@@H](C(=O)O)OC(=O)C2=CC=C(C=C2)C)C(=O)O 
11957639 Inactive C1CC(NC(C1)CCN)CCN 
11957622 Inactive C[Se]C[C@@H](C(=O)O)N 
11957621 Inactive COC1=C(C=CC(=C1)CCN)O 
11957614 Inactive CC(=O)O 
11957608 Inactive CC(C)(CCP(=O)(O)O)C(=O)O 
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11957601 Inactive CN1C=C(N=C1)CCN 
11957593 Inactive CC1=CNN=C1 
11957581 Inactive CC(=NCCCC[C@H](C(=O)O)N)N 
11957565 Inactive CC(=O)O 
11957562 Inactive CC(C)[N+]1(C2CCC1CC(C2)C(=O)OC(CO)C3=CC=CC=C3)C 
11957558 Inactive CC1=C(C(=O)NO1)CC(C(=O)O)N 
11957555 Inactive C1CNCC(=C1)C(=O)O 
11957538 Inactive CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]([C@@H](CC1=CC=CC=C1)N)O 
11957537 Inactive CO[C@H]1CC=C2CCN3[C@]2(C1)C4=C(CC3)COC(=O)C4 
11957520 Inactive C1=C2C(=CC(=C1Cl)Cl)N=C(N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O 
11957517 Inactive CC(C)(C)NCC(COC1=CC=CC2=C1NC(=O)N2)O 
11957491 Inactive CN1C(=NC(=O)C(=N1)[O-])SCC2=C(N3C([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-] 
11957485 Inactive C[N+](C)(C)COP(=O)([O-])OP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O 
11957478 Inactive C[N+](C)(C)CCOC(=O)CBr 
11957464 Inactive CCN(CC)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)(C(P(=O)(O)[O-])(Br)Br)[O-])O)O 
11957441 Inactive C1CCN(C1)CCOC(=O)CC2=CC(=C(C=C2)Cl)Cl 
11953777 Inactive C1[C@H]([C@@H]([C@H](N1)CO)O)O 
11665606 Inactive COC1=C(C=C(C=C1)CCN)O 
11601888 Inactive C[C@@H]1O[C@@H](CS1)C[N+](C)(C)C 
10404739 Inactive C(CC(=O)N[C@H](CSN=O)C(=O)NCC(=O)O)[C@@H](C(=O)O)N 
10018826 Inactive CCCN1CCCC2C1CC3=CN=C(N=C3C2)N 
9964741 Inactive CN(C)C(=NCCC[C@@H](C(=O)O)N)N 
9922558 Inactive CC(CC1=CNC2=C1C=C(C=C2)O)N 
9884487 Inactive CC[N+](CC)(CC)CC(=O)NC1=C(C=CC=C1C)C 
9855833 Inactive C[C@H](CC1=CC=CC=C1)NCC#C 
9836150 Inactive CC1=C(C2=C(N1)C=CC(=C2)O)CCN 
9795082 Inactive CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)C 
9604977 Inactive CC1=N/C(=N\NC2=CC=C(C=C2)C(=O)[O-])/C(=C(C1=O)C=O)COP(=O)([O-])[O-] 
9549280 Inactive CC(=O)/C(=C(/NC1=C(C=CC(=C1)Br)Br)\O)/C#N 
6918215 Inactive CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC 
6917797 Inactive C1CC(CN(C1)CCC=C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)O 
6917794 Inactive CCCN(CCC)C1CCC2=C(C1)C(=CC=C2)O 
6604094 Inactive C1CN(CC2=CC=CC=C21)C(=N)[NH3+] 
6603931 Inactive CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C3=CC=C(C=C3)OCC(=O)NC4=CC=C(C=C4)C#N 
6603901 Inactive CCCC1=C(C=CC(=C1O)C(=O)C)OCCCOC2=CC=C(C=C2)OCC(=O)O 
6603697 Inactive C(/C=C\C(=O)O)N 
6532796 Inactive CC1=N/C(=N/NC2=C(C=C(C=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])/C(=C(C1=O)C=O)COP(=O)([O-])[O-] 
6440459 Inactive C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O 
6436473 Inactive C1CN(CC1)CC#CCN2C(=O)CCC2 
6419997 Inactive C1=C(NC=N1)CCNC(=O)CCN 
6419304 Inactive COC1=CC=C(C=C1)C2=N[N+](=C(C=C2)N)CCCC(=O)O 
6409633 Inactive C/C(=N\O)/C(=O)C 
6324610 Inactive CCOC(=O)C12CC1/C(=N/O)/C3=CC=CC=C3O2 
6093162 Inactive CC1C(O1)P(=O)([O-])[O-] 
6093160 Inactive 
C1=CC(=CC(=C1)NC(=O)NC2=CC=CC(=C2)C(=O)NC3=C4C(=CC(=CC4=C(C=C3)S(=O)(=O)[O
-])S(=O)(=O)[O-])S(=O)(=O)[O-])C(=O)NC5=C6C(=CC(=CC6=C(C=C5)S(=O)(=O)[O-
])S(=O)(=O)[O-])S(=O)(=O)[O-] 
5702253 Inactive C1CNCC2=C1C(=O)NO2 
5702251 Inactive C1=CC(=CC=C1C(=O)NCCN)Cl 
5702250 Inactive CCCCCCCCCCCCCCCCCC(=O)OC(CC(=O)O)C[N+](C)(C)C 
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5702214 Inactive CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC 
5702206 Inactive CC(=O)O 
5702160 Inactive C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N 
5462653 Inactive C(CN)C#N 
5353800 Inactive CN(C)C(=O)/N=N/C(=O)N(C)C 
5353788 Inactive CCO/C(=N/C1=C[N+](=NO1)N2CCOCC2)/[O-] 
5312115 Inactive C[C@H](CC1=CC2=C(C=C1)OC(O2)(C(=O)[O-])C(=O)[O-])NC[C@@H](C3=CC(=CC=C3)Cl)O 
5311302 Inactive CNC1=NC=NC2=C1N=CN2[C@H]3C[C@@H]([C@H](O3)COP(=O)(O)[O-])OP(=O)(O)[O-] 
5310987 Inactive C(/C=C/C(=O)O)N 
5310956 Inactive C1[C@@H]([C@H]1C(=O)O)[C@@H](C(=O)O)N 
5284443 Inactive CNC[C@@H](C1=CC(=CC=C1)O)O 
5282759 Inactive CCCCCCC/C=C\CCCCCCCCC(=O)O 
5281708 Inactive C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O 
5281670 Inactive C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O 
4549312 Inactive CC1=CC=CC=C1CNC2=NC=NC3=C2N=CN3C4C(C(C(O4)CO)O)O 
4234241 Inactive C1CC2C(C1)C3CC2CC3OC(=S)[S-] 
4177957 Inactive CC1=C(C2=C(N1C(=O)C3=CC=CC=C3)C=CC(=C2)OC)CC(=O)O 
3870203 Inactive C1=C(C=C(C(=C1[N+](=O)[O-])O)O)[N+](=O)[O-] 
3864541 Inactive CCN1C=C(C(=O)C2=C1N=C(C=C2)C)C(=O)[O-] 
3519541 Inactive CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)CC(C)(C)C=O 
3074827 Inactive CC1(CCC(CC1)NC(=O)[C@H](CCC(=O)O)N)C 
3040551 Inactive C[C@H]([C@H](C1=CC=C(C=C1)O)O)NCCC2=CC=C(C=C2)O 
3035523 Inactive C1=CC(=CC=C1CN2C=CNC2=S)O 
3033332 Inactive CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C 
2837663 Inactive CC(C)(C(COC1=CC=CC2=C1N(C(=O)C=C2OC)C)O)O 
2794990 Inactive C(CCN=C(N)N)CN 
2735510 Inactive C[N+](C)(C)CC=O 
2734952 Inactive C(=NN)(N)N 
2734687 Inactive C(=NN)(N)N 
2733517 Inactive C1[C@@H](N[C@@H]1C(=O)O)C(=O)O 
2733277 Inactive COC(=O)C(CC1=CC=C(C=C1)Cl)N 
2724466 Inactive C1CCC(CC1)(C(=O)O)N 
2723891 Inactive C(CC(=O)O)[C@@H](C(=O)O)N 
2723890 Inactive COC1=C(C=CC(=C1)C(CO)O)O 
1617430 Inactive C(CC[C@H](C(=O)O)N)CCP(=O)(O)O 
1549098 Inactive C([C@@H](C(=O)O)N)S(=O)O 
736715 Inactive C1=C(NC=N1)/C=C/C(=O)O 
689043 Inactive C1=CC(=C(C=C1/C=C/C(=O)O)O)O 
688272 Inactive CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC 
657346 Inactive C[C@H]1OC[C@H](O1)C[N+](C)(C)C 
656765 Inactive CCN1C2=CC(=C(C=C2NC1=O)Cl)Cl 
656717 Inactive C[C@]1(CC2=CC(=C(C(=C2C1=O)Cl)Cl)OCC(=O)O)C3CCCC3 
451515 Inactive CC1=CN(C(=O)NC1=O)[C@H]2C[C@H]([C@H](O2)CO)N=[N+]=[N-] 
449215 Inactive C1[C@@H](C(=O)NO1)N 
447196 Inactive C1=C(C(=O)NC(=O)N1C[C@@H](C(=O)O)N)I 
446727 Inactive C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)/C=C/Br)CO)O 
443586 Inactive C1=C(C=C(C=C1O)O)[C@@H](C(=O)O)N 
443239 Inactive [C@H]([C@@H](C(=O)O)O)(C(=O)O)N 
442897 Inactive CC(CO)(C1CC2=C(C3=CC=CC=C3N=C2O1)OC)O 
441350 Inactive C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N 
441334 Inactive CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O 
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441333 Inactive CC(C)NCC(C1=CC(=CC(=C1)O)O)O 
440005 Inactive C(C[C@@H](C(=O)O)N)CN=C(N)N[N+](=O)[O-] 
439744 Inactive C1=CC(=C(C=C1C[C@@H](C(=O)O)N)I)O 
439280 Inactive C1=CC2=C(C=C1O)C(=CN2)C[C@@H](C(=O)O)N 
433294 Inactive [Li+] 
377339 Inactive C1C(C(C(C(N1)CO)O)O)O 
260390 Inactive CNCCC1=CNC2=C1C=C(C=C2)O 
205536 Inactive C1=C(ONC1=O)CN 
198382 Inactive C1C(C=CC=C1C(=O)O)N 
194216 Inactive CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)N)SC1)C(=O)O 
175540 Inactive CC(C)NC[C@@H](COC1=CC=C(C=C1)CC(=O)N)O 
169743 Inactive CCN1CCC2=C(CC1)OC(=N2)N 
169373 Inactive CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(C3=CCC=CC3)N)SC1)C(=O)O 
167529 Inactive C=CC[C@@H](C(=O)O)N 
160453 Inactive C1=CC=C2C(=C1)C(=O)N(C2=O)[C@@H](CCC(=O)O)C(=O)O 
160436 Inactive C1=CC2=C(C=C1O)C(=CN2)CCN 
157991 Inactive CC(=O)N[C@H](C(=O)O)C(C)(C)SN=O 
155107 Inactive C1CNCC=C1C(=O)O 
145685 Inactive C1=C(NC=N1)CC(=O)O 
135313 Inactive C(CC(=O)O)[C@@H](C(=O)O)N=C(N)N 
120729 Inactive CC1(CCCC(N1C)(C)C)C 
114924 Inactive CCCCCCCCCCCCCCSCC(=O)O 
107812 Inactive C(CS(=O)O)N 
104766 Inactive C1C[C@](C[C@@H]1C(=O)O)(C(=O)O)N 
104762 Inactive C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)O)C(=O)N 
102542 Inactive COC1=C(C=CC(=C1)C(CN)O)O 
102484 Inactive C1=CC(=CC=C1C(CN)O)O 
99562 Inactive CN1C=NC2=C1C(=O)N(C(=O)N2C)CC#C 
97587 Inactive C(CN)CP(=O)(O)O 
92913 Inactive CC(CC1=CC=CC=C1)N(C)CC#C 
92222 Inactive C1=CC(=C(C=C1C[C@H](C(=O)O)N)O)O 
92136 Inactive C(C[C@@H](C(=O)O)N)CC(=O)O 
89034 Inactive CS(=N)(=O)CC[C@@H](C(=O)O)N 
84003 Inactive C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O 
80289 Inactive C1=CC=C(C=C1)C(=N)N 
74724 Inactive C[N+](C)(C)CCO 
71417 Inactive CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C 
69398 Inactive C(CCN)CC(=O)O 
66449 Inactive C1=CC(=CC=C1CCN)O 
66091 Inactive C1=C(NC=N1)C[C@@H](C(=O)O)N 
66068 Inactive CCN(CC)CCNC(=O)C1=CC=C(C=C1)N 
57004 Inactive C(CC(C(F)F)(C(=O)O)N)CN 
55918 Inactive C1CC(=O)NN=C1C2=CC=C(C=C2)N3C=CN=C3 
40958 Inactive C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)Cl 
40632 Inactive CC1=CN(C(=O)C=C1)C2=CC=CC=C2 
40539 Inactive C([C@@H](C(=O)O)N)N1C(=O)NC(=O)O1 
39912 Inactive C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O 
39859 Inactive CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O 
39562 Inactive C1=CC=C2C(=C1)C(=NN2CC3=C(C=C(C=C3)Cl)Cl)C(=O)O 
39214 Inactive CC1=NC=C(C(=N1)N)CNC(=O)N(CCCl)N=O 
31307 Inactive C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C
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=C[C@@]43C)F)O 
31195 Inactive C(P(=O)(O)[O-])(P(=O)(O)[O-])(Cl)Cl 
24066 Inactive C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N 
22880 Inactive CN[C@H](CC(=O)O)C(=O)O 
22475 Inactive C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C 
22411 Inactive CC(=O)SCC[N+](C)(C)C 
18343 Inactive C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O 
18283 Inactive CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO 
17882 Inactive C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C 
16817 Inactive C[C@H]1[C@@H](C[C@H](O1)C[N+](C)(C)C)O 
16486 Inactive C1CN[C@@H]1C(=O)O 
13347 Inactive CSC(=N)N 
12035 Inactive CC(=O)N[C@@H](CS)C(=O)O 
11545 Inactive C[N+](C)(C)CC(=O)O 
11236 Inactive C(=O)(N)NN 
10729 Inactive C1=NC2=C(NC1=O)NC(=NC2=O)N 
10255 Inactive CC(=C)[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O 
9539 Inactive C(CCNCCCN)CN 
9532 Inactive C(CCN)CN 
9444 Inactive C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N 
9433 Inactive CN1C2=C(C(=O)N(C1=O)C)NC=N2 
9367 Inactive CC(C)NNC(=O)C1=CC=NC=C1 
9363 Inactive CCN(CC)C(=O)C1=CC(=C(C=C1)O)OC 
9082 Inactive C(CS)N 
8743 Inactive C1=C(NC(=CC1=O)C(=O)O)C(=O)O 
8246 Inactive CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C 
7550 Inactive C[N+]1=CC=CC(=C1)OC(=O)N(C)C 
7172 Inactive CNCC(C1=CC=C(C=C1)O)O 
6322 Inactive C(C[C@@H](C(=O)O)N)CN=C(N)N 
6252 Inactive C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O 
6207 Inactive C(COCCOCCN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O 
6198 Inactive COC1=CC2=C(C=C1)NC=C2CCN 
6172 Inactive CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC 
6114 Inactive CC(C[N+](C)(C)C)OC(=O)C 
6112 Inactive C1CSS[C@@H]1CCCCC(=O)O 
6076 Inactive C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3N=CN=C4N)O)OP(=O)(O1)O 
6035 Inactive C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)Br)CO)O 
5961 Inactive C(CC(=O)N)[C@@H](C(=O)O)N 
5960 Inactive C([C@@H](C(=O)O)N)C(=O)O 
5938 Inactive C[N+](C)(C)CCCCCC[N+](C)(C)C 
5917 Inactive C1CCC2=NN=NN2CC1 
5860 Inactive C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C 
5849 Inactive C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C 
5831 Inactive C[N+](C)(C)CCOC(=O)N 
5818 Inactive C1=C(NC=N1)CCN 
5723 Inactive COC1=C(C=CC(=C1)C2=NNC(=O)C=C2)OC(F)F 
5665 Inactive C=CC(CCC(=O)O)N 
5593 Inactive CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2 
5520 Inactive CP(=O)(C1=CC[NH2+]CC1)[O-] 
5503 Inactive CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2 
5429 Inactive CN1C=NC2=C1C(=O)NC(=O)N2C 
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5426 Inactive C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O 
5355 Inactive CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC 
5335 Inactive C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N 
5242 Inactive C(=O)(C(=O)[O-])N 
5123 Inactive C1=CN(C(=O)NC1=O)CC(C(=O)O)N 
4971 Inactive CC1=C(C2=CC3=C(C(=C(N3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1N2)C)CCC(=O)O)CCC(=O)O)C)C=C)C)C=C 
4943 Inactive CC(C)C1=C(C(=CC=C1)C(C)C)O 
4922 Inactive CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1 
4909 Inactive CCC1(C(=O)NCNC1=O)C2=CC=CC=C2 
4843 Inactive C1CC(=O)N(C1)CC(=O)N 
4838 Inactive C1CNCCC1S(=O)(=O)O 
4779 Inactive C1=CC=C(C(=C1)CP(=O)(O)O)C2=CC(=CC=C2)CC(C(=O)O)N 
4740 Inactive CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C 
4652 Inactive C1=CC(=CC=C1CC(C(=O)O)N)Cl 
4650 Inactive C1=CC(=O)C=CC1=O 
4488 Inactive C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F 
4389 Inactive C1CC(N(C1)C(=O)CCC(=O)O)C(=O)O 
4386 Inactive C1=CC=C(C=C1)NC2=CC=CC=C2C(=O)O 
4362 Inactive CCN1C(=O)C=CC1=O 
4353 Inactive CC(=O)NBr 
4201 Inactive C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O 
4197 Inactive CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2 
4038 Inactive CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl 
3857 Inactive C(C(C(=O)O)N)P(=O)(O)O 
3845 Inactive C1=CC=C2C(=C1)C(=O)C=C(N2)C(=O)O 
3825 Inactive CC(C1=CC=CC(=C1)C(=O)C2=CC=CC=C2)C(=O)O 
3758 Inactive CC(C)CN1C2=C(C(=O)N(C1=O)C)NC=N2 
3727 Inactive C(C(=O)N)I 
3657 Inactive C(=O)(N)NO 
3454 Inactive C1=NC2=C(N1COC(CO)CO)NC(=NC2=O)N 
3446 Inactive C1CCC(CC1)(CC(=O)O)CN 
3433 Inactive CC1=NC2=C(N1)C(=O)N(C(=O)N2CC3=CC=CO3)C 
3373 Inactive CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C 
3331 Inactive C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N 
3291 Inactive CCC1(CC(=O)NC1=O)C 
3132 Inactive C1=CC=C(C=C1)CC(CS)C(=O)NCC(=O)O 
3125 Inactive CC(CC1=CC=C(C=C1)O)(C(=O)O)N 
3122 Inactive C(CCC(C(=O)O)N)CCP(=O)(O)O 
3019 Inactive CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl 
2944 Inactive C1=C(NC(=NC1=O)N)N 
2935 Inactive C(CC(=O)NCS(=O)(=O)O)C(C(=O)O)N 
2910 Inactive C1C2CC(C1C=C2)C3NC4=CC(=C(C=C4S(=O)(=O)N3)S(=O)(=O)N)Cl 
2907 Inactive C1CNP(=O)(OC1)N(CCCl)CCCl 
2796 Inactive CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl 
2763 Inactive CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl 
2733 Inactive C1=CC2=C(C=C1Cl)NC(=O)O2 
2727 Inactive CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl 
2576 Inactive CCCC(C)(COC(=O)N)COC(=O)NC(C)C 
2519 Inactive CN1C=NC2=C1C(=O)N(C(=O)N2C)C 
2471 Inactive CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2 
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2331 Inactive C1=CC=C(C=C1)C(=O)N 
2284 Inactive C1=CC(=CC=C1C(CC(=O)O)CN)Cl 
2266 Inactive C(CCCC(=O)O)CCCC(=O)O 
2249 Inactive CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O 
2244 Inactive CC(=O)OC1=CC=CC=C1C(=O)O 
2207 Inactive C(CP(=O)(O)O)C(C(=O)O)N 
2196 Inactive COC1=CC=C(C=C1)C(=O)N2CCCC2=O 
2145 Inactive CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N 
2141 Inactive C(CN)CNCCSP(=O)(O)O 
2123 Inactive CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C 
2094 Inactive C1=C2C(=NC=NC2=O)NN1 
2083 Inactive CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O 
2071 Inactive C1CC(C2=C1C=C(C=C2)C(=O)O)(C(=O)O)N 
1989 Inactive CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2 
1986 Inactive CC(=O)NC1=NN=C(S1)S(=O)(=O)N 
1893 Inactive C1=CC2=C(C(=C1)[N+](=O)[O-])NN=C2 
1779 Inactive C1=C(C=C2C(=C1Cl)C(=O)C=C(N2)C(=O)O)Cl 
1775 Inactive C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3 
1774 Inactive CC1(CCC=[N+]1[O-])C 
1742 Inactive C1=CC(=CC=C1C(=O)NN)O 
1738 Inactive COC1=C(C=CC(=C1)CC(=O)O)O 
1727 Inactive C1=CN=CC=C1N 
1678 Inactive C(C[N+](=O)[O-])C(=O)O 
1676 Inactive CCCN1C2=C(C(=O)NC1=O)NC=N2 
1645 Inactive C1=CC(=CC(=C1)N)C(=O)N 
1641 Inactive C1=CC(=CC=C1C(CN)CP(=O)(O)O)Cl 
1564 Inactive C1=CC(=CC=C1C(CN)(CS(=O)(=O)O)O)Cl 
1390 Inactive CN1C=CN=C1 
1365 Inactive CN1C2=C(N=C1C3=CC=C(C=C3)S(=O)(=O)O)N(C(=O)N(C2=O)CC=C)C 
1340 Inactive C1=CC2=C(C=CNC2=O)C(=C1)O 
1256 Inactive CC(=C)C1CCC(=CC1)C(=O)O 
1245 Inactive COC1=C(C=CC(=C1)C(C(=O)O)O)O 
1233 Inactive C1=C(ONC1=O)C(C(=O)O)N 
1232 Inactive C1CN(C(=O)C1N)O 
1228 Inactive C1CN(CC(N1)C(=O)O)CCCP(=O)(O)O 
1222 Inactive CC(C1=CC=C(C=C1)C(=O)O)(C(=O)O)N 
1216 Inactive C(CC(C(=O)O)N)CP(=O)(O)O 
1123 Inactive C(CS(=O)(=O)O)N 
1066 Inactive C1=CC(=C(N=C1)C(=O)O)C(=O)O 
1046 Inactive C1=CN=C(C=N1)C(=O)N 
903 Inactive CC(=O)NCCC1=CNC2=C1C=C(C=C2)O 
896 Inactive CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC 
650 Inactive CC(=O)C(=O)C 
564 Inactive C(CCC(=O)O)CCN 
401 Inactive C1C(C(=O)NO1)N 
275 Inactive C(CON=C(N)N)C(C(=O)O)N 
178 Inactive CC(=O)N 
119 Inactive C(CC(=O)O)CN 
 
